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Abstract
Cellular responses to viral infection and non-self tissues depend on 
presentation of antigenic peptides by polymorphic MHC class I molecules. 
The regulatory mechanisms controlling MHC class I expression are 
fundamental to effective immune responses, and in the pig are not fully 
understood. In this study the cellular responses of SLA class I genes to 
cytokines were studied by measuring SLA class I expression at the cell 
surface and also by fusing the promoters of the classical genes SLA-1, -2 
and -3  and non-classical genes SLA 6 and -7 independently to a luciferase 
reporter gene. Cell surface expression of SLA class I was measured on Max 
cells, Shimozuma cells and porcine aortic endothelial ceils isolated from 
inbred pigs of the d/d haplotype and outbred pigs of an unknown haplotype. 
IFN -a and -7  treatment increased SLA class I expression on d/d PAECs and 
Max cells but not on outbred PAECs or Shimozuma cells. Analysis of SLA 
class I promoter activity in Max cells showed constitutive activity of SLA-1, -2, 
-3, -6, -7 and MIC-2 promoters. In summary, classical SLA promoters were 
responsive to IFNs and co-expression of the transcription factors IRF-1, NF- 
k B  p65 and CIITA. In contrast to their human counterparts, combined 
treatment with TNF-a and IFN-a/-y had no synergistic effect on classical SLA 
class I promoter activity. SLA-1 responded to TNF-a and co-expression of 
the transcription factors IRF-3, -7 and -9 . Non-classical promoters were not 
induced by IFN-a or -y or CIITA. SLA-7 was responsive to TNF-a and co­
expression of IRF-1 but not co-expression of NF-kB. Interestingly, basal 
expression of MIC-2 remained unaffected by cytokines or co-expression of 
transcription factors. These results suggest locus-specific responses of SLA 
class I genes to cytokines and transcription factors, which can be explained 
in part by sequence variation in three key SLA class I promoter motifs: ISRE, 
Enhancer A and SXY. Furthermore, this study has demonstrated that the 
porcine virus CSFV decreases SLA class I surface expression early during 
infection and that this effect correlates to decreased constitutive activity of 
SLA-1, -2 and -7  promoters.
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1.1 The major histocompatibility complex
The major histocompatibility complex (MHC) is a genomic region 
found in all higher vertebrates studied to date (Trowsdale, 1995). The 
complex was first described in 1937 following transplantation studies in mice 
as a genetic region that plays an important role in the acceptance or rejection 
of grafts between allogeneic individuals (Gorer, 1937; Gorer, 1948). The 
complex contains an array of genes, many of which are expressed at the cell 
surface and have immunological functions including a set of highly 
polymorphic genes that code for two classes of MHC molecules; MHC class I 
and MHC class II (Horton et al., 2004). In humans these genes are also 
known as Human Leukocyte antigen (HLA) I and II. MHC class I and II gene 
products are vital in the immunological dialogue that occurs between T 
lymphocytes and other cells of the body and have two principal functions. 
Firstly they present antigenic peptides derived from intracellular pathogens 
such as viruses, bacteria and parasites to cytotoxic T lymphocytes and 
secondly they are ligands for natural killer cells.
1.2 The MHC of swine
The porcine equivalent of MHC is known as the Swine Leucocyte 
Antigen (SLA). It was first described in the seventies, when a correlation was 
found between acute graft rejection and a group of surface antigens present 
on peripheral lymphocytes in pigs (Vaiman et al., 1970; Viza et al., 1970). 
The SLA complex is located on chromosome 7 and is disrupted by the
1: Introduction
centromere (Geffrotin et al., 1984; Rabin et al., 1985). The first genetic map 
of the SLA complex was published by Velten et al (1998) and the entire 
region now has been sequenced. The organisation and content of the SLA 
complex has been remarkably well conserved during mammalian evolution, 
emphasising the fundamental importance of this region in immunity. For 
comparison, the content and organisation of human and swine MFIC class I, 
II and III regions are shown in figure 1.1. In common with human and other 
animal species, the swine MHC consists of three major clusters or regions of 
genes: SLA class I, II and III. The class I region contains the classical and 
non-classical MHC class i genes as well as the MHC class I chain-related 
(MIC) genes. The class II region contains the MHC class II genes and 
several other genes that are important in the MHC presentation pathway 
such as TAP and LMP. The class III region also contains a number of genes 
with important immunological functions including the cytokines tumour 
necrosis factor alpha (TNF-a), lymphotoixin a (LTa) and lymphotoxin b (LTb). 
The most striking difference between pig and human MHC is that the pig 
MHC complex is much more compact than in human. This is most apparent 
in the class I region, in humans this region spans 1.8 Mb and contains some 
80 genes whereas the swine class I region spans 1.1 Mb and contains 54 
genes (Velten et al., 1999). The genes encoded within the SLA class I region 
are the focus of this study, therefore the current understanding of the 
organisation, functions and expression patterns of SLA class I genes will now 
be discussed.
Class I Class III Class II
Figure 1.1 Comparative map of the major histocompatibility complex in humans and swine
The genetic map of human MHC is outlined above. The swine MHC, aligned using anchor genes that are 
perfectly conserved between human and swine, is depicted in red. Swine MHC genes whose positions 
have been mapped are shown. Human genes with immunological importance are shown in gold, class II 
sequences in cyan and class la genes in red. Porcine genes of immunological importance are typed in 
bold blue text while the class la sequences are in red font. Numbers represent genomic distances in kb. 
Reproduced with kind permission (Whitelegg, 2001).
1.2.1 The SLA class I region
Our present understanding of the SLA class I region has been gained 
by traditional serological methods and more recently, by molecular 
techniques such as the generation of YAC and BAC libraries (Rogel-Gaillard 
et al., 1997; Rogel-Gaillard et al., 1999) and the identification of YAC and 
BAC clones spanning the class I region (Velten et al., 1999). Serological 
analyses of the SLA class I region has identified some 74 haplotypes and 
three class I series, A, B and C. Whilst the majority of haplotypes express 
these three series, exceptionally rare haplotypes have also been identified 
that express more than three SLA class I series and others which express a 
single locus (Renard et al., 2001). Several pig haplotypes have been studied 
to date by a number of groups, the most detailed information available is from 
two haplotypes: H01 and H04 (or d/d). Recently, sequencing of the MHC 
class I region of the H01 haplotype pig has provided a more detailed 
understanding of this region with respect to gene content, intron and exon 
organisation and promoter structure, allowing predictions of expression to be 
made. Three classes of SLA class I genes have been identified: classical (or 
class la) genes, non-classical (class lb) and MHC class I chain related (MIC) 
genes (or class lc). A systematic nomenclature for the genes and alleles of 
the SLA based upon the World Health Organisation’s nomenclature for 
human MHC was proposed recently (Smith et al., 2005).
1.2.2 Classical (class la) genes
The classical SLA genes are highly polymorphic group of genes 
whose function is to present antigenic peptides to circulating CD8+ T cells. In
humans these genes are HLA-A, -B and -C. In pigs a total of seven classical 
SLA class I loci have been identified: SLA-1, SLA-2, SLA-3, SLA-4, SLA-5, 
SLA-9 and SLA-11, the arrangement of these genes with respect to each 
other is shown in figure 1.2A. With the exception of SLA-11, all of these 
genes are transcribed in the same direction. Of the class la genes, only 
SLA-7, SLA-2 and SLA-3 are known to be functional and these genes 
correspond to the serologically defined SLA C, B and A series respectively. 
SLA-1, -2, -3 and -5 contain the “blueprint” organization of classical MHC 
class I molecules that is; a leader sequence, three exons encoding the 
extracellular a1, a2  and a3  domains, a transmembrane region and three 
intra-cytoplasmic exons. SLA-1, -2 and -3 are expressed whereas the 
expression of SLA-5 has not been determined. Despite comprising the 
correct intron/exon organization in order to be functional, the promoter region 
of SLA-5 contains mutations that may prevent expression. The coding 
sequence of SLA-9 contains a stop codon within exon three (encoding the a2 
subunit), which would cause premature termination of transcription should 
this gene be transcribed. SLA-11 and SLA-4 have truncated sequences; 
SLA-11 lacks exon 1 and SLA-4 lacks exons 6 and 8 and encodes only 
fractions of exons 5 and 7. Therefore SLA-4, SLA-9 and SLA-11 are 
considered to be pseudogenes (Chardon et al., 2001).
Overall, the structures of SLA-1, SLA-2 and SLA-3 genes are very 
similar and while these genes are ubiquitously expressed, the relative levels 
of expression of each gene differ. Given that these genes are highly
Centromere
SLA-4 SLA-3 SLA-5
SLA-1
Figure 1.2 A: Schematic of SLA class la genes
The organisation of the seven SLA class la genes within the class I region on 
chromosome 7 of the pig is shown Genes that are known to be expressed are 
shown as solid red blocks, genes for which expression is unknown are shown 
as checkered blocks and pseudogenes are striped boxes. Arrows represent 
the direction of transcription and the relative distance (in kilobases) between 
each gene is indicated.
Centromere SLA-7 MIC-1
SLA-6 SLA-8
Class lb
MIC-2
V
Class lc
Figure 1.2 B: Schematic o f SLA class lb and lc genes
The organisation of the non-classical class lb and lc genes within the class I 
region on chromosome 7 is shown. Class lb genes are depicted as yellow 
boxes, class lc as green boxes and the MIC-1 pseudogene as a checkered 
boxes. The the direction of gene transcription is indicated by the direction of 
the arrow point and approximate distances between each gene (in kilobases) 
are indicated.
homologous, analysis of the promoter regions of these genes may provide an 
explanation for the variability in expression observed.
1.2.2.1 Classical SLA class I gene promoter regions
The 5’ flanking regions of PD1 and PD7 genes of the d/d haplotype pig 
have been examined in detail (Frels et al., 1990, Maguire et al., 1990). 
These studies permitted the promoter regions of the SLA class I genes SLA- 
1, -2, and -3 genes of the H01 pig to be identified (Renard et al., 2001). In 
each study a promoter domain of approximately 1 kb was identified upstream 
of each SLA class I gene. In the H01 pig, classical SLA promoter regions 
contain a series of conserved, putative regulatory motifs located within distal 
and proximal promoter domains. The distal domain contains enhancer and 
silencer sites. The proximal domain contains a region homologous to a 
functional motif within the mouse H-2k gene, a proximal enhancer, an 
Enhancer A and an interferon stimulated response element (ISRE). In 
addition, the proximal domain contains regulatory elements common to MHC 
class I, class II and |32-microglobulin promoters, namely three transactivator 
motifs W, X and Y and a series of proximal or "core" elements including CAT 
and TATA boxes and a CAP binding motif. The functions of these regulatory 
motifs and the factors which interact with them have been not been tested 
experimentally in for the H01 haplotype. However, their human counterparts 
have been studied in detail, and will be discussed later.
1.2.3 Non-classical (class lb) genes
A cluster of three non-classical class lb genes have been identified 
within the class I region of the H01 haplotype pig: SLA-6, SLA-7 and SLA-8. 
These genes are located adjacent to the junction between the class I and 
class III regions, approximately 500 kilobases upstream of the class la 
genes. Figure 1.2B shows the organization of these genes. SLA-6 and -7 
are transcribed in the same direction whereas SLA-8 is encoded on the 
opposite strand. Six ‘alleles’ of SLA-6 have been described which differ from 
H01 SLA-6 by a single amino acid and would therefore give rise to a 
monomorphic product (Chardon et al., 2001). The SLA-6 gene of the H01 
pig shares 99% sequence homology with PD6, a non-classical gene of the 
NIH d/d mini pig (Chardon et al., 2001). The polymorphisms of SLA-7 and -8 : 
remain to be established, but it is assumed that they will have few 
polymorphisms in keeping with the monomorphic characteristic of non- 
classical genes in other mammals. Overall, the organization of SLA class lb 
genes is consistent with the “blueprint” for MHC class I genes, and the 
products of the three genes are predicted to be membrane-anchored 
glycoproteins (Chardon et al., 2001). Interestingly, SLA-6, -7 and -8 encode 
seven exons, in contrast to the 8 exons of class la genes. The functional 
implications of these differences remain to be established, as does the 
association of SLA class lb with (32-microglobulin.
Until recently, information regarding the expression of SLA class lb 
genes was limited. SLA-6 is ubiquitously expressed in all tissues and all 
breeds examined (Ehrlich et al., 1987; Crew et al., 2004). Similarly, Crew et
al (2004) reported constitutive expression of SLA-8 on several tissues with 
the exception of the brain. SLA-7 is expressed in a tissue specific manner; 
transcripts were reported at high levels in cultured swine fibroblasts, at very 
low levels in the spleen and testes and was not detected in the kidney or 
PBMCs (Chardon et al., 1999; Crew et al., 2004).
The exact functions of SLA class lb genes are not well understood. 
Detailed analysis of coding sequences implies that they encode membrane 
anchored glycoproteins with the capacity to bind peptides, although the 
nature of these peptides is unknown (Chardon et al., 2001). The restricted 
polymorphisms of class lb genes means that the potential repertoire of 
peptides that could be presented by these molecules would be limited. There 
are no direct molecular homologues of non-classical SLA genes in the 
human or mouse; therefore predictions of functions of these genes cannot be 
extrapolated from sequence comparisons with human genes alone. 
However, given the importance of human and mouse class lb genes in the 
regulation of NK and antigen-dependant T cell activities, and the relative 
conservation and/or co-evolution of MHC class I gene function during 
mammalian evolution, it is predicted that porcine class lb genes will have 
functions in parallel with those of humans and mice, that are distinct from 
class la genes. In the human there are three non-classical HLA class I 
genes: HLA-E, -F and -G. All of these genes encode membrane-anchored 
glycoproteins and alternative transcripts of HLA-G encode soluble forms of 
this protein (Lefebvre et al., 2001). HLA-E and -G are capable of binding 
peptides whereas HLA-F is expressed as an empty heterodimer devoid of
peptide (Wainwright et al., 2000). The most unique features of these 
molecules are the nature of the peptides which they present, which are 
primarily derived from the leader sequences of classical HLA class I 
molecules, their roles as ligands for NK cell receptors and characteristic 
tissue specific expression patterns.
1.2.3.1 Non-classical SLA class I gene promoter regions
With the exception of SLA-8 which lacks an ISRE, the promoter 
regions of SLA class lb genes contain the same regulatory motifs as SLA 
class la genes (Chardon et ai, 2001). However, there are some differences 
in the nucleotide sequences of these motifs which may affect the binding of 
transcription factors, these are discussed in more detail in results chapter 2.
1.2.4 MHC class I chain-related (class lc) genes
In the pig, only two MIC-like genes, MIC-1 and MIC-2, have been 
identified. These genes are located within the SLA class I region in close 
proximity to the class lb genes (figure 1.2B, in green). The MIC-2 gene 
encodes 6 exons and has a molecular structure compatible with that of a 
functional gene, whereas MIC-1 has a truncated sequence and is therefore 
considered to be a pseudogene (Chardon et al., 2001). Interestingly, the 
promoter region of MIC-2 contains a consensus heat shock element, but 
lacks an ISRE, indicating that the mechanisms regulating MIC-2 expression 
are distinct from those that regulate class la and lb genes (Chardon et al., 
2001). Currently, knowledge of the transcription, expression and functions of
MIC-2 in the pig is limited, however, studies on human class lc genes may 
allow some predictions of the expression patterns and functions of porcine 
MIC-2 to be made.
In humans, the MIC genes were first described as a group of five 
genes related to, but highly divergent from class la and lb genes (reviewed 
by Bahram, 2000). Two of these five genes MICA and MICB encode 
functional molecules and contain a genomic structure in parallel with the 
canonical MHC class I. Studies on human class lc genes have highlighted 
four important differences between MHC class la and lb and the MIC gene 
products. Firstly, expression patterns of MIC genes are different to class la 
and lb genes. MIC expression is high in mucosal tumors, the epithelia of the 
subcapsular thymic cortex, endothelial cells and monocytes and relatively low 
or absent elsewhere (Zwirner et al., 1998). Secondly, MICA and MICB lack 
an ISRE and accordingly, expression of MIC is not induced by interferons 
(Holmes et al., 2002). Thirdly MICA and MICB gene promoters contain a 
region which shares homology to heat shock protein (HSP) gene promoters 
which is absent from classical and non-classical HLA class I promoters. The 
core of this region houses a heat shock response element (HRE) consisting 
of multiple repeats of the pentanucleotide motif 5’GAAn-3’ which is common 
to a number stress-induced genes including the HSP70 gene (Groh et al., 
1996). The function of the HSE of MICA and MICB was demonstrated by 
heat shocking cells; incubation of cells at 42 - 42.5°C results in an increase in 
MIC expression at the mRNA level, suggesting that these genes play a role 
in the cellular response to stress (Groh et al., 1996).
Another characteristic which sets MIC proteins apart from other class I 
proteins is that MIC-A and -B do not bind peptides or require p2- 
microglobulin for correct folding, stability or expression at the cell surface. 
Therefore these genes do not play a role in antigen presentation to CD8+ T 
cells (Groh et al., 2001). Instead they are ligands for the NKG2D receptor 
expressed on NK andyS T-cells. Engagement of MIC with the NKG2D 
receptor induces cytotoxic killing of ceils expressing MIC and therefore 
increased MIC expression cells provides a stress signal to the immune 
system that is distinct to that of MHC class I and II molecules and is 
important in innate immunity for surveillance of virus infected cells or cells 
undergoing tumourogenesis. For example, Groh et al (2001) demonstrated 
that cell surface expression of MIC increases in cells infected with 
cytomegalovirus (CMV), which induced NK mediated lysis of infected cells.
1.3 Structure and functions of MHC class I proteins
1.3.1 Overview of the structure of MHC class I proteins
The MHC class I molecule is a type 1 transmembrane protein 
composed of two polypeptide chains; a 44-49 kDa heavy chain non- 
covalently associated with a 12 kDa light chain, (32-microglobulin (Fruh & 
Yang, 1999). In humans, mice and pigs the heavy chain is encoded by the 
highly polymorphic MHC class I genes whereas the (32-microglobulin gene is 
not MHC-encoded. The heavy chain polypeptide is approximately 350 amino 
acids in length and folds into three distinct extracellular domains a1, a2 and 
a3 plus a transmembrane and cytoplasmic region (Bjorkman etal., 1987),
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Figure 1.3: Structure of MHC class I molecules and the peptide binding 
grove.
Figure A, shows a cartoon of MHC class I at the cell surface. The a1 and a2 
domains of MHC fold together to form a peptide binding grove (peptide shown in 
red). B shows the structure of the peptide binging grove in detail; the structure 
comprises two segmented a helices resting on 8 anti-parallel p strands forming 
a cleft or grove. A peptide bound to the grove is shown in figure C (peptide in 
green) (Bjorkman etal., 1987).
which associate with p2-microglobulin (figure 1.3 A & B). The a1 and a 2  
domains fold together into a single structure comprising two segmented a  
helices resting on 8 antiparallel p strands. This results in the formation of a 
cleft or groove, the peptide-binding region of MHC (figure 1.3 C).
The a1 and a 2  domains of the MHC protein contain the most variation 
in amino acid residues. Variation is concentrated in the amino acids forming 
the extremities of the groove region and the point of contact between MHC 
and the peptide. These variations dictate the nature of the peptide that can 
be bound. By contrast, the a3  region is highly conserved between MHC 
molecules, this is important as this region contains a projection that interacts 
with the cytotoxic T cell CD8 co-receptor (Salter et al., 1989). The light 
chain, p2-microglobulin, is also highly conserved within the individual and 
between species. This region is not directly involved in peptide binding and 
presentation but is essential for maintaining the structural integrity of the 
MHC class I molecule.
1.3.2 Presentation of peptides to T cells
As discussed above, MHC class I molecules bind peptides that are 
derived from cytosolic proteins and display them at the cell surface. These 
peptides can be derived from endogenous (“self) or exogenous (“foreign”) 
sources such as viruses, bacteria and parasites. Exogenous peptides are 
recognised as foreign by CD8+ T lymphocytes that initiate a specific immune 
response that ultimately results in killing of the infected cell, containment of
infection and generation of immunological memory. In comparison MHC 
class II proteins present to CD4+ T lymphocytes which are predominantly T 
helper cells.
The molecular structure of the MHC-antigen complex is arranged such 
that the T cell receptor (TcR) is in contact with both the peptide and some of 
the polymorphic residues of the MHC class I molecule. T cell activation 
requires recognition of both the antigen and the MlHC molecule and is 
therefore said to be ‘MHC restricted.’ In order to prevent cytotoxic killing of 
healthy cells, it is essential that T cells with specificity for 'self antigens are 
eliminated from the T cell repertoire. To prevent this, negative selection by 
endogenous antigen occurs in the thymus.
1.3.3 Requirements of peptides for MHC class I presentation
Efficient peptide presentation by MHC class I depends on a number of 
factors (reviewed in Palmer & Cresswell, 1998). Firstly, antigenic proteins 
must be degraded into peptides of an appropriate length for incorporation into 
the binding groove; 8 to 10 amino acids long. Secondly, peptides must 
contain appropriate amino acid motifs permissible for incorporation into the 
peptide-binding groove of polymorphic MHC molecules. Thirdly, peptide 
generation must be rapid, this is important during viral infections, where viral 
replication may be rapid. In this instance it is essential that peptides are 
presented to the immune system quickly, so that the spread of viral infection 
can be controlled. Some viruses replicate slowly and the amount of viral 
proteins available for degradation may be limited. In such cases protein
degradation must be highly efficient, in order to capitalise on the proteins 
available for presentation to cytotoxic T lymphocytes (CTLs). Most 
importantly, the whole process of antigen presentation and the gene products 
involved need to be inducible, so that under appropriate circumstances such 
as a viral infection, antigen presentation to T cells can be maximised.
1.3.4 The antigen presentation pathway
Intracellular antigen processing pathways determine which peptides 
are available for presentation on MHC class I and are therefore important for 
shaping the immune response. The antigen processing pathway involves 
multiple steps: proteasomal cleavage, transport into the ER, binding to MHC 
molecules and transport of MHC class l/peptide complexes to the cell surface 
(summarised in 1.4 and discussed in detail below). Each step of the pathway 
is a potential target for intervention by viruses. This will be discussed later.
1.3.4.1 Role of the proteasome in cytosolic proteolysis and peptide 
generation.
The proteasome is a barrel shaped cytoplasmic and nuclear organelle 
specialised for the elimination of cellular proteins marked for degradation and 
synthesis of peptides for presentation on MHC class I (Figure 1.4 A). 
Impaired proteasomal function causes a dramatic decrease in MHC class I 
peptide presentation at the cell surface, underlining the important role of this 
organelle in antigen presentation (Kessler et al., 2003). The proteasome is 
made up of a proteolytic chamber, the 20S core subunit, capped at each end 
by a regulatory 19S subunit. The 20S core comprises four stacked rings,
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Figure 1.4: Summary of the MHC class I presentation pathway.
Proteins are degraded by the proteasome into peptides of various lengths (A). 
Most importantly for MHC class I presentation, peptides of 9-12 amino acids in 
length are produced. These peptides are translocated into the ER lumen by a 
specialised pump, the transporter associated with antigen presentation (TAP)
(B). Newly synthesised MHC class I heavy chains are also transported into the 
ER lumen where they bind to calnexin, (32-microgloulin and ERp57. Calnexin 
disassociates from the complex and is substituted by calreticulin and together 
these proteins are known as the peptide loading complex (C). The peptide 
loading complex associates with TAP and peptides are loaded into the binding 
groove of the heavy chain, an interaction that requires the ER chaperone tapasin 
(D). The MHC class I is now fully assembled. MHC class I leave the ER and 
are transported via the trans-golgi network to the cell surface where they are 
displayed to circulating CD8+ T cells (E). Adapted from Palmer & Cresswell 
(1998).
each containing seven subunits. Active sites for proteolysis are located on 
the internal surfaces of the two innermost rings of the chamber and 
preferentially bind acidic, basic or hydrophilic residues within target proteins. 
The 19S subunits regulate proteolysis by guarding the entrance of the 
proteasome and preventing non-specific degradation of cytosolic proteins. 
They are composed of a ring of a  subunits forming an axial channel which is 
able to control the influx and efflux of proteins by regulating the opening and 
closing of the entrance of the proteolytic chambers. The 19S subunits also 
contain six ATPases which unravel incoming proteins and feed them into the 
20S core (Braun et al., 1999). The speed and efficiency of peptide 
generation must be increased during viral infections, this is mediated by 
interferon gamma which induces the expression of genes encoding three 
additional proteasome subunits LMP-2, LMP-7 and MECL-1. These subunits 
are incorporated into the proteasome generating an “immunoproteasome” 
with enhanced peptide production capability (Aki et al., 1994).
In order to prevent non-specific degradation of cellular proteins, 
several mechanisms exist that regulate degradation and targeting of proteins 
to the proteasome. Most commonly, proteins destined for destruction are 
tagged with ubiquitin, this involves conjugation of ubiquitin to lysine residues 
within the target protein sequence. Alternatively, the inherent nature of a 
protein can predispose it to rapid degradation; proteins containing regions 
rich in proline (P), glutamic acid (E), serine (S) and threonine (PEST 
sequences) are rapidly degraded and have shorter half lives than proteins 
lacking such sequences (Gromme & Neefjes, 2002). In addition, some
proteins contain ‘destruction boxes’ these are sequences that dictate 
degradation at specific points in the cell cycle, cyclin is the classic example of 
such a protein (Bastians et al., 1999). The identity of the N-teminal amino 
acid of a protein also determines the rate of degradation. Proteins with N- 
terminal argenine are destabilised and rapidly degraded whereas methionine 
at this position stabilises proteins, this phenomenon is referred to as the N- 
end rule (Stryer, 2001).
As well as presenting peptides derived from proteins targeted for 
degradation, MHC class I presents peptides derived from metabolically stable 
proteins as well as peptides from proteins which are contained within sub- 
cellular compartments. The mechanism by which the proteasome has 
access to such proteins could not be explained until Schubert et al. (2000) 
proposed that peptides from metabolically stable or compartmentalised 
proteins are actually derived from defective ribosomal products (DriPs) 
produced during translation. Polyribosomes are fairly inefficient and 
frequently make translational errors resulting in the synthesis of proteins that 
contain errors or are incorrectly folded. Erroneous proteins are targeted to 
the proteasome for degradation and misfolded proteins are retrotranslocated 
from the ER through the translocon into the cytoplasm for degradation into 
peptides (Huppa & Ploegh, 1997).
1.3.4.2 Peptide trimming
Despite the proteasome being specialised for protein degradation it 
transpires that the generation of peptides compatible with MHC class I
binding is a relatively inefficient process. The proteasome produces peptide 
products that range between 3 and 22 amino acids in length, with around two 
thirds of these products being too short for MHC binding and a large 
proportion requiring further processing before being compatible with the MHC 
binding groove (Kisselev et al., 1999). Peptides that are longer than 15 
amino acids in length require trimming, this is carried out by cytoplasmic 
aminopeptidase tripeptidyl peptidase II (TPPII) and subsequently by 
cytoplasmic aminopeptidases such as leucine aminopeptidase (LAP) and 
thimet oligopeptidase (TOP) (Reits et al., 2004). Some oversized peptides 
are trimmed in the ER by the ER-associated aminopeptidases ERAAP and 
ERAP1 (Saric et al., 2002; Serwold et al., 2002). Most peptides will be 
completely degraded into single amino acids by these peptidases, however, 
those which escape complete degradation may enter the MHC class I 
presentation pathway. In common with proteosomal degradation, the speed 
of digestion by aminopeptidases is increased by interferon (Reits et al., 
2004).
1.3.4.3 Translocation of peptides into the ER
Peptides must be transported into the lumen of the endoplasmic 
reticulum (ER) for loading onto MHC class I molecules. Targeting of proteins 
to the ER normally requires signal sequences however, in the case of 
peptides, this process is mediated by a specialised pump; the transporter 
associated with antigen processing (TAP) (figure 1.4 B). The TAP pump is a 
heterodimer of TAP-1 and TAP-2 proteins integrated into the luminal 
membrane of the ER which fold together to form an extra-luminal peptide
binding domain and a pore through which peptides translocate in an ATP- 
dependant manner (Reits et al., 2000). In common with the proteosomal 
proteins LMP-2 and -7, the genes that encode TAP-1 and -2 are encoded 
within the MHC of humans and pigs and their expression is induced by 
interferons (Fisk et al., 1994).
1.3.4.4 Folding of MHC class I heavy and light chains -  the peptide loading 
complex.
Correct assembly of MHC class I molecules and binding of peptides 
requires the co-operative action of several accessory molecules and 
chaperones collectively known as the peptide loading complex (PLC) which 
includes; TAP1 and TAP2, tapasin, calreticulin and ERp57. Newly 
synthesised MHC class I heavy chains are transported into the ER where 
they bind calnexin. Subsequent binding of p2-microglobulin is simultaneous 
with release of the MHC class I heavy chain, substitution of calnexin with 
calreticulin and recruitment of ERp57 (Lehner & Cresswell, 2004) (figure 1.4 
C). Together calreticulin and ERp57 are an ER quality control mechanism 
that regulates correct folding of class I glycoproteins and ensures that 
incorrectly folded complexes are not transported to the cell surface. 
Calreticulin monitors the glycosylation status of MHC class I ensuring that 
immature heavy chains are not incorporated into the PLC. Finally, the ER 
chaperone tapasin binds to the a2  and a3  domains of MHC and to the TAP 
transporter, this interaction enables peptides to be loaded onto class I heavy 
chains and signifies the completion of MHC class I assembly (Sadasivan et 
al., 1996). MHC class I proteins are then released from the PLC, exit the ER
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and are transported, via the golgi, to the cell surface where they are 
displayed to CD8+ T cells (figure 1.4 E).
1.3.5 MHC class i molecules are ligands for NK cell receptors
In addition to recognition by CTLs, MHC class I proteins are 
recognised by Natural Killer (NK) cells and play an important role in innate 
immunity. NK cells are a heterogeneous population of bone marrow derived 
lymphocytes that are instrumental in the innate response against pathogens. 
They were first described as cells which could specifically recognise and kill 
tumour cells (Herberman et al., 1975). We now know that their primary 
functions are (i) cytotoxicity; to seek out and destroy virally infected or tumour 
cells and (ii) cytokine production; to secrete IFN-y.
NK cells recognise aberrant MHC class I expression. This is vital for 
recognition of tumour cells and during viral infections when class I expression 
may be down regulated, a phenomenon known as "missing self” (Ljunggren 
& Karre, 2002). It is important to note that NK cell killing is not by default 
when MHC expression is absent, since erythrocytes that do not express 
MHC are not targeted. A more appropriate description for targets of NK 
cytoxicity is “altered” or “stressed self.” The importance of NK cell 
recognition of MHC is reflected by the identification of several classes of 
genes encoding MHC receptors in several mammalian species. Interestingly, 
the function of MHC recognition by NK receptors appears to have evolved 
independently in different mammalian species; comparative studies of NK
genes sharing similar functions in different species are too distantly related to 
have a common ancestor (Parham, 2005).
1.3.6 Regulation of NK cell activity by inhibitory and activating 
receptors
NK cell activity is tightly regulated by the interactions of inhibitory and 
activating receptors on the surface of NK cells with receptors expressed on 
target cells, including two families of receptors that interact with MHC. The 
first are the Killer Immunoglobulin like receptors (KIR) in humans (section 
1.3.7) and c-type lectin like receptors (Ly49) in rodents (section 1.3.8). The 
second are heterodimers of CD94 and members of the NK group 2A family 
(section 1.3.9). Each family includes activating and inhibitory forms of 
receptor, dictated by the presence of immunoreceptor tyrosine-based 
activation or inhibitory motifs "ITAM" or “ITIM” motifs in the cytoplasmic 
regions. ITAM and ITIM motifs mediate their effects via distinct biochemical 
pathways, summarised in figure 1.5. Inhibitory receptors such as KIR2DL 
contain one or more ITIM motif [(HeA/al/Leu/Ser)-X-Tyr-XX-(LeuA/a!) where x 
denotes any amino acid] (Lanier, 2003). Upon engagement of an inhibitory 
receptor with an MHC ligand the ITIM motif is phosphorylated and Src- 
homology (SH) containing phosphatases are recruited. These phosphatases 
inhibit NK cell activation by counteracting ‘activation’ signals, the exact 
mechanisms that mediate this effect are not fully understood. It is important 
to note that inhibitory receptors do not globally repress NK cell activation, 
rather it is the balance between activating and inhibitory signals that dictate 
the nature of the response generated.
KIR2DS 
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Figure 1.5: Activating and inhibitory signals mediated by ITAM and ITIM 
motifs upon NK receptor-MHC engagement.
This figure shows NK cell receptors that interact with MHC class I (blue), their 
associated adaptor molecules (green) and the mechanism by which they initiate 
and inhibitory or activating signal. Inhibitory receptors contain im mu noreceptor 
tyrosine-based inhibition motifs (ITIM) in the cytoplasmic domain 
[(lle/Val/Leu/Ser)-X-Tyr-XX-(Leu/Val) where x denotes any amino acid, shown 
in blue]. Upon engagement of an MHC class I ligand, ITIM motifs are 
phosphorylated by Src-homology containing phospatases (SHP), resulting in an 
inhibitory signal (left panel). The DAP adaptor molecules associated with 
activating receptors contain immunoreceptor tyrosine-based activation motifs 
(ITAM) [YxxL/lx6-8YxxL/l or YxxM (where x is any amino acid), shown in red]). 
The activating receptors KIR2DS, NKG2C, -E and -H  (centre panel) associate 
with DAP12 (centre panel). Upon engagement with MHC class I ligands, 
protein tyrosine kinases of the Src family are activated and phosphorylate 
tyrosine residues of the DAP12 ITAM leading to recruitment and activation of 
the tyrosine kinases Zap70 or Syk. NKG2D associates with DAP10 (right 
panel). Interaction of this receptor with class lc ligands results in 
phosphorylation of the DAP10 ITAM by phosphatidylinositol-3 kinase (PI3 
kinase) and activation of NK cell activity. Adapted from Lanier, 2003.
NKG2D
In the case of activating receptors, ITAM motifs contain at least one 
activation motif (YxxL/lx6-8YxxL/l where x is any amino acid) with one 
exception, the adaptor molecule DAP10, which contains an YxxM motif. 
Engagement of activating receptors with their corresponding ligands 
activates protein tyrosine kinases of the Src family which phosphorylate 
ITAMs on tandem tyrosine residues. This leads to the recruitment and 
activation of the tyrosine kinases Zap70 and Syk. In the case of NKG2D 
(section 1.3.10), phosphorylation of the ITAM motif of the adapter molecule 
DAP10 causes recruitment and activation of phosphatidylinositol-3 kinase 
(PI3 kinase) (Lanier, 2003). In addition, an alternative (short form) transcript 
of NKG2D is expressed in activated NK cells which can associate with 
DAP10 and DAP12 (Diefenbach et al., 2002). This means that under 
appropriate circumstances, NKG2D can stimulate both signal transduction 
pathways representing both stimulation and co-stimulation by the same 
receptor.
1.3.7 Killer Immunoglobulin like receptors (KIR) and MHC class I
KIRs are members of the immunoglobulin (Ig) superfamily, expressed 
on NK cells and a subset of T cells. The KIR receptors vary in the number of 
extracellular Ig domains (two or three) and the length of their cytoplasmic 
tails (long or short). Long cytoplasmic domains contain ITIMs and are 
inhibitory receptors; short cytoplasmic domains lack ITIMs and are activating 
receptors. KIRs interact with the a1 and a2 domains of a number of classical 
and non-classical HLA class I molecules. The interactions between KIR 
receptors and their respective class I ligands are summarised in figure 1.6.
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Figure 1.6: HLA class I alleles are inhibitory ligands for NK killer 
immunoglobulin receptors (KIRs).
In the human, classical and non-classical MHC class I are recognised by 
specific members of the killer immunglobulin-like (KIR) family of receptors. KIRs 
contain up to three extracellular domains (blue circles) and four immunoreceptor 
tyrosine-based activation motifs (red squares). This figure shows individual KIR 
receptors and their HLA class I ligand. Engagement of KIR/HLA provides an 
inhibitory signal which blocks NK cytotoxicity (Moretta et al., 1996).
KIR3DL2 recognises HLA-A3, KIR3DL1 recognises HLA-Bw4 and the 
KIR2DL subfamily recognises distinct groups of HLA-C alleles (Dohring et al., 
1996, Gumperz et al., 1995, Moretta et al., 1996). In addition, KIR2DL4 has 
been shown to bind HLA-G, although there is conflicting data suggesting that 
HLA-G is the ligand for ILT2 and ILT4 rather than KIR2DL4 (Allan et al., 
1999; Navarro etal., 1999, Rajagopalan & Long, 1999).
1.3.8 Leucocyte immunoglobulin-like receptors (LIR or ILT)
The LIR are a family of 13 Immunoglobulin-like receptors. 
Predominantly expressed on B and T cells, some members of this group are 
expressed on NK cells. LIR-1 has four extracellular domains and four ITIMs 
within the cytoplasmic domain and is a receptor for classical HLA molecules 
as well as the non-classical molecule HLA-G (Gonen-Gross et al., 2003). 
LIR-1 recognises the highly conserved a3 domain of HLA-class I which may 
explain its broad reactivity for classical and non-ciassical HLA class I. LIRs 
also recognises UL16 binding proteins (ULBP) and the human 
cytomegalovirus virus MHC class I homologue UL18 (reviewed by Radaev et 
al., 2002). Interestingly LIR-1 has a higher affinity for UL18 than for HLA 
class I and since CMV down-regulates MHC class I expression, UL18 may 
be important for avoiding NK cell recognition of virus infected cells (Chapman 
etal., 1999).
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1.3.9 Murine Ly49 and MHC class I
Ly49 are a polymorphic family of 9 inhibitory receptor genes (LyA-l) 
encoded on the mouse NK complex. Ly49 homologues have been identified 
in the rat (Dissen et al., 1996), and in the pig (Gagnier et al., 2003) but are 
absent in humans. These receptors are type II transmembrane glycoproteins 
and are expressed as homodimers at the cell surface. In common with other 
members of the c-type lectin superfamily, the extracellular region of Ly49 
contains carbohydrate recognition domains and it is through these domains 
that Ly49 recognise the a1 and a2 domains of murine MHC class I 
molecules. This interaction is dependent upon association of p2- 
microglobulin (Lanier, 1998).
1.3.10 NKG2 family
The NKG2 family (NKG2A-F) are c-type lectins encoded on 
chromosome 12 of the human and 6 of the mouse. The family includes both 
activating and inhibitory receptors. NKG2 are expressed at the cell surface 
as heterodimers with the invariant chain CD94, with the exception of NKG2D 
that is expressed as a homodimer in association with the adaptor protein 
DAP10. NKG2A, -B  and -C  are inhibitory receptors that recognise the non- 
classical MHC molecule HLA-E (Posch et al., 1998). In the mouse NKG2A 
recognises the non-classical MHC class I Qa-1 (Vance et al., 1998). HLA-E 
and Qa1 are unusual in that they bind and present signal peptides derived 
from the leader sequences of MHC class I heavy chains, therefore monitoring 
these MHC molecules is used to measure “normal” class I expression.
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NKG2D is a divergent member of the c-type lectin-like family of NK 
receptors and shares only 20 to 30 % homology with other members of the 
NKG2 family. It is an activating receptor expressed on NK cells, CD8+ap T 
cells and CD8+y5 T cells as a homodimer in association with the adaptor 
molecule DAP10. The ligands for NKG2D in the human are the stress- 
inducible MHC class I chain related proteins MICA and MICB and the 
Cytomegalovirus encoded UL16 binding proteins (ULBP) (Bauer et al., 1999; 
Cosman et al., 2001). In the mouse, ligands for NKG2D are the retinoic acid 
early inducible gene (Rae1) and H60 (Cerwenka et al., 2000; Diefenbach et 
al., 2000). Expression of MIC, Rae-1 and H60 is usually restricted to tumour 
cells, suggesting a specialised role for NKG2D in tumour recognition. 
Recently, a single porcine UL16 binding protein (PULBP) was identified that, 
with the exception of the brain, is ubiquitously expressed (Garcia-Borges et 
al., 2005). Increased expression of PULBP is induced by retinoic acid and 
heat stress. PULBP does not bind human NKG2D, presumably because of 
the cross species difference between pig and human NKG2D, and its 
interaction with porcine NKG2D has not been confirmed.
1.4 Regulation of MHC class I expression by cytokines and 
transcription factors.
Given the pivotal role of MHC in the immune system, it is vital that the 
transcription and expression of MHC class I gene expression is tightly 
regulated and can be induced under appropriate circumstances, such as 
during a viral infection. Over the past two decades the mechanisms by which 
cellular factors such as cytokines and transcription factors regulate MHC
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class I expression have been unravelled. Focus will now be placed on the 
cytokines that orchestrate class I transcription, the transcription factors that 
these cytokines induce and subsequently how these transcription factors 
interact with the MFiC class I promoter to direct transcription. For simplicity, 
this section will consider the human MHC class I promoters.
1.4.1 Interferon
Interferons were first described as a substance which protected cells
against viral infection (Isaacs & Lindenmann, 1957). Following intensive
investigation since their discovery, the interferon family of cytokines are now
recognised as major components of innate and adaptive immune responses,
of particular importance during viral infections. Upon interaction with their
receptor, IFNs stimulate the expression of a variety of interferon sensitive
genes (ISGs) which, among other effects, culminates in the induction of the
I
‘anti-viral state’ where viral replication and protein synthesis are inhibited. 
Most importantly for this study, interferon stimulation induces the expression 
and activation of interferon regulatory factors, which bind the ISRE of MHC 
class I genes, stimulating transcription. During a viral infection, increasing 
surface class I expression facilitates immune surveillance of foreign peptides 
by CD8+ T cells, promoting cytotoxic killing of virus infected cells. As well as 
inducing the transcription of MHC class I heavy chains, interferon induces the 
expression of p2-microglobulin, peptide transporters, chaperones and the 
proteosomal subunits essential for the maturation of newly synthesised class 
I molecules. The IFN families, the induction of IFN gene expression by viral
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factors and how IFN signalling pathways culminate in inducing MHC class I 
gene transcription will now be discussed.
There are two types of interferon, type I and type II, which interact with 
different cellular receptors to initiate both distinct and overlapping 
biochemical pathways. Type I IFNs are produced by most cells, are induced 
by viral infection and include the extensively studied IFN-a and IFN-p. IFN-a 
is a family of at least 12 members. Each IFN-a species appears to have a 
distinct profile of biological activities, for example some are more potent 
stimulators of NK and T cell activity whereas others seem to be more 
important as antiviral and antiproliferative agents (Bogdan et al., 2004). 
Several other type I IFNs have been identified including IFN-e and IFN-k 
(humans and mice), IFN-co (humans), IFN-x (sheep). IFN-5 (pigs) and limitin 
(mice) [reviewed by (Pestka et al., 2004)]. Recently, a new family of 
interferon-like cytokines have been discovered in humans: IFN-A.1, IFN-^2 
and IFN-^3 (also known as IL-28, IL-28B and IL-29 respectively) (Kotenko et 
al., 2003). Like type I IFNs, IL-28 and -29 induce an antiviral state in cells 
and induce gene transcription through ISRE motifs, however, in contrast to 
type I IFNs these cytokines do not appear to have antiproliferative effects 
(Kotenko etal., 2003; Sheppard et al., 2003).
Type II interferon is IFN-y. It was first described as an interferon-like 
virus inhibitor produced by mitogen stimulated lymphocytes (Wheelock, 
1965). In general, IFN-y secretion is restricted to specialised cells of the
immune system including activated NK cells, macrophages and effector T 
cells although low level production of IFN-y has been detected in non- 
immune cells such as fibroblasts and erythroid cells (Rady et al., 1995). IFN- 
y is a potent activator of macrophages and induces a TH1 response by 
inducing differentiation of naive T cells into Th1 helper cells and inhibiting 
proliferation of TH2 cells.
1.4.1.1 Induction of type I interferon during viral infections
Type I IFNs are rapidly produced during a viral infection when viral 
factors such as envelope glycoproteins, CpG DNA, double stranded RNA 
(dsRNA) and single stranded RNA are recognised by cellular pattern 
recognition receptors, namely the toll-like receptors (TLRs) and the mannose 
receptor (MR). These receptors are important on a range of cell types 
including antigen presenting cells and have been shown to bind to a variety 
of ligands enabling recognition of a wide selection of pathogens. During a 
viral infection, the MR and TLRs each recognise distinct intermediates of viral 
replication and initiate a series of cell signalling cascades which activate the 
transcription factors ATF2, c-JUN, IRF-3 and NF-kB. All of the TLRs studied 
to date have been shown to induce NF-kB activation in response to viral 
stimuli via signalling cascades that require adaptor proteins, of which MYD88 
is the most well understood example (see figure 1.7 for details). By contrast, 
IRF-3 activation appears to be restricted to TLR3 in viral infections and TLR4 
in bacterial infections (Bowie & Haga, 2005). In both cases, activated 
transcription factors translocate to the nucleus and bind to promoter regions 
of IFN -a and -p  genes, inducing transcription (Figure 1.7).
This figure shows a summary of the viral factors recognised by individual Toll 
like receptors (TLRs) and the mannose receptor (MR) and how the transcription 
of type I interferons is induced by activation of the transcription factors IRF-3 
ATF-2/c-Jun and NF-kB (reviewed by Takeda and Akiras, 2005; Moynagh, 
2005). PKR and TLR3 recognise dsRNA. The dsDNA-dependant protein kinase 
(PKR) (green ovals) recognises dsRNA (Alexopoulou et al., 2001). When TLR3 
binds dsRNA, TRAF-6, TAK1 and TAB2 (solid gold) form a complex which 
translocates into the cytosol and interacts with PKR resulting in phosphorylation 
of the TAK1 subunit. TAK1 then activates IKK and MKK6, which in turn activate 
NF-kB and MAP kinase (Tabeta et al., 2004). In addition, ATF/c-Jun, IRF-3 and 
NF-kB are activated by TLR3 signalling, these pathways are not shown but 
commonly involve the recruitment of adaptor proteins such as MYD88 (purple 
square) and activation of IRAK. TLR9 and TLR7 recognise viral DNA in 
intracellular endosomal compartments (Heil et al., 2004). TLR9 recognises CpG 
dsDNA. TLR7 recognises ssRNA (Lund et al., 2003). The MR recognises 
terminal mannose and fucose groups on viral glycoproteins (Milone & 
Fitzgerald-Bocarsly, 1998).
In response to TLR or MR signalling signalling, IRF-3 forms homodimers, ATF- 
2 forms a heterodimer with c-Jun and the regulatory subunit of NF-kB ,IkBcx, is 
lost. These activated transcription factors translocate to the nucleus and bind 
the promoter regions of type 1 IFN genes. Transcription of the IFN-p promoter 
is induced when ATF2/c-Jun complexes bind the PRDIV region, IRF-3 binds the 
ISRE motif within the PRDIII region and NF-kB bind the kB motifs within the 
PRDII region. IFN-a1 transcription is induced when IRF-3 binds the ISRE motif.
Figure 1.7: Induction of type i IFNs during a viral infection
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Figure 1.7: Induction of type I IFNs during a viral infection
Both TLR3 and the dsRNA-dependant protein kinase (PKR) recognise 
dsRNA. Viruses produce dsRNA during replication as an intermediate in 
RNA synthesis (RNA viruses) or as a by-product of symmetrical transcription 
of DNA virus genomes. Interestingly, PKR knockout mice can still induce IFN 
in response to synthetic analogue of dsRNA, poly(l:C) (Goh et al., 2000). 
This observation lead to the search for additional receptors that recognise 
dsRNA and subsequently, Alexopoulou et al. (2001) identified TLR3, which 
binds dsRNA and induces the activation of NF-kB and IRF-3. This research 
group also used a series of dominant negative signalling components to 
demonstrate that the IL-1 receptor-associated kinase (IRAK) and TRAF6 
mediate TLR3 signalling. A direct link between TLR3 and viral dsRNA was 
finally demonstrated by Tabeta et al. (2004) using TLR3 -/- mice in which 
TLR3 was shown to contribute to type I IFN production in response to murine 
CMV infection.
Both TLR9 and TLR7 recognise DNA sequences contained within 
intracellular endosomal compartments. TLR9 recognises DNA sequences 
containing unmethylated CpG dinucleotides released from endocytosed 
viruses (Lund et al., 2003) and induces type I IFN via a MYD88-dependent 
pathway. TLR7 (mouse) and TLR8 (human) recognise GU-rich ssRNA in 
endosomal compartments (Heil et al., 2004). Since TLRs 7, 8 and 9 can also 
recognise host DNA in vitro, it is assumed that their function is to recognise 
abnormal localisation of nucleic acids rather than ‘non-self sequences or 
motifs. To put this point into context, host DNA is rareiy contained within
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endosomal compartments, whereas many viruses enter cells by hijacking 
cellular receptor mediated endocytosis and releasing DNA into endosomes.
Mannose receptors (MR), expressed on natural interferon producing 
cells (NIPC), bind to glycosylated viral envelope proteins and mediate IFN 
synthesis (Milone & Fitzgerald-Bocarsly, 1998). Studies using viruses 
containing mutated N-linked glycosylation sites and viruses treated with 
glycosylase enzymes demonstrated that correct glycosylation of envelope 
proteins is required for recognition by the MR (Charley et al., 1991; Laude et 
al., 1992). Fluman glycoproteins typically contain N-acetylglucosamine and 
sialic acid groups and therefore the MR can differentiate between self and 
non-self glycoproteins.
1.4.1.2 Induction of IFN-D
As previously discussed, the majority of IFN-y produced originates 
from activated immune effector cells. In common with the IFN-a and -p  
genes, the IFN-y gene contains complex arrangement of positive and 
negative regulatory elements that bind transcription factors in a co-operative 
manner and orchestrate the transcriptional activation of this gene. Among 
these transcription factors are NF-kB, members of the nuclear factor 
activating transcription factor (NFAT) family (Sica et al., 1997), signal 
transducer and activator of transcription (STAT), T-bet (Szabo et al., 2000), 
AP-1, CREB-ATF, GATA-3 and yin-yang (Ye etal., 1996).
1.4.1.3 IFNs induce the transcription of ISGs - the ‘delayed’ response
Following transcription, secreted IFN can have an autocrine effect, 
acting on the secreting cell or a paracrine effect, stimulating neighbouring 
cells and thus preventing viral replication and further spread of the virus. In 
both cases, IFNs binds to specific cellular receptors: IFN-a and IFN-(3 bind 
IFNAR-1 and IFNAR-2 and IFN-y binds IFNGR-1 and IFNGR-2. Receptor 
binding initiates signal transduction cascades involving the Janus activated 
kinases (JAKs) and members of the signal transducer and activator of 
transcription (STAT) family transcription factors. JAKs phosphorylate 
tyrosine residues of STATs which then form hetero or homodimers, 
translocate to the nucleus and bind the regulatory promoter elements of IFN 
sensitive genes. STATs drive the transcription of an array of genes, many of 
which encode transcription factors and proteins with anti-viral properties. 
Most importantly for this study, IFNs induce the activation of members of 
interferon regulatory factor (IRF) family of transcription factors and NF-kB, 
which in turn induce the transcription and expression of MHC class I.
1.4.2 The Interferon regulatory factor (IRF) family of transcription 
factors
IRFs are a family of seven transcription factors that are activated in 
response to IFNs and viral infections and induce the expression of IFN 
inducible genes including MHC class I. IRFs mediate diverse transcriptional 
responses to IFN stimulation that depend on the cell type, interactions with 
other transcription factors and post-translationai modifications of the IRF 
involved. Some IRFs are transcriptional inducers while others have been
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shown to be transcriptional repressors. Characteristically, each IRF contains 
a 155 amino acid DNA binding domain comprising five repeated tryptophan 
residues and it is through this motif that they bind the ISREs of IFN sensitive 
genes. In humans, IRF-1, -2, -3 -7 and -9 bind the consensus sequence G/A 
G/C TTTC of HLA class I promoters (Chang et al., 1992; Drew et al., 1995b; 
Drew et al., 1995a; Massa & Wu, 1995; Gobin & van den Elsen, 2000; 
Lefebvre et al., 2001).
IRF1 and IRF-2 were the first members of the IRFs to be 
characterised. They are constitutively expressed at low levels in most cell 
types and their expression and activation is induced by protein kinase A 
(PKA), protein kinase C (PKC) or casein kinase II which in turn are induced 
by IFN-a, -p, -y , TNF-a and interleukin -1 and -6. Upon activation IRF-1 is a 
transcriptional activator. It binds the ISRE of HLA-A, -B, -C  and -F promoters 
and the distal ISRE of the HLA-G promoter driving transcription in response 
to IFN-y stimulation (van den Elsen et al., 2004). IRF-1 can induce 
transcription in co-operation with other transcription factors; following co­
stimulation with TN F-a and type 1 IFNs it forms a complex with NF-kB and 
mediates synergistic induction of class I expression (Drew et al., 1995b; 
Johnson, 2003). . In addition to HLA class I genes, IRF-1 induces the 
transcription of TAP1 and LMP2, demonstrating the importance of this 
transcription factor in global regulation of antigen presentation (White et al.,
1996).
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IRF-2 competes for ISRE binding sites with IRF-1 and was first 
described as a transcriptional repressor of the IFN-p gene (Harada et al.,
1989). We now know that IRF-2 is a transcriptional repressor of a variety of 
ISGs and has been shown to bind the ISRE of HLA-A, -B -C  and -F  and 
repress transcription (Gobin et al., 1999). It transpires that IRF-2 can also 
function as a transcriptional activator and has been shown to induce the 
transcription of a functionally diverse group of genes including vascular cell 
adhesion molecule -1 (VCAM-1), the human histone 4 gene and the MHC 
class II transactivator (ClITA) (Jesse et al., 1998, Masumi et al., 2003, Xi & 
Blanck, 2003 ). Induction of CIITA is not only unusual because this gene is 
actually an ISG, which are usually repressed by IRF-2, but also because in 
this instance IRF-2 co-operates with IRF-1 to facilitate CIITA transcription (Xi 
& Blanck, 2003).
IRF-3 is particularly important in the immediate, early response to 
dsRNA and the induction of IFNs during viral infections. It expressed 
constitutively and becomes activated during a viral infection when dsRNA is 
detected by TLR3, -4 and PKR as described above (Au et al., 1995). 
Phosphorylated IRF-3 translocates to the nucleus where it can bind to and 
induce transcription of ISGs including the cytokines IFN-a, IFN-p (reviewed in 
Malmgaard, 2004) and Regulated on Activation Normal T-cell Expressed and 
Secreted (RANTES) (Lin et al., 1999). Direct binding of IRF-3 to HLA 
promoters has not been described in the literature but is assumed, given the 
homology of the IRF-3 binding domain to that of IRF-1 and -2.
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IRF-7 is only constitutively expressed at low levels in lymphoid tissues 
but becomes expressed at high levels and activated by phosphorylation 
following IFN stimulation (Zhang & Pagano 2002). Activated IRF-7 can either 
form a homodimer or a heterodimer with IRF-3. IRF-7/3 heterodimers are 
important in the delayed response to viral infection where they provide 
positive feedback and potentate IFN induction. IRF-9 is constitutively 
expressed in an inactive form and lacks the intrinsic ability to induce 
transcriptional responses as a mono- or homo-dimer. However, IFN 
signalling induces this transcription factor to form a heterotrimeric complex 
with STAT1 and STAT2, called ISGF3y which binds to the promoters of ISGs 
(Kraus et al., 2003).
1.4.3 Nuclear Factor kappa B
Nuclear factor kappa B (NF-kB) is considered to be a central mediator 
of cellular stress responses because of the diversity of the signals that 
activate it and the genes that it regulates. It was first identified in B 
lymphocytes as a nuclear transcription factor that binds to a 10 bp DNA 
element in the kappa immunoglobulin light-chain promoter enhancer motif 
(Sen et al., 1986). We now know it modulates the expression of a spectrum 
of genes involved in cell adhesion, cell proliferation, apoptosis, cell migration, 
angiogenesis and the immune response where it activates transcription of 
cytokines, chemokines, interleukins, immunoglobulins, acute phase proteins 
and MHC class I genes. Of particular relevance to this study is the activation
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of NF-kB by the cytokine tumour necrosis factor alpha (TNF-a) and by TLR 
signalling during a viral infection (described above).
Five distinct NF-k B subunits have been identified including NF-k B1 
(p50/p105), NF-k B2 (p52/p100), Re IA (p65), RelB, and c-Rel. NF-k B1 and 
NF-k B2 undergo proteolytic processing to liberate p50 and p52, respectively. 
Each NF-k B subunit contains a conserved 300 amino acid domain, called the 
rel homology domain (RFID), which is responsible for subunit dimerisation as 
well as DNA binding. In resting cells, inactive NF-k B homo- or heterodimers 
are constitutively present in the cytoplasm with Ik B, the intracellular inhibitor 
of NF-k B. Upon activation by cytokines Ik B is inactivated and degraded 
releasing NF-k B, which translocate to the nucleus where it binds promoter 
regions containing the k B motif GGGGATTCCCC. Classical FILA class I 
promoters contain two k B motifs within the Enhancer A region: k B1 and k B2. 
Gobin et al., (1998) tested these motifs in classical and non-classical 
promoters for transcription factor binding and activation, using HLA class I k B 
sequences to drive the expression of a luciferase reporter. In HLA-A, both 
k B sites bind to p65, p50 and c-Rel subunits of NF-k B and co-transfection of 
NF-k B strongly induced luciferase activity driven by the HLA-A Enhancer A 
region. By contrast, only the k B1 site of HLA-B binds NF-k B and 
accordingly, transactivation by NF-k B was weaker than for HLA-A, 
demonstrating locus specific activation by this transcription factor. Neither of 
the k B sites of HLA-C bind, or are induced by NF-k B, although an alternative 
transcription factor Sp1 was shown to bind this region. The non-classical
HLA are also differentially transactivated by NF-k B. The k B1 site, but not 
k B2, of HLA-F binds p50 and p65 and the k B sites of HLA-E do not bind any 
NF-k B species. The k B sites of HLA-G, the most divergent of all HLA class I, 
only bound p50 homodimers. None of these genes were transactivated by 
NF-k B in co-transfection studies. The locus-specific variation in NF-k B 
mediated regulation of HLA correlates to nucleotide differences in k B motifs 
and explains in part, different constitutive and cytokine-induced levels of 
classical and non-classical HLA expression. More recently, a putative k B site 
in the promoter region of MICA was shown to bind p50 and p65 homo-dimers 
and mediate an increase in MICA mRNA in activated T-lymphocytes 
following inhibition of Ik B (Molinero et al., 2004).
1.4.4 The SXY region and the MHC class I enhanceosome
The SXY module of MHC class I promoters consists of four regulatory 
elements namely the S (or W) box, the X1 and X2 boxes and the Y box which 
are co-operatively bound by a multi-protein complex which functions as an 
enhanceosome and drives transcription of class I (and class II) genes. The 
enhanceosome comprises; regulatory factor X5 (RFX5), RFXB and RFXAP, 
collectively known as regulatory factor X (RFX), cyclic AMP response 
element binding protein (CREB)/activating transcription factor (ATF) and 
nuclear factor Y (reviewed by van den Elsen et al., 2004). These 
transcription factors are collectively known as the MHC class I 
enhanceosome. An additional transcription factor, the MHC class II 
transactivator (CIITA) also directs MHC class I transcription via the SXY
module. Cl ITA was first described as a transcription factor required for 
constitutive and IFN-y induced expression of MHC class II, however it 
transpires that it can also transactivate MHC class I genes (Martin et al.,
1997). Cl ITA does not bind directly to promoter DNA sequences. It interacts 
with RFX/CREB/NFY transcription factors bound to the SX Y  box region of the 
class I and class II promoters. The crucial importance of the SXY module in 
MHC class I and II transactivation is demonstrated in patients lacking one of 
the RFX subunits or Cl ITA, who suffer from a severe combined 
immunodeficiency called Bare Lymphocyte Syndrome (BLS), in which 
patients completely lack expression of MHC class II and have reduced levels 
of expression of MHC class I (Reith & Mach, 2001).
1.4.5 Summary of Human MHC class I promoter regulation
MHC class I expression in humans is regulated by the interaction of 
transcription factors with regulatory motifs within the promoters of MHC class 
I genes. These mechanisms of transcriptional regulation provide a model for 
comparative studies of porcine MHC class I regulation. Our current 
understanding of transcription factor-promoter interactions in the human is 
summarised in Figure 1.8. The key motifs in class I promoters that regulate 
transcription are; an Enhancer A which binds NF-kB, an ISRE which binds 
members of the interferon regulatory factor (IRF) family of transcription 
factors (shown in the figure 1.8 as IRF-1 for simplicity) and an SXY domain 
which binds RFX/CREB/NFY and CIITA. Overall, the expression of classical 
class I genes is (HLA-A-B and -C) is regulated by these transcription
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Figure 1.8: Transcriptional regulation o f HLA class I genes
The regulation of classical and non-classical HLA class I genes at the promoter 
level is summarised above in the context of four core promoter regions: the distal 
ISRE, Enhancer A, ISRE and SXY. STAT1 homodimers bind the distal ISRE of 
HLA-E following IFN-y stimulation, a similar motif in the HLA-G promoter binds 
IRF-1 in response to IFN-a. The Enhancer A regions of HLA-A, -B, -E and -F 
bind NF-kB in response to multiple stimuli, including TNF-a. The ISRE of HLA-A, 
-B, -C and -F bind IRFs in response to IFNs. With the exception of HLA-G, HLA 
class I SXY motifs bind RFX CREB and NF-Y (green) and are further 
transactivated by co-operative binding of CIITA. Comparison of HLA promoters 
with the (32-microglobulin promoter shows that the same regulatory motifs and 
transcription factors control expression of this gene, although the arrangement of 
these motifs differs in the (32-microglobulin promoter. Adapted from van den 
Elsen etal., 1998; 2004).
factors, with the exception of HLA-C, which does not bind NF-kB. 
Nucleotide variation in Enhancer A and ISRE sequences directly influences 
the binding of transcription factors to these sites and therefore the level of 
promoter activation and class I expression induced by IFN and NF-kB 
pathways differs between MHC class I loci.
The non-classical genes are divergent from classical HLA genes both 
in sequence and function. This is reflected in the transcriptional regulation of 
these genes. HLA-G is expressed on trophoblast cells at the materno-foetal 
interface and was alo shown to be expressed in melanoma tumours, and 
may be involved in immunotolerance of tumour ceils. Accordingly, the tight 
transcriptional regulation of this gene is reflected at the promoter level. HLA- 
G is not induced by NF-kB, IRF-1 or CIITA via the usual motifs. Instead, 
HLA-G transcription is induced by IFNs via binding of IRFs to a hybrid distal 
GAS/ISRE element located upstream of the core regulatory motifs (Lefebvre 
et al., 2001). The Enhancer A of HLA-G binds p50 and the generic 
transcription factor Sp1, but is not transactivated by NF-kB p65 (Rousseau et 
al., 2000). In addition, there is no apparent regulation by transcription factor 
binding to the SXY region and HLA-G is not transactivated by CIITA. This is 
because the X1 box does not bind RFX5 and therefore CIITA binding is 
prevented (Rousseau et al., 2004). HLA-G expression is also up regulated 
by cell stress and contains a heat shock element that binds to heat shock 
factor 1 (HSF-1) (Ibrahim et al., 2000)
Like HLA-G, HLA-E, is not induced by NF-kB or IRF-1 but is induced 
in response to IFN-a via STAT1 binding to a distal GAS upstream of the 
ISRE that mediates classical HLA responses to type 1 IFN (Gobin & van den 
Elsen, 2000; Gustafson & Ginder, 1996). HLA-E is also responsive to CIITA 
through the SXY regulatory module.
Interestingly, the p2-microglobulin promoter shares the same 
regulatory motifs as HLA class I promoters, although the organisation of 
these motifs differs slightly, the ISRE is 5’ to the Enhancer A.
1.4.6 Regulation of expression of MHC class I genes of the d/d pig
In 1982, Singer et al used an HLA cDNA to probe genomic DNA 
obtained from pigs homozygous at the d locus (d/d pig) and isolated a 
genomic clone encoding a major SLA antigen, PD1 (paralogous to SLA-1). 
When transferred into mouse L cells this gene directed the synthesis of SLA 
heavy chains which associated with murine p2-microglobulin, were expressed 
at the cell surface and were induced by mouse IFN-a (Satz & Singer, 1984). 
Similar results were obtained with a second SLA antigen, PD14 (Satz et al., 
1985). Both of these studies provide evidence that the mechanisms 
regulating constitutive and IFN-induced expression of MHC class I are 
conserved in the mouse and pig. Therefore the region which controls 
transcription, the MHC class I promoter, was examined. Preliminary 
sequencing of PD1 and PD14 identified a series of conserved regulatory 
domains in the 5’ regions upstream of the transcriptional start site including a
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CAT and TATA box. Subsequent studies identified a positive and negative 
regulatory element within the promoter of PD1 that controlled expression 
(Ehrlich et al., 1988). The negative element was unique as it shared no 
homology with other known regulatory elements and its activity was 
dependent upon a downstream enhancer. A transgenic mouse expressing 
PD1 was made, skin grafts from this transgenic mouse were rejected in the 
parental strain, demonstrating that SLA was expressed and recognised as a 
functional transplantation antigen (Frels et al., 1985). The tissue distribution 
of PD1 expression in the transgenic mouse was similar to that observed in 
the pig, indicating that the cellular factors that regulate porcine MHC class I 
expression are conserved between mouse and pig species. This was 
confirmed by treatment of transgenic mice with IFN-a/p, which increased 
PD1 expression. Interestingly the magnitude of SLA class I responses to 
type I IFN induction varied between tissues; IFN-induced PD1 expression in 
the brain was 6 times higher than in lymph nodes (Satz & Singer, 1984). The 
conclusions of this study were that both constitutive and IFN induced 
expression of PD1 is controlled in a tissue specific manner and that 
regulation is controlled by a 1 kb region 5’ to the PD1 coding sequence. A 
putative ISRE motif was subsequently identified in the promoter region of 
PD1. Analysis of a series of truncated PD1 promoter constructs 
demonstrated that deletion of the ISRE region abolishes IFN-a/p induced 
expression in vitro and that deletion of two upstream silencers (-894 and - 
516) increases constitutive PD1 expression in transfection studies in vitro 
and in vivo in a second transgenic mouse expressing PD1 containing a 
truncated 5’ flanking region (Maguire et al., 1990). Further analysis of a 589
bp region containing the novel silencer domain region -503 to -1091 
upstream of PD1 coding sequence identified two functional motifs associated 
with this region: an enhancer (-731 to -  771) and silencer (-676 to -731). 
Distinct cellular factors are associated with each motif and the binding sites 
for each group of factors overlap. It was demonstrated that levels of MHC 
class I expression are directly associated with the levels of silencer binding 
factors present in a particular cell type. Although enhancer binding factors 
were shown to be preferentially expressed, binding of these factors to the 
enhancer motif is inhibited in the presence of silencer binding factors 
(Weissman & Singer, 1991). For example, PD1 expression is low in the 
kidney, where high levels of silencer binding factors are expressed and high 
in B cells where silencer binding factor expression is low.
Concurrently, the expression of a second classical MHC class I gene 
PD7, with high sequence homology to PD1, was examined in pig and 
transgenic mouse tissues (Frels et al., 1990). Interestingly, PD7 was 
expressed at much lower levels in tissues than PD1. In order to find an 
explanation for this observation two strains of transgenic mice which differed 
in the length of the 5’ flanking region upstream of PD7 revealed a silencer 
element with tissue specific activity, which regulates PD7 expression in 
lymphoid tissues and skin and contributes to the tissue specific expression of 
this gene. Sequence comparison of the Enhancer A region of PD1 
(GGGGAGTCCCC) with PD7 (GAGGAGTCCCC) reveals a mutation in the 
second residue (highlighted in bold). This correlates with observations in 
humans where mutations in second and tenth residues of Enhancer A
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prevents binding of a nuclear factor and abolishes Enhancer A activity 
(Johnson, 2003), therefore it was hypothesised that this nucleotide difference 
may account for reduced expression of PD7 in a number of tissues in vivo 
compared to PD1.
1.4.7 Regulation of expression of MHC class I genes of the H01 pig
Recently, the MHC class I region of the H01 pig was fully sequenced 
revealing 8 class I genes (SLA-1, -2, -3, -5, -6, -7, -8 and MIC2) with the 
correct intron/exon organisation in order to be functional (Chardon et al., 
2001; Renard et al., 2001). Analyses of 5’ flanking regions of these genes 
reveal promoter elements that share homology with the promoter regions of 
human and mouse MHC class I genes and those of the d/d pig already 
discussed here. The functions of the regulatory motifs encoded within class I 
genes of the H01 pig have not been investigated experimentally before and 
are the focus of this study.
1.5 Viruses and MHC class I
Given the importance of MHC class I in anti-viral immunity, it comes 
as no surprise that many viruses have evolved ways of circumventing class I 
mediated antigen presentation. To date, an impressive number and variety 
of mechanisms of disrupting MHC class I have been documented. There are 
viral mechanisms that target almost every step and component of the MHC 
class I antigen presentation pathway, from inhibition of transcription through 
to endocytosis and degradation of cell surface MHC class I. Figure 1.9
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Figure 1.9: Viruses target the MHC class I antigen presentation pathway in 
order to avoid immune recognition.
A summary of the MHC class I presentation pathway from gene transcription 
through to cell surface expression is shown. At each step in this pathway 
examples of viral intervention, leading to reduced or impaired peptide 
presentation are indicated in bold black text and the corresponding virus and viral 
protein (where known) are indicated in green text. Specific organelles are 
labelled in blue text. In an uninfected cell, peptides are produced by the 
proteasome and transported into the ER by the TAP transporter, where they are 
loaded onto newly synthesised MHC class I heavy chains. Fully assembled 
MHC class I is transported to the cell surface via the trans golgi network.
provides an overview of the MHC class I presentation pathway and some 
examples of viruses and specific viral proteins that disrupt it.
Adenovirus type 12 down regulates MHC class I expression by 
targeting the transcription of MHC class I at the promoter level. In 
Adenovirus type 12 transformed cells, nuclear NF-kB is hypophosphorylated 
and cannot bind and drive transcription of the MHC class I promoter (Hou et 
al., 2002). In addition, a transcriptional repressor COUP-TFII remains 
associated with the MHC class I promoter, preventing binding and 
transactivation by NF-kB.
Several viruses use cell surface MHC class I as a target for immune 
evasion. Varicella Zoster Virus (VZV) has been shown to down regulate 
surface expression of MHC class I molecules on human fibroblasts and T 
cells early in infection. This is mediated by the product of the early gene 
ORF66. Further biochemical analyses demonstrated that MHC class I 
molecules were retained in the golgi following synthesis in the ER but the 
mechanism for this remains unclear (Abendroth et al., 2001).
HIV-1 exploits the cellular phosphoferin acidic cluster sorting protein-1 
(PACS) in order to disrupt MHC class I cell surface expression (Piguet et al., 
2000). PACS protein is a ‘coat’ protein that organises the transport of furin 
protein between transport endosomes and the goigi. The HIV Nef protein 
bridges together the cytoplasmic domains of PACS protein and MHC class I 
this results in the removal of MHC class I from the cell surface by
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endocytosis. MHC class I is then transported to the trans golgi network 
(TGN) where they are retained. Similarly, the K3 protein of Kaposi’s 
Sarcoma-associated Herpesvirus (KSHV) removes MHC class I from the cell 
surface by increasing endocytosis. Class I molecules are then targeted to 
lysosomes (via the TGN) where they are destroyed (Hou et al., 2002).
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are able to 
inhibit expression of MHC class I by a different mechanism. Both these 
viruses encode ICP47, an immediate early protein that blocks MHC class I 
assembly by inhibiting the transporter associated with antigen presentation 
(TAP), thereby preventing the transport of peptides into the ER (Jugovic et 
al., 1998). MHC class I molecules cannot be assembled without peptides 
and therefore no new MHC class I molecules are transported to the cell 
surface.
While it is advantageous to block some expression of MHC class I, 
complete blockage of MHC class I expression (‘missing self) would attract 
the attention of NK cells and would not be advantageous for viruses. 
Therefore, in order to evade destruction by both NK and CD8+ T cells a virus 
must employ strategies to disrupt both MHC class I expression of peptides as 
well as prevent recognition by NK cells. Human cytomegalovirus (HCMV) is 
a well documented example of a virus that is proficient in immune evasion, 
particularly in modifying MHC class I expression. HCMV encodes a number 
of unique short (US) viral proteins dedicated to the disruption of classical 
HLA class I expression at several stages of the peptide presentation pathway
resulting in the prevention of peptide presentation to CD 8+ T cells. 
Interestingly, HLA-A expression is inhibited early during infection whereas 
disruption of HLA-G expression occurs later (48hpi), and to a lesser extent 
than HLA-A alleles. It is hypothesised that differential regulation of HLA-G 
occurs so that a continuous interaction with the inhibitory ligand KIR2DL4 is 
maintained, ensuring that NK cell activation and secretion of IFN-y is 
prevented (Pizzato et al., 2004).
Given the fundamental importance of MHC class I in the immune 
response to viruses it is anticipated that disruption of SLA class I would be an 
important immune evasion strategy for viruses that infect pigs, particularly for 
viruses that cause persistent infections, such as Classical Swine Fever virus 
(CSFV). The immune evasion strategies of CSFV are not well understood, a 
greater understanding of these mechanisms could provide valuable 
information with applications in vaccine design and target identification for 
therapeutic intervention.
1.6 Classical Swine Fever
Classical Swine Fever (also known as hog cholera) is a highly 
contagious, often fatal disease that affects domestic pigs and wild boar (Sus 
scrofa) with the latter acting as a natural reservoir for the disease. 
Inactivated virus can be used safely and efficiently as a vaccine, however 
vaccinated animals cannot be serologically distinguished from animals 
infected with field isolates and therefore vaccination was banned by the 
European Union in 1990. Until a better vaccine or medicinal therapeutic is
developed, slaughter remains the only truly efficient means of controlling 
spread of this disease when an outbreak occurs. Outbreaks of CSF carry a 
high economic cost; the 1997-1998 epidemic in The Netherlands is estimated 
to have cost around US$ 2.3 billion and required some 11 million pigs to be 
slaughtered (Meuwissen etal., 1999).
1.6.1 Clinical perspective and causative agent
CSF causes a variety of clinical disease states ranging from acute to 
chronic. Disease symptoms vary for each state but are generally 
characterised by fever, leukopenia, haemorrhage and mortality of up to 90% 
in cases of severe acute infection. Infection during early stages of pregnancy 
often results in abortion and stillbirths whereas infection during late stages of 
pregnancy results in the birth of persistently infected animals. These animals 
become reservoirs for infection.
The causative agent of CSF is classical swine fever virus (CSFV). 
CSFV is a member of the Pestivirus genus in the Flaviviradae family, which 
also includes bovine viral diarrhoea virus (BVDV) and border disease virus 
(BDV). The CSFV genome is a single positive-stranded RNA of about 12.5 
kb in length, comprising a single open reading frame which encodes a 4000 
amino acid polyprotein. The polyprotein is co- and post-translationally 
processed into 12 proteins, summarised in figure 1.10. The N terminal 
protease Npro is a cysteine autoprotease and is of particular interest for this 
study because of its recently demonstrated role in host immune evasion.
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Figure 1.10: Schematic organisation of the CSFV genome and functions of 
polyprotein cleavage products.
The CSFV genome comprises a single stranded, positive-sense single RNA 
encoding a polyprotein of approximately 400 amino acids. The polyprotein is 
processed into a series of structural and non-structural proteins as indicated. 
Specific functions have been described for most of the CSFV proteins, these are 
indicated, along with their approximate sizes (in nucleotides).
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Normally during a viral infection, IRF-3 is activated and translocates to 
the nucleus where it binds to IFN-a and -p promoters, initiating transcription 
of these genes. During CSFV infection, Npro inhibits IFN-a production by 
depleting IRF-3 (Larocca et al., 2005). In addition, CSFV has been shown to 
inhibit activation and IFN-a production by dendritic cells (DCs), although the 
mechanism and involvement of Npro in the inhibition of type 1 IFNs has not 
been determined in this system (Carrasco et al., 2004).
As mentioned above, CSFV causes a persistent infection and 
therefore must be able to avoid recognition by the host immune response. 
One important question that remains to be answered is how does CSFV 
achieve a persistent infection and does this virus affect MHC class I 
expression in order to achieve this? One aim of this thesis is to address this 
question, but in order to study MHC class I expression one must first 
understand the mechanisms that regulate the expression of this family of 
genes. Understanding class I expression and the mechanism that CSFV 
uses to disrupt it would provide valuable information for vaccine design and 
may identify targets for therapeutic intervention.
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Objectives
• To characterise cell lines and antibodies that can be used as tools to 
study SLA class I expression.
• To identify cellular factors that regulate MHC class I expression at the 
cell surface.
• To produce tools that can be used to investigate SLA class I 
expression at the promoter level.
• To determine which SLA class I gene promoters are constitutively 
active.
• To examine sequence variation in putative regulatory motifs identified 
by Chardon et al (2001) and make predictions about which 
transcription factors will bind these motifs and drive transcription.
• To evaluate transcription factor activation of MHC class I expression 
experimentally and compare promoter responses of classical and non- 
classical SLA class I genes.
• To relate variation of classical and non-classical SLA class I gene 
responses to transcription factors to sequence variations within SLA 
class I promoter regions.
• To determine the effect of CSFV on SLA class I expression and 
understand the mechanism of this immune evasion strategy.
The aims of this project were:
2.1 Reagent suppliers
Unless otherwise stated chemicals were supplied by Sigma-Aidrich 
Company (Dorset, England), buffers and kits for molecular biology were 
purchased from Qiagen (Germany) and enzymes were purchased from 
Promega (U.K.).
2.2 Media, buffers and solutions
All media were autoclaved or filter-sterilised before use. All solutions 
were prepared in sterile or distilled water unless otherwise stated.
2.2.1 Cell culture media
RPMI: Roswell memorial park institute medium (RPMI) (Invitrogen) 
containing 20% (v/v) foetal calf serum (FCS), 100 U/ml streptomycin, 100 
U/ml penicillin and 20mM L-glutamine. Only FCS that has been certified free 
from bovine viral diarrhoea virus (BVDV) was used. Certified sera is free 
from BVDV specific antibodies and viral particles following propagation in cell 
culture for several passages. Prior to use, FCS was heated to 56°C for 30 
mins to inactivate complement.
IMDM: Iscoves Modified Dulbecos Medium (IDIM) (Invitrogen) supplemented 
with 10 % (v/v) FCS (certified BVDV free), 100 U/ml streptomycin, 100 U/ml 
penicillin and 20 mM L-glutamine. Serum free IMDM was as above but did 
not contain FCS.
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EDTA-trvpsin: 136 mM NaCI, 5.3 mM KCI, 5.5 mM NaHCOs, 0.02% (w/v) 
trypsin, 0.01% (w/v) ethylenediaminetetraacetic acid (EDTA), and 0.1% (w/v) 
phenol red.
2.2.2 Bacterial culture media
Luria Broth (LB) medium: 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% 
(w/v) NaCI in dH20.
Agar plates: 1.5% (w/v) Bacto agar (Oxoid N° 1) in LB medium.
Ampicillin resistance: 50 jug/ml ampicillin.
2.2.3 Immunofluorescence microscopy buffers
Paraformaldehyde fixative: 4% (w/v) paraformaldehyde (PFA) in PBS, pH 
7.5-8.0.
Methanol/Acetone Fixative: 50% (v/v) methanol, 50% (v/v) acetone.
Blocking buffer: 50mM Tris (pH 7.4), 150mM NaCI, 0.2% (w/V) gelatine, 1% 
(v/v) Igepal, 30% (v/v) 30% normal goat serum (NGS) (Harlan Sera Labs 
UK).
Mouse block buffer: 2% (w/v) normal mouse serum (Harlan Sera Labs UK) in 
blocking buffer.
Wash buffer: 0.1% (v/v) Tween-20 in PBS.
Reporter assay buffers
Z buffer: 60 mM Na2HPO4,40 mM NaH2P04, 10 mM KCI, 1 mM MgS04
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ONPG substrate buffer: 60 mM Na2HP04) 40 mM NaH2P04, adjusted to pH 
7.0 and containing 4 mg/ml o-nitrophenyl-/?-D-galactopyraniside (added 
immediately prior to use).
2.2.4 FACS Buffers
FACS diluent: 0.6% bovine serum albumin (w/v) 0.6% sodium azide (v/v) in 
phosphate buffered saline and 2% (v/v) horse serum, adjusted to pH 7.4. 
FACS fixative solution: 1.0 to 1.5% PFA in PBS.
2.2.5 DNA manipulation buffers
Agarose gel DNA electrophoresis buffers
5QX TAE buffer: 2 M Tris-base, 5.5% (v/v) glacial acetic acid, 50mM EDTA. 
Ethidium bromide solution: 1.5% (w/v) ethidium bromide in dH20.
2.2.6 Plasmid and Bacterial Artificial Chromosome buffers
DNA preparation buffers
Suspension medium: 50 mM glucose, 25 mM Tris/HCI (pH 8.0), 10 mM 
EDTA.
Lvsis buffer: 0.2 M NaOH, 1% (w/v) SDS.
Potassium acetate buffer: 3 M potassium acetate, 11% (v/v) acetic acid.
TE Buffer: 10 mM Tris-HCI, pH 8.0 and 1 mM EDTA, pH 8.0.
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2.3 Cell lines and viruses
2.3.1 Cell lines
Max cells: Max cells (swine kidney cells that express the SLA d/d 
haplotype were obtained from the Federal Research Centre for Virus 
Diseases of Animals (Tubingen, Germany) and have been described 
previously (Pauly et al., 1995). Max were grown at 37°C in IMDM 
supplemented with 10% FCS.
Porcine aortic endothelial cells (PAEC): PAECs were isolated from 
swine aorta from outbred pigs of unknown haplotypes (referred to as outbred 
PAECs). d/d PAECs were obtained from a d/d minipig (referred to as d/d 
PAECs). Animal tissues were donated by H. Takamatsu (IAH, Pirbright) from 
animals kept under Fiome Office regulations and in accordance with the 
neccesary ethical considerations. Both PAECs and d/d PAECs were 
prepared using the protocol described previously (Vallee et al., 2001). 
Briefly, the aorta was removed from an outbred or d/d minipig (aged 6-8 
weeks). Minor blood vessels were ligated and the aorta was washed 
thoroughly by flushing with PBS and RPMI media. The aortal lumen was 
filled with collagenase IV solution (0.1 % in PBS, Worthington) and incubated 
at 37°C for 4 minutes. The aorta was then massaged and rinsed with 50 ml 
of RPMI media. Luminal cells were pelleted by centrifugation (500 g, 10 
min), resuspended in RPMI and plated onto 25 cm2 tissue culture flasks pre­
coated with gelatine (10% in PBS). PAECs were maintained on gelatine- 
coated flasks and cultured at 37°C in RPMI supplemented with 20% FCS.
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Shimozuma cells: The Shimozuma cell line was provided by Dr. H. 
Takamatsu, IAH Pirbright. These cells were derived from a pig with 
malignant lymphoma producing porcine endogenous retrovirus (PERV), both 
the retro virus and PRV reverse transcriptase have been isolated and well 
characterised (Suzuka et al., 1986). Shimozuma cells were grown in IMDM 
under standard cell culture conditions.
2.3.2 Virus and infection protocols
2.3.2.1 CSFV stock and preparation
The virulent isolate of CSFV Brescia, used for all infections, was 
provided by the Institute for Animal Science and Health (Lelystad, The 
Netherlands) and adapted for cell culture by serial passage on Max cells in 
the manner described by Van Gennip et al., (2004). Virus was isolated by 
freeze-thaw lysis and centrifugation at 1500g for 10 minutes and titrated by 
immunostaining with anti-E2 antibody WH303 (Bensaude et al., 2004) and 
used in experiments at a multiplicity of infection (moi) of 2 TCID50. The virus 
containing supernatant was stored at 4°C or -70°C.
2.3.2.2 Virus infection
For CSFV studies, Max cells were infected for 1 hour at 37°C, washed
/
in PBS then supplemented with IMDM (containing 10% FCS) or RPMI 
(containing 20% FCS) respectively. Infection was allowed to progress for the 
time indicated in each experiment. Flasks of uninfected cells were 
maintained in cell culture for the same time period as infected cells and were 
used as negative controls in FACS and transfection studies.
2.4.1 Antibodies recognising MHC class I
The monoclonal antibodies 2.27.3 (Ivanoska et al., 1991), 74.11.10 
(Pescovitz et al., 1984), 2.12.3 and 2.32.1 [Ivanoska et al,. unpublished data 
cited in (Lunny & Pescovitz, 1988)] and 16.7E4 (Lunney, 1994) were supplied 
as hybridoma cell lines to the Institute for Animal Health, Pirbright. Antibody 
preparations were supplied by Brenda Jones (Institute for Animal Health, 
Compton). Immunoglobulins were isolated from the hybridoma using the 
miniperm system according to manufacturers protocol (Sartorius Ltd, Epsom, 
UK). The monoclonal antibody PT-85 was purchased from VMRD (Pullman, 
WA) and has been described previously (Davis et al, 1987). Briefly, 
thymocytes from outbred pigs were used to immunise Balb/c (H2-d) mice and 
hybridomas were produced, those that lysed 97% of porcine cells were 
selected.
2.4.2 Conjugated antibodies and dyes
Goat anti-mouse and anti-rabbit Alexa488 (green) and Alexa594 (red) 
conjugates were purchased from Molecular Probes (The Netherlands). Goat 
anti-rabbit and anti-mouse horseradish-peroxidase (HRP) conjugates were 
purchased from Promega (UK). Goat anti-mouse IgG, lgG2a, lgG2b and IgM 
antibodies conjugated to phycoerythrin were purchased from Biosource (UK). 
4'-6-diamidino-2-phenylindole (DAPI) was purchased from Sigma. 
Phalioidin594 was purchased from Molecular Probes (UK).
2.4 Antibodies
2.5 Plasmid DNA tools
2.5.1 Transfection control plasmids
The vector pJATLacZ, a p-galactosidase reporter gene under the 
control of the rat (3-actin promoter (Didcock et al., 1999) was used as a 
control for transfection efficiency and normalisation of luciferase assay data.
The pGL3-Control vector (Promega) contains the firefly (Photinus 
pyralis) luciferase gene under the control of SV40 promoter and enhancer 
sequences and was used as a positive control for luciferase activity in 
transfection experiments.
2.5.2 Transcription factor activity control plasmids
The control plasmids used to monitor transcription factor activity were 
kindly provided by Dr. Stephen Goodborn (St. George’s Hospital Medical 
School, Tooting, London).
The reporter plasmid p(9-27 ISRE)4tkA(-39) lucter contains 4 copies of 
the ISRE consensus sequence (AGGAAATAGAAACTG) arranged in tandem 
upstream of the firefly luciferase reporter gene of the ptkA(~~39) Lucter 
plasmid (Reid et al., 1989; King & Goodbourn, 1998) and was used as a 
control to monitor responses to IFN-a.
The luciferase reporter plasmid p(IRF-1*GAS)6tkA(-39) Lucter 
contains 6 copies of the gamma activated sequence (GAS) consensus 
sequence (TTTCCCCGAAA) arranged in tandem upstream of the firefly
luciferase reporter gene of the ptkA(-39)lucter plasmid (King & Goodbourn, 
1994; 1998).
The luciferase reporter plasmid pKB6tkluc, contains 6 NF-kB binding 
sites upstream of the luciferase gene under the control of the Herpes Simplex 
thymidine kinase promoter, and was used as a positive control to monitor 
cellular responses to TNF-a and NF-kB p65 co-transfection.
A control reporter p[(AAGTGA)4]5tkA(-39)!ucter (HEX-4) was used to 
monitor IRF-1 activity. This plasmid contains a luciferase gene under the 
control of a synthetic promoter containing the herpes simplex virus thymidine 
kinase TATA box and 5 tandem repeats of an IRF-1 and 2 binding sequence 
(AAGTGA).
2.5.3 Transcription factor expression plasmids
IRF-1 and IRF-2 expression plasmids pEFPIink2.IRF-1 and 
pEFPIink2.IRF-2 are based on the mammalian expression vector pEFPIink2 
(Marais et al., 1995) which was derived from pEFBos (Mizushima & Nagata,
1990) that uses the elongation factor 1 a promoter to direct high levels of 
expression of cloned cDNAs. These plasmids contain full length human 
cDNA encoding IRF-1 and IRF-2 respectively and were kindly provided by 
Dr. S. Goodbourn, (St. George’s Hospital Medical School, Tooting, London).
The IRF-3 expression plasmid containing full length human cDNA 
encoding IRF-3 within the pcDNA3.1 backbone was provided by Oanh Dang
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and M. David (USCD, CA). Similarly, pcDNA3.1-lRF-7 contains the full 
length human cDNA encoding IRF-7 and was kindly provided by. S. 
Goodbourn, (St. George’s Hospital Medical School, Tooting, London).
The IRF-9 expression vector pcDNA3-IRF-9.vp16 encodes a 
constitutively active form of IRF-9 comprising a hybrid cDNA containing the 
DNA binding domain of IRF-9 fused to the transactivator domain of the HSV1 
VP16 protein and has been previously described (Kraus et al., 2003). Briefly, 
cDNAs encoding full length IRF-9 and 80 C-terminal amino acids of the vp16 
transactivator domain were produced by PCR. A second round of PCR was 
then used to generate IRF-9.VP16 hybrid cDNA inserts which were then 
cloned into the mammalian expression vector pcDNA3 (Invitrogen). This 
plasmid was kindly provided by Dr. C Horvarth (The Mount Sinai School of 
Medicine, New York, USA).
NF-kB expression vectors pRc/CMV.p50 and pRc/CMV.p65 contain 
human p50 or p65 cDNAs respectively within the vector pRc/CMV and were 
a gift from Heike Pahl, University of Freiberg.
The CIITA expression vector pcDNA3.1-CIITA (1315) contains CIITA 
cDNA derived from human B-cells in the pcDNA3 backbone and was a gift 
from Prof. Cheong-Hee Chang, Indiana University School of Medicine, USA.
2.6.1 Small scale preparation of plasmid DNA (miniprep)
Single colonies were picked from agar plates, added to 5 ml of LB 
containing the appropriate antibiotic in a 20 ml universal tube and incubated 
overnight in a 37°C orbital shaker at 2000 rpm. 1.5 ml of the culture was 
removed and the bacteria were pelleted for 2 minutes at 16,000g. Pellets 
were re-suspended in 100 pi of suspension medium and placed on ice for 5 
minutes. 200 pi of lysis buffer was added; the suspension was mixed by 
inverting the tube 4-5 times and placed on ice for 5 minutes. 150 pi of 
potassium acetate buffer was then added. The solution was mixed by 
inverting and placed on ice for a further 5 minutes. The suspension was 
centrifuged for 5 minutes at 16,000g. The supernatant was carefully 
decanted into 500 pi of phenol/chloroform solution and mixed by vortexing. 
The mixture was centrifuged for 10 minutes at 16,000g and the top layer was 
pipetted off. The DNA was precipitated with 1 ml of ice-cold absolute ethanol 
and incubated at room temperature for 2 minutes. DNA was pelleted by 
centrifugation at 16,000g for 10 minutes, rinsed in 70% ethanol and air-dried 
for 10 minutes. The resulting DNA pellet was redissolved in 20 pi of TE and 
stored at 4°C prior to use.
2.6.2 Large scale preparation of plasmid DNA (maxiprep)
For a preparation of a large concentration of DNA plasmid, a small- 
scale culture was prepared as above and diluted 1:500 in LB containing an 
appropriate antibiotic for selection. Cultures were incubated overnight at 
37°C in an orbital shaker. Bacterial cells were harvested and pelleted at
2.6 DNA manipulation techniques
6000 g for 20 minutes at 4°C. Cell pellets were re-suspended in 10 ml of 
suspension medium and left at room temperature for 5 minutes. Twenty ml of 
lysis buffer was added; the suspension was mixed by inverting the pot 4-5 
times and placed on ice for 5 minutes. Fifteen ml of potassium acetate buffer 
was added; the solution was mixed by inverting and placed on ice for a 
further 15 minutes. The suspension was centrifuged for 15 minutes at 15,000 
rpm in Sorval GSA rotor and the supernatant was removed by filtration 
through muslin cloth. Supernatants were then added to an equilibrated 
Qiagen-tip 500 column (Qiagen, UK) and allowed to pass through the resin 
by gravity flow. The column was washed twice with Qiagen wash buffer and 
the DNA was eluted with 15 ml of Qiagen elution buffer. The DNA was 
precipitated with isopropanoi and immediately centrifuged for 20 minutes at 
15,000g. The pellet was rinsed in 70% ethanol, air-dried at RT and 
redissolved in 300 pi of TE. DNA concentrations were determined with an 
Ultrospec 2100 UV spectrophotometer (Pharmacia biotech, UK).
2.6.3 Purification of DNA fragments from agarose
DNA bands were purified using the Geneclean Turbo kit (BIO 101, 
USA) according to the manufacturers instructions. Briefly, DNA bands were 
visualised on a UV light source, excised and melted in an equal volume of an 
aqueous solution of a guanidine chaotropic binding salt and transferred to a 
DNA binding column. The column was washed twice with a salt solution 
containing ethanol and the DNA was eluted with RNAse/DNAse-free elution 
solution or RNAse/Dnase-free dH20.
2.6.4 Restriction enzymes digestion
Digestion reactions were set up as follows: 2 pi 10X digestion buffer, 2 
pi RNAse, 0.5 pi of each enzyme, 100 ng DNA template, made up to a final 
reaction volume of 20 pi with dH20. DNA digestion was performed at 37°C in 
a water bath for at least 1 hr. All enzymes and enzyme reaction buffers 
were purchased from Promega.
2.6.5 Ligation
Insertvector moiar ratios of 3:1, 1:1 and 1:3 were used for ligation of 
SLA promoters (insert) into pGL3-basic (vector). Each ligation reaction 
consists of 50 ng of linearised dephosphorylated vector, SLA promoter insert, 
1 pi of 10X ligation buffer, 1-3 U of T4 DNA ligase and distilled water to a 
final volume of 20 pi. Ligation reactions were performed overnight at 16°C. 
To calculate the appropriate amount of SLA promoter insert to include in the 
ligation reaction, the following equation was used;
No of vector x kb size of insert x insertvector molecular ratio = ng insert 
Kb size of vector
2.6.6 Transformation of competent bacteria
1-10 ng of plasmid DNA or 2 pi of ligation reaction was added to 50 pi 
of frozen E. coli JM109 (Promega) or TOP10 (Invitrogen) competent cells 
(thawed on ice). The mixture was flicked gently, placed on ice for 20 minutes 
and heat-shocked for 45 seconds at 42°C in a water bath. 950 pi LB broth 
was added to the mixture and the tube was incubated for 1.5 h at 37°C with
shaking. Cells were pelleted at approximately 1000 g for 10 minutes and re­
suspended in 200 pi of LB broth. Finally, 50-150 pi of the mixture was plated 
onto an agar plate containing the appropriate antibiotic for selection and 
incubated overnight at 37°C.
2.6.7 Generation and small-scale preparation of Bacterial Artificial 
Chromosomes
Bacterial artificial chromosomes (BACs) 207G8 (AJ251829), 490B10 
(AJ131112) and 493A6 (AJ251914) used in this study were kindly provided 
by Christine Renard and Patrick Chardon (LREG, INRA, France). Small 
scale production of these BACs is described in detail in (Chardon et al., 
2001). These BACs were derived from a genomic library comprising some 
107000 clones spanning the entire haploid genome of a male, Large White 
pig homozygous for the MFIC H01 haplotype, their generation has been 
described previously (Rogel-Gaillard et al., 1999). Screening of the entire 
BAC library using primers designed for amplification of conserved regions of 
MFIC class I sequences (exons 1 to 4) identified 18 BAC clones containing 
SLA class I genes, including those used in this study (Velten et al., 1999). A 
precise map of the spatial arrangement of SLA class I genes was elucidated 
by sequence and southern blot analysis of these BAC clones which also 
confirmed the validity of the first physical map of the SLA class I region 
elucidated from a yeast artificial chromosome (YAC) library (Velten et al., 
1998).
2.7.1 Primer design
Sequence data for full-length promoter regions of each SLA class I 
gene (defined in Renard et al., 2001) were downloaded from the Entrez 
Nucleotide website (National Centre for Biotechnology Information, U.S. 
National Library of Medicine, Bethesda, USA), and screened for restriction 
sites complimentary to those present in the multiple cloning region (MCR) of 
pGL3-basic using GCG software. Restriction sites that could potentially be 
used for cloning SLA class I promoters into pGL3 basic are summarised in 
table 1. Nhe\ and HindlW sites were selected for cloning because they are 
absent from the coding sequence of each SLA class I promoter and are 
present in the MCS of the pGL3 basic vector. To enable directional cloning, 
forward primers and reverse primers were designed to incorporate Nhe\ and 
Hind\\\ sites respectively. In addition, three additional bases were included 5’ 
to the restriction site to facilitate restriction enzyme interaction and digestion. 
Finally, Primer 3 software was used to screen each primer and primer pair in 
silico for hairpin loop formation, primer dimerisation and melting temperature. 
Primers were then purchased from MWG Biotech (Germany). Table 2 lists 
the primers used for PCR amplification of full-length promoter regions (from 
the upstream enhance silencer sites, to the ATG) for each SLA class I gene.
2.7 Production of SLA class I promoter reporter constructs
Table 1: Summary of restriction sites within SLA promoter
Gene and position o f restriction enzyme sites
Restriction
site SLA-1 SLA-2 SLA-3 SLA-5 SLA-6 SLA-7 SLA-8 MIC-2
Kpnl . 1424 1430 151 347, 1728
Sad - 1047 - - 1620 - - 1333
Mlui - - - - - - - -
Nhei - - - - - - - -
Smal - - 1428 - - - - 1724
Xhol - - - - - - - -
Blgl 164 166 - 1165 - - - -
Hindlll - - - - - - - -
Table 2: Primers used for PCR amplification of SLA promoters
Primer
Target
gene 5' to 3' Primer sequence
Anticipated 
product 
size (bp)
sia-1-Nhel_F
sla-1-Hindl!!_R
SLA-1
SLA-1
GGGGCTAGCAAGGAAAATCATTCTCTGAGC
GGGAAGCTTGATCCTCAGCCTCGGGGTCT
1069
Promsla-2b-Nhel_F 
Promsla-2b-Hindl I l_R
SLA-2
SLA-2
CTAGCTAGCTACATACCAAACACTCCT
CCCAAGCTTTGCGTGGAGAGTTTATAA
1330
sla-3-Nhel_F
sla-3-Hindlll_R
SLA-3
SLA-3
GGGGCTAGCATACTTTAATAGTATCTTCTATG
AGAAAGCTTTACCAGTCAGGGCCAGGG
1402
sla-5-Nhel_F
sla-5-Hind!il_R
SLA-5 
SLA-5
GGGGCTAGCGTTTTAATAGTATCTTCTCTG 
AAAAAGCTT CCCGAGAGCAGCAGG AAGAGG
1093
Promsla-6b-Nhel_F
Promsia-6b-Hindlll_R
SLA-6
SLA-6
CTAGCTAGCAGAGTCACAGTTTGGGAA
TTTAAGCTTCTGAGTTTGGCTGGTCTG
988
Promsla-7b-Nhel_F
Promsla-7b-Hindlll_R
SLA-7
SLA-7
CTAGCTAGCTCCCTGTCTCTGGTGTGA
TTTAAGCTTAACGCACCCTCGGGGT
997
Promsla-8a-Nhel_F
Promsla-8a-Hindlll_R
SLA-8
SLA-8
CTAGCTAGCGCTGCCTCCATAATGATC
TTTAAGCTTGACCGAATCCTGTGGGT
962
promMIC2-Nhel_F
promMIC-2-Hindlll
MIC2
MIC2
CTAGCTAGCAACCCATGGGATACTGATTC
ATAAAGCTTGCCAGAAACGACAGGTAACGG
1228
2.7.2 Polymerase chain reaction
For gradient PCR, reaction mixtures were set up as follows: 10 pi 10x 
High Fidelity Buffer (Eppendorf), 2 pi 10 mM dNTPs, 1 pi 200pM forward 
primer, 1 pi 200pM reverse primer, 80 ng BAC DNA template and 0.5 pi 
Triple Master Enzyme (contains Taq polymerise and pfu Eppendorf), made 
up to a final reaction volume of 100 pi with filtered water. The reaction
mixture was divided into 10 samples and placed in a Eppendorf 
thermocycler.
Optimum PCR annealing temperatures for each primer pair were 
determined by performing PCRs across a temperature gradient of 45 to 72°C 
using a gradient thermocycler (Eppendorf). PCR product size was 
determined by gel electrophoresis on a 0.8% (w/v) agarose gel. Optimum 
annealing temperatures, defined by PCR product size and yield, were used in 
all subsequent PCR reactions. PCR products were extracted from agarose 
gels and subcloned into pcDNA3.1/V5-His/TOPO (Invitrogen) as a shuttle 
vector. The insert was excised with Nhe\ and Hind\\\ and analysed by gel 
electrophoresis to confirm the size of SLA promoter inserts.
The following PCR cycling parameters were used:
Denature 94°C for 30 sec
Denature 94°C for 30 sec ^
Anneal at gradient temperature for 30 sec >  30 cycles
Elongation for 2 minutes
Final elongation at 72°C for 10 minutes
After completion of the program, PCR products were mixed with 6X 
gel loading dye and the resulting mixture was run on a 1% (w/v) agarose gel. 
The DNA fragments were visualised by ethidium bromide staining and 
viewed on a UV light source. Appropriate PCR products were excised from 
gels and isolated as described below.
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2.7.3 Sub-cloning of SLA class I promoters
SLA class I promoter sequences were amplified by PCR and isolated 
as described above. First, PCR products were cloned into the T-tailed vector 
pcDNA3.1A/5-His/TOPO (Invitrogen) following the manufacturer’s protocol. 
Promoters inserts were then excised with Nhe\ and HindW and analysed by 
gel electrophoresis on a 0.8% (w/v) agarose gel to confirm the size of each 
insert. The DNA containing each SLA promoter was extracted and purified 
as above and ligated into the promoter-less vector pGL3-basic (Promega, 
UK) upstream of the firefly luciferase gene. Piasmids were then analysed by
' X
digestion with Nhel and Hind\\\ followed by gel electrophoresis to re-confirm 
the size of promoter inserts. The sequences of SLA promoter inserts within 
pGL3-basic were confirmed by DNA sequencing. Table 3 summarises the 
SLA promoter constructs generated in this study.
Table 3: Summary of the SLA promoter reporter constructs produced
Construct name SLA promoter insert insert size
pGL3-SLA1 SLA-1 1069
PGL3-SLA2 SLA-2 1330
pGL3-SLA3 SLA-3 1402
PGL3-SLA-6 SLA-6 988
pGL3-SLA-7 SLA-7 997
pGL3-MIC-2 MIC-2 1228
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2.7.4 Sequencing
2.7.4.1 Sequencing primers
pGL3-SLA promoter constructs were sequenced with the forward and 
reverse primers specific for individual SLA class I promoters listed in table 2. 
Primers specific for pGL3-basic were also used, these were as follows:
forward primer RVfor 5’ -CTAGCAAAATAGGCTGTCCC- 3’ 
reverse primer GLrev 3’-CTTTATGTTTTTGGCGTCTTC-5\
2.7.4.2 Sequencing reaction
Sequencing templates were approximately 350 ng of small scale 
preparation of plasmid DNA diluted in 10 pi of deionised water. The DNA was 
heat-treated for 1 minute at 96°C. The samples were prepared using the Dye 
Terminator Cycle Sequencing Quick-Start kit (Beckman Coulter, USA). The 
following reagents were added to the DNA sample: 3.2 pmoles of sequencing 
primers, 4 pi of reaction buffer, 4 pi of Quick-start solution and dH20 to a final 
reaction volume of 20 pi. The following cycling parameters were used:
Denature 96°C for 20 sec 
Anneal 50°C for 20 sec 
Polymerise 60°C for 4 minutes 
Hold at 4°C
30 cycles
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The PCR products were then precipitated with 2 volumes of 3 M 
NaOAC, pH 5.2. The DNA pellet was cleaned with 3 washes of 70% ethanol. 
Forty pi of sample loading solution was added and samples were analysed 
with an automatic capillary sequencer CEQ 8800 Genetic Analyses System 
(Beckman Coulter, USA). Sequence trace data were analysed using 
Chromas (version) and compared with the reference BAC sequences using 
DNAsp (version and programme name). A minimum of two clones of each 
construct were sequenced four times.
2.7.5 Computational analysis of DNA sequence data
Sequence analysis was carried out using components of the 
Wisconsin Package version 10.1 (Genetics Computer Group (GCG), 
Madison, USA). Sequence alignments were carried out using DNAsis 
software using standard multiple sequence alignment criteria. Properties of 
primers such as predicted annealing temperature, hairpin loop formation and 
internal purine-pyrimadine bond formation were assessed using the 
predictive software Primer3 (Rozen & Skaletsky, 2000). The program 
TFSEARCH version 1.3 searches highly correlated sequence fragments 
against TFMATRiX transcription factor binding site profile database in the 
TRANSFAC databases by GBF-Baunschweig (Heinemeyer et al., 1998). 
This program was used to search for transcription factor binding sites in SLA 
class I promoters.
2.8.1 Standard transfection protocol
Cells were grown to 70-80% confluency (either on 24 well plates or on 
Petri dishes) and were transiently transfected with plasmid DNA using a 
liposomal “Lipofectamine” transfection system (Invitrogen, UK). 
Lipofectamine was used at a ratio of 1 pg plasmid DNA to 2.5 pi 
lipofectamine (the optimum ratio for pGL3-SLA promoter constructs were 
determined experimentally, data not shown) and according to the 
manufacturer’s protocol. For transfections on 24 well plates, 1.25 pi of 
Lipofectamine and 25 pi of serum-free IMDM were mixed with 0.5 pg plasmid 
in 25 pi of serum-free IMDM (per plasmid per well). The mixture was 
vortexed and left for 45 minutes at RT. in the meantime, cells were washed 
three times with serum-free IMDM. 50 pi of each plasmid 
DNA/Lipofectamine/IMDM mixture was then added to each well and topped 
up to a final volume of 400 pi with serum free IMDM. Cells were incubated 
with the transfection mixture at 37°C for one hour. Next, 400 pi IMDM 
supplemented with 20% FCS was added to each well and cells were 
incubated for a further 48 hrs (unless stated otherwise). For cytokine 
stimulation experiments, cells were transfected as above and incubated in 
I DIM for 32 hours. Cytokine was then added at the appropriate dilution for 
the time indicated in each experiment, usually 16 hours. Cells were then 
harvested and processed for beta-galactosidase and luciferase assays as 
standard.
2.8 Cell culture techniques
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2.8.2 Co-transfections with transcription factor expression plasmids
The optimum amount of transcription factor expression vectors to be 
co-transfected with pGL3-SLA promoter constructs was determined by 
titration of each transcription factor expression vector against luciferase 
activity driven by the SLA-1 and SLA-7 promoters. A combination of 0.1 pg 
transcription factor expression vector, 0.4 pg pcDNA3 was found to be 
optimal, greater amounts of transcription factor expression vector were found 
to inhibit SLA-1 driven luciferase activity. Max cells were transiently 
transfected with 0.5 pg of SLA promoter constructs, 0.5 pg pJat-lac, 0.4 pg of 
pcDNA3 and 0.1 pg of one of the following expression vectors: 
pEFPIink2.IRF-1, pEFPIink2.IRF-2, pcDNA3-IRF-3, pcDNA-IRF-7, pcDNA3- 
IRF-9.vp16, pRc/CMV.p50, pRc/CMV.p65 or pcDNA3.CIITA(1315). For 
control experiments, 0.5 pg of the following control plasmids was used: 
pGL3-control, p(9-27 ISRE)4tkA(-39)Lucter, p(IRF-1*GAS)6tkA(-39)Lucter, 
pkB6tkluc, p[(AAGTGA)4]5tkA(-39)Lucter. Transfections were carried out as 
above, using plasmid DNA and Lipofectamine at a ratio of 1:2.5, see figure
2.1 for a summary.
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0.5 ng pGL3-SLA 
promoter reporter in 
25 pi serum free 
IMDM
1.25 ml
Lipofectamine™ in 25 
pi serum free IMDM
0.1 pg transcription 
factor expression 
vector AND 0.4 pg of 
the corresponding 
backbone vector
+ 1.25 ml 
Lipofectamine™ in 
50 pi serum free 
IMDM
Incubate at RT°C for 45 minutes
I
Add 50 pi of each mix to each well
I
0.5 pg pJatLacZ in 
50 pi serum free 
IMDM
1.25 ml
Lipofectamine™ in 
50 pi serum free 
IMDM
Max cells, single well 
of a 24 well plate
Top up to 400 pi with serum free IMDM 
and incubate for 1 hour at 37°C
I
Add 400 pi IMDM containing 20% FCS 
!
Incubate for 48 hours at 37°C
I
Harvest cells and perform luciferase 
and p-galactosidase assays
Figure 2.1: Protocol for co-transfection of Max cells with multiple plasmids
Typically co-transfection experiments included 0.5 pg of SLA promoter 
reporter construct, 0.5 pg pJatLacZ control, 0.1 pg of transcription factor 
expression plasmid and 0.4 pg of a backbone plasmid corresponding to 
that of the latter. Each plasmid was incubated with lipofectamine and 
serum free media media at a plasmid DNA to lipofectamine ration of 1.25 
as shown above.
2.8.3 Luciferase and p-galactosidase assays
For transfections carried out in 24 well plates, 80 pi of lysis buffer 
(Promega) was added to each well. Cells were scraped and lysates were 
transferred into 1.5 ml tubes and vortexed briefly. Supernatants were 
transferred into 1.5 ml tubes and placed on ice prior to use in luciferase and 
p-galactosidase assays. 20 pi of cell lysate was used for both types of 
reporter assay. Luciferase assays were performed according to 
manufacturers instructions and luciferase activity was measured using a 
Wallac 1205 Betaplate luminometer (PerkinElmer lifesciences, Pharmacia).
For p-galactosidase assays, cell lysates were diluted in 0.5 mi of Z 
buffer, vortexed briefly and 200 pi of substrate buffer (o-nitrophenyl-/^D- 
galactopyraniside) was added. Samples were vortexed briefly and incubated 
for 1 hour at 37°C. 200 ml 1M Na2C 0 3 was added to inactivate p-
galactosidase enzyme and stop the reaction. 200 ml of sample was then 
transferred to a 96 well plate and absorbance was read at 420 nm using a 
Labsysteme Multiscan plus plate reader spectrometer (Labsystems, UK).
2.8.4 Cytokine treatments
Porcine interferon alpha folFN-g): For FACS and transfection 
experiments d/d PAECs or Max cells were incubated with 200 U/ml of 
recombinant porcine IFN-a (PBL Biomedical labs, USA) in RPMI or IMDM 
respectively, for 16 hrs at 37°C.
-98-
Porcine interferon gamma (olFN-v): d/d PAECs or Max cells were 
incubated with 0.2 pg/ml recombinant porcine IFN-y (Biosource, USA) in 
RPMI or IMDM respectively, for 16 hrs at 37°C.
Tumour necrosis factor aloha (TNF-g): d/d PAECs or Max cells were 
incubated with 0.5 pg/ml recombinant human TNF-a (R&D Systems, USA) in 
RPMI or IMDM respectively, for 12-16 hrs at 37°C. TNF-a is referred to as 
hTNF-a in the text.
2.9 Indirect Immunohistochemistry
2.9.1 indirect immunofluorescence
PAECs and Max were cultured on 13-millimetre glass coverslips in 
RPMI or IMDM respectively to 70-80% of confluency. Cells were washed with 
PBS three, times and fixed with 100% methanol for 10 minutes or 4% PFA for 
10 minutes with shaking at RT. Cells were rinsed with PBS three times and 
blocked in blocking buffer for 20 minutes with shaking at RT. Cells were 
rinsed three times in PBS then incubated with the primary antibody diluted in 
blocking buffer for 20 minutes with shaking. See table 4 for dilutions used for 
each primary antibody. Cells were then washed in PBS and incubated with 
the Alexa488 or Alexa594 conjugated secondary antibody at 1:500 dilution of a 
1 mg/ml stock in blocking solution for 20 minutes in the dark. Cells were 
washed three times in PBS before being dyed for 5 minutes with a 1:20,000 
dilution of a 5 mg/ml stock of DAPI in PBS. Finally cells were washed in
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distilled water and coverslips were mounted onto Superfrost slides (BDH, 
UK) using Fluoromount G (Southern Biotechnology, USA).
2.9.2 Indirect immunofluorescence analysis of MHC class I
PAECs and Max were cultured on 13-millimetre glass coverslips in 
RPMI or IMDM respectively to approximately 80% of confluency. For surface 
staining, cells were washed three times in PBS and incubated with detergent 
free blocking buffer for 20 minutes at RT°C with shaking. Cells were then 
incubated with PT-85 (1 pi in 1000 pi of blocking buffer) for 30 mins at RT°C. 
Cells were then washed in PBS and incubated with the Alexa488 or Alexa594 
conjugated secondary antibody at 1:500 dilution of a 1 mg/ml stock in 
blocking solution for 20 minutes in the dark and then fixed in 
acetone/methanol for 2 minutes. Cells were washed three times in PBS- 
Tween-20 then incubated with DAPI (1:20,000 dilution of a 5 mg/ml stock) for 
10 minutes to stain nuclear DNA. Finally cells were washed in distilled water 
and coverslips were mounted onto Superfrost slides (BDH, UK) using 
Fluoromount G (Southern Biotechnology, USA).
For internal staining of MHC class I, cells were washed in PBS three 
times then fixed for 60 seconds with methanol/acetone. Cells were incubated 
with blocking buffer (containing 0.5% NP-40) for 20 minutes at RT°C then 
permiabilised with 1% (v/v) NP40 at 37°C for 15 minutes. Cells were 
incubated with PT-85 (dilution as above) for 45 minutes at RT°C, washed 
three times in PBS-Tween 20 and incubated with goat anti-mouse Ig
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conjugated to Alexa488 (1:500 in blocking buffer containing 0.5% NP40) for 30 
minutes in the dark. Cells were then washed three times and nuclear DNA 
was stained with DAPI and cells were mounted on glass slides as above.
2.9.3 Image analysis
Preparations were viewed at 60X/1.4 NA with a Nikon E800 
microscope and images were captured with a Hamamatsu C-4746A CCD 
camera. Captured images were analysed using Improvision Openlab 3.1 
software (Improvision, UK).
2.9.4 Analysis of MHC class I surface expression by FACS
Following virus infection, cytokine or control treatment for the time 
period indicated for each experiment, cells were washed in PBS, incubated 
with 2mls of versine/trypsin until detached and collected by gentle 
centrifugation. Cell pellets were resuspended in FACS diluent, allowing 25 pi 
of cell suspension per sample. Twenty five pi of cell suspension was added 
to each well of a 96 well, round bottomed plate as required. To wash the 
cells, plates were centrifuged at 500g for 2 minutes at 4°C, supernatants 
disposed of and pellets dispersed by gentle shaking. Cells were incubated 
with 25 pi of primary antibody at an appropriate dilution (given in table 4) and 
150 pi of FACS diluent in darkness at 4°C for 20 minutes. Control samples 
for autofluorescence and non-specific binding of secondary antibody were 
incubated with 25 pi of FACS diluent in place of primary antibody. Cells were
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washed twice as above and 25 pi of phycoerythrin-conjugated goat anti- 
mouse lgG2a, 2b, or IgM (Southern Biotechnology Associates) was added to 
each well, including control samples for non-specific binding of secondary 
antibodies, to detect bound primary antibodies. 150 pi of FACS diluent was 
added to each well and plates were incubated at 4°C in darkness for 20 
minutes. Finally, cells were washed twice, re-suspended in 100 pi FACS 
fixative, sealed and stored at 4°C prior to analysis. Cells surface MHC class I 
expression was analysed by FACS (FACScan, Becton Dickson) using the 
CellQuest program. The degree of cell membrane MHC class I expression 
was expressed as mean fluorescence intensity (MFI).
Table 4: table of antibodies and dilutions used in FACS experiments
Antibody Specificity Ig subclass Dilution
PT-85
2.27.3 
74.11.10 
2.32.1
2.12.3 
16.7E4
MHC class I 
SLA class I 
SLA class I
SLA class I, d/d haplotype 
SLA class I, d/d haplotype 
SLA class I, c/c haplotype
lgG2a
lgG2a
lgG2b
lgG2b
IgM
IgM
1:1000
Neat
Neat
Neat
Neat
Neat
2.10 Statistical analyses
All statistical analyses were performed using the statistical software package 
SPSS version 10.4 for Windows according to the manufacturers instructions.
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Chapter 3: Cellular characterisation o f SLA c/ass I expression in 
porcine cells.
3.1 Introduction
In the pig, the polymorphic nature of MHC class I and the variation in 
allele expression by individuals makes studying cell surface expression of 
MHC class I complicated. However, characterisation of SLA class I 
expression is simplified with the use of the NIH inbred mini pig, which are 
homozygous on both alleles for the whole SLA locus (Pennington et al., 
1981). In addition, several mouse antibodies that are specific for pig SLA 
have been produced, including antibodies that can distinguish the d/d 
haplotype from other haplotypes. The principle aims of this chapter were to 
explore the tools available for studying SLA class I, namely antibodies and 
porcine cell lines and to use these tools to characterise SLA class I 
expression on a series of porcine cell lines and in response to cytokine 
stimulation and viral infection. In addition, this study aimed to expand the 
technical applications of the antibodies available for SLA class I studies.
In order to address these aims, firstly cell lines from NIH d/d inbred 
pigs which express high levels of SLA class I were isolated. Secondly, a 
panel of SLA class I specific antibodies were used to investigate surface and 
intracellular expression of SLA class I on these cells, using FACS and 
immunofluorescence. Finally, changes in surface expression in response to 
cytokine stimulation or infection with a pathogen, classical swine fever virus,
-103-
were investigated. In the human, mouse and pig it is well established that 
MHC class I expression is induced by interferon and pro-inflammatory 
cytokines. It has been shown that modulation of MHC class I expression is 
an important immune evasion mechanism for many viruses. In this study, the 
porcine virus CSFV was used to determine whether infection can modulate 
expression of SLA class I. There has been little work done on the 
mechanism of inhibition of SLA class I expression by a pig virus. This has 
important implications for vaccine design and mechanism of T cell killing in 
the pig. Isolation of primary cells from pigs also provides a host cell model to 
study field strains of virus, which may not replicate in cultured cell lines and 
since these celts are highly differentiated, they should rapidly respond to 
stimulation by cytokines or viruses.
3.2 Expression of SLA class I on primary cells
3.2.1 Porcine aortic endothelial cells and responses to interferon
Porcine aortic endothelial cells (PAECs) were isolated from the aortas 
of both Landrace cross Large White pigs of unknown haplotype (referred to 
herein as ‘outbred’ PAECs) and from NIH minipig inbred at the MHC locus, 
expressing the d/d (H04) haplotype (referred to herein as ‘d/d’ PAECs). 
PAECs were incubated with pIFN-a (200 u/ml for 16 hours) or media alone, 
harvested and incubated with a panel of antibodies specific for MHC class I. 
The panel of antibodies (listed in table 4) comprises a series of antibodies 
raised in mice against SLA class I including locus-specific antibodies for the 
HQ4 haplotype (d/d). Binding of each antibody to SLA class I was detected
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with isotype specific goat anti-mouse immunoglobulin antibodies conjugated 
to phycoerythrin. In control experiments for non-specific binding, PAECs 
were incubated with goat-anti mouse immunoglobulin isotype specific 
antibodies alone. SLA class I expression was then examined by FACS for 
each antibody and condition. Figure 3.1 shows FACS profiles of SLA class I 
expression on outbred and d/d PAECs from a single experiment, 
representative of several repeats. For each antibody, histograms 
representing constitutive (black histograms) and IFN-a induced (red 
histograms) SLA class I expression are compared. Constitutive SLA class I 
expression was detected on outbred PAECs by PT-85 and 2.27.3 and on 
inbred PAECs by PT-85, 2.27.3 and 2.12.3 antibodies. PAECs from d/d pigs 
express higher constitutive levels of SLA class I than PAECs from outbred 
pigs. Interestingly, the antibody 2.12.3 did not detect SLA class I on outbred 
PAECs (compared to isotype control), but did detect SLA class I expression 
on d/d PAECs, showing that the epitope for this antibody is specific for the 
d/d haplotype and either not a common epitope among outbred pigs or not 
expressed by the individual examined.
Interferon induced MHC class I to a greater extent on the cell surface 
of inbred PAECs compared to outbred PAECs. Interestingly, interferon had 
no effect on the PT-85 or 2.12.3 epitopes on outbred cells and caused only a 
marginal increase on the epitope recognised by 2.27.3. However, on inbred 
pig cells, interferon induced an increase in the SLA epitopes recognised by 
each antibody tested, especially that of 2.12.3, where the MFI increased by 3 
logs. Serological analyses have deduced that 2.12.3 has an exclusive
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Figure 3.1: Comparison of SLA class I expression and IFN responses on 
PAECs derived from inbred and outbred swine.
PAECs were isolated from the aortas of an outbred pig and an inbred NIH mini 
pig expressing the d/d haplotype. Cells were incubated with media alone (black 
histograms) or pIFN-a (red histograms) for 16 hours, harvested and incubated 
with antibodies specific for MHC class I: PT-85, 2.27.3a and 2.12.3. Antibody 
binding was detected with goat anti-mouse isotype specific antibodies conjugated 
to pyhcoerythrin and cells were analysed by flow cytometry (FACScan, 
Beckman). Controls for autofluorescense and non-specific secondary antibody 
binding were also included. In each experiment the secondary antibody control 
did not exceed a mean fluorescence intensity of 10 (data not shown). This figure 
shows a single experiment, representative of at least three repeats. Cells were 
untreated (black histograms) or cultured in the presence of IFN-a for 16 hours 
(red histograms).
specificity for the H04 (d/d) haplotype. These results also suggest that 
interferon induction of SLA class I can be masked in cells expressing a mixed 
population of SLA molecules. There appears to be haplotype or allele 
specific interferon induction, indicating that some alleles of SLA class I are 
more sensitive to interferon induction than others. For this reason, d/d 
PAECs should be used in future studies.
The antibodies PT-85 and 2.27.3 were then used to detect SLA class I 
by indirect immunohistochemistry. The antibody 2.12.3 was not used for two 
reasons; results from this study demonstrated that MFIC class I is not always 
detected by 2.12.3 on resting cells by FACS and secondly, this antibody is an 
IgM and therefore has limited technical applications. Since the antibodies 
PT-85 and 2.27.3 have not been used for this technique previously, a 
technique to analyse cell surface and intracellular SLA class I by indirect 
immunohistochemistry required development. Preliminary experiments 
showed that PT-85 and 2.27.3 do not recognise SLA class I on cells that had 
been fixed with methanol or paraformaldehyde. Therefore, surface MFIC 
class I was stained with PT-85 or 2.27.3 on unfixed PAECs at room 
temperature. Cells were incubated with each of these antibodies, washed in 
PBS then incubated with a goat antibody conjugated to Alexa488 specific for 
mouse IgG to detect antibody binding to MFIC class I and then fixed. For 
intracellular staining of SLA class I cells were fixed (60 secs) with methanol 
and acetone, washed and permeabilised with 0.5% NP40 and stained with 
PT-85 or 2.27.3. Figure 3.2 shows SLA class I detected by PT-85 at the cell 
surface (panel A) and inside the cell (panel B). Intracellular class I was found
AFigure 3.2: Cell surface and intracellular MHC class I expression in PAECs
A technique for analysing SLA class I expression by indirect 
immunofluorescence was developed. For cell surface staining (panel A), 
PAECs were incubated with PT-85, a mouse monoclonal antibody specific for 
MHC class I in the absence of detergent. Antibody binding to SLA class I was 
detected with goat anti-mouse antibody conjugated to Alexa488 (green). Cells 
were then fixed in Methanol/Acetone (1:1) and cellular DNA was labeled with 
DAPI stain (blue). For intracellular staining (panel B), PAECs were briefly fixed 
with metanol/acetone, incubated for 15 minutes with 0.5 % NP40 at 37°C and 
incubated with PT-85. Nuclear DNA was stained with DAPI (blue). Cells were 
viewed at 100 (A) or 60X (B) with a Nikon E800 microscope and images were 
captured with a Hamamatsu C-4746A DCC camera as described in the 
materials and methods. Internal SLA class I is located in peri-nuclear vesicles 
presumed to be within the Golgi and ER.
as anticipated in a peri-nuclear location within vesicular structures that 
resemble the endoplasmic reticulum or golgi, staining for ER/golgi markers 
would be required to confirm this. Using this method, cell surface class I 
could not be detected by PT-85, presumably because chemical fixation 
denatures surface class I. The antibody 2.27.3 produced very similar results 
to PT-85 and therefore is not shown.
3.2.2 Primary pig lymphoma cells (Shimozuma cells) and responses to 
cytokine induction
Shimozuma cells are a swine malignant lymphoma-derived cell line in 
which SLA class I expression has not previously been characterised. 
Shimozuma cells were cultured in the presence of cytokines hTNF-a, pIFN-a 
or pIFN-y for 16 hours, harvested, incubated with antibodies specific for MHC 
class I (PT-85, 2.27.3, 74.11.10 and 2.12.3) and analysed by FACS. 
Constitutive expression of MHC class I on Shimozuma cells was not detected 
by any of the antibodies tested (data not shown). Interestingly, this primary 
B-cell line, which might have been expected to express SLA class I, have lost 
this surface expression, a common characteristic of transformed cells which 
underlines the value of using primary cell line in these studies.
3.2.3. Primary Max pig kidney cells and responses to interferon
Max cells isolated from the kidney of a NIH d/d mini pig and 
immortalised by transfection with SV40 were a gift from A. Saalmuller 
(Federal Research Centre for Virus Diseases of Animals, Germany). These 
cells have the added advantage that they survive in cell culture for 20 
passages before SLA class I cell surface expression is lost, compared to 
PAECs that can only be used for 5-10 passages (data not shown). In order 
to determine constitute and interferon-induced SLA class I expression, Max 
cells were stained with a panel of antibodies recognising inter-species, 
porcine-specific or d/d haplotype specific antibodies PT-85, 2.27.3 and 2.12.3 
antibodies described above and one additional antibody, 2.32.1 and analysed 
by FACS. Figure 3.3 shows that Max cells express high constitutive levels of 
SLA class I, which was detected by PT-85, 2.27.3 and 2.32.1 but not 2.12.3 
(open black histograms). These results support the findings for PAECs from 
the d/d haplotype.
Max cells were treated with either pIFN-a (figure 3.3 left pane)) or 
plFN-y.(right panel) for 16 hours and processed for FACS analysis as above. 
Both IFN-a (red histograms) and IFN-y (blue histograms) increase cell 
surface SLA class I expression. Expression of the epitope recognised by PT- 
85 is more weakly induced by IFN-a/-y than the epitopes recognised by
2.27.3 and 2.32.1. As seen in outbred PAECs, SLA class I recognised by
2.12.3 is not constitutively expressed on Max cells and like inbred PAECs, a 
large increase in expression is seen after treatment with IFN-a/-y. Overall,
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Figure 3.3: MHC class I expression is up regulated by IFN-a and IFN-y on Max 
cells.
Max cells were grown in the presence of IFN-a (red histograms) or IFN-y (blue 
histograms) or media alone (open black histograms) for 16 hours, harvested and 
incubated with mouse antibodies specific for a highly conserved element of MHC class I 
(PT-85), SLA class I (2.27.3) or d/d haplotype SLA class I (2.32.1 and 2.12.3). Solid 
grey histograms represent isotype controls used for each antibody and unstimulated 
Max cells are shown as open black histograms. These data show a single experiment 
but are representative of trends observed in multiple repeats.
SLA class I was induced to a greater extent by IFN-y than IFN-a. This 
suggests that IFN-y, which is secreted by activated T cells, is a more potent 
inducer of cellular responses such as IRF activation than IFN-a.
The immunofluorescense microscopy procedure developed above 
was used to detect surface SLA class I expression on Max cells and 
determine the effect of IFN-a/-y on SLA class I expression. Max cells were 
grown on 13 mm glass coverslips to 70-80% confiuency and incubated with 
pIFN-y in media or media alone for 16 hours. Cell surface MHC class I was 
then stained with PT-85 antibody as described above. In figure 3.4, 
constitutive expression of MHC class I on the cell surface of Max cells can be 
visualised by immunofluorescense microscopy (panel A, in green), cellular 
DNA is labelled with DAPI (blue). An increase in cell surface expression of 
MHC class I was detected with PT-85 antibody following IFN-y treatment 
(panel B, in green). These results demonstrate that indirect 
immunofluorescence microscopy can be used to monitor gross changes in 
cellular expression of MHC class I.
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Figure 3.4: IFN-y induces cell surface expression of MHC class I.
Max cells were grown at 37° on cover slips for 24 hours then incubated with 
media alone or pIFN-y for a further 16 hours. Cell surface MHC class I 
was stained with PT-85 followed by Alexa488 conjugated goat anti mouse 
antibody (green). Cells were then fixed in acetone/methanol (1:1 v/v) and 
cellular DNA was labelled with DAPI (blue). Cells were viewed at 
60X/1.4NA with a Nikon E800 microscope and images were captured with 
a Hamamatsu C-4746A DCC camera as described in the materials and 
methods. This figure shows un-stimulated Max cells (panels a to c) and 
IFN-y stimulated (panel d to f).
3.3 Effect of CSFV infection on MHC class I expression in porcine cells
The continuous interactions between host and pathogens during their 
co-evolution have shaped the immune system, but also the counter 
measures used by pathogens. Down-regulation of cell surface MHC class I 
expression is a common immune evasion strategy employed by viruses to 
avoid recognition by CTLs. Selective disruption of specific MHC class I 
alleles also allows a virus to avoid NK cell lysis. CSFV causes a persistent 
infection in pigs and therefore must be able to circumvent detection by the 
immune system. This thesis investigated whether CSFV infection affects 
MHC class I expression. Since CSFV infection of Max cells has not been 
previously reported, it was first necessary to determine if Max cells could 
support CSFV infection and replication and be used in such an investigation.
3.3.1 Max cells can be infected with field isolates of Classical Swine 
Fever Virus.
Max cells were infected with the Brescia strain of CSFV for 24 hours, 
fixed with methanol and incubated with a mouse monoclonal antibody 
specific to the E2 protein of CSFV as a marker of cellular infection. Nuclear 
DNA was stained with DAPI and uninfected cells were used as a negative 
control. Figure 3.5 shows that Max cells infected with CSFV express the 
CSFV E2 protein in the cytosol (green). Uninfected cells were negative for 
E2. Immunofluorescence staining of E2 protein was used as a positive 
control for virus infection in FACS experiments. This was important for SLA 
class I expression studies in CSFV infected cells (see below), since the E2
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Max cells were incubated at 37°C with the Brescia strain of CSFV for 24hrs. 
Control cells were uninfected. Cells were fixed with methanol and incubated 
with a mouse monoclonal antibody specific for the E2 protein of CSFV. 
Antibody binding to E2 was detected using a goat antibody specific for mouse 
Ig conjugated to Alexa488 (green). Cells were viewed at 60X/1.4NA with a 
Nikon E800 microscope and images were captured with a Hamamatsu C- 
4746A DCC camera as described above. Cellular DNA was labeled with DAPI 
(blue) in uninfected control cells (A) and cells infected with CSFV (B). The E2 
protein of CSFV can be detected in the cytosol of infected Max cells (B) but is 
absent in uninfected cells (D).
Figure 3.5: Max cells can be infected with field strains of CSFV
antibody cannot be easily used in FACS analysis for double staining with
2.27.3 or PT-85 as it is also a mouse lgG2a antibody.
3.3.2 CSFV down-reguiates constitutive SLA class I surface expression.
Next, the effect of CSFV infection on cell surface SLA class I 
expression was investigated. Max cells were infected with CSFV Brescia for 
24, 48, 72 or 96 hours, control cells were incubated with media alone. Cells 
were harvested, incubated with the panel of antibodies listed in table 4 and 
cell surface expression of SLA class I was then measured by FACS. 
Antibody binding to MHC class I was detected with an appropriate isotype 
control conjugated to PE and as in previous experiments, a conjugate control 
was included for non-specific binding of these secondary antibodies. As a 
control for CSFV infection, cells were stained for E2 expression by 
immunofluorescence as described above.
In the experiments depicted in figure 3.6, 100% of cells were positive 
for CSFV E2. Graphs show data generated from a series of repeats of the 
experiment described above and individual graphs represent the mean 
average percentage decrease in MHC class I expression, obtained from 
pooled mean fluorescence intensity data, at each viral infection time point 
compared with uninfected control cells (normalised to 100%). Error bars 
represent the standard deviation from this mean percentage decrease. Table 
5 summarises the raw data (MFIs) from these experiments including the 
mean MFI ± standard deviation. Finally, Mann U Whitney tests were 
performed on unpaired raw (MFI) data to determine statistical significance.
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Figure 3.6: CSFV down-regulates MHC class I surface expression on Max 
cells.
Cell surface MHC class I expression on Max cells was measured at 24, 48, 72 
and 96 hpi with CSFV Brescia by flow cytomertry using a panel of antibodies 
specific for MHC class I. Graphs show the percentage of class I expression 
relative to an uninfected control (normalised to 100%) at each time point 
obtained with antibodies PT-85, 74.11.10 and 2.27.3. Error bars indicate 
standard deviation from the mean relative percentage. Mann U Whitney tests 
were performed on unpaired raw data, significant (p=<0.05) results are 
indicated by an asterisk. A significant decrease in MHC class I expression was 
detected with PT-85 (blue). 74.11.10 (red) showed a trend of down-regulation 
whereas no decrease in MHC class I expression was detected using the 
antibodies 2.27.3 (yellow) or 2.12.3 (data not shown). Raw MFI data are 
summarised in table 5 below.
Antibody Uninfected 24 hpi 48 hpi 72 hpi 96 hpi
PT-85 180.1 ±45.5/7 =5 104.4 ± 28.1 77=5 95.8 ± 31.8 n =5 79.7 ± 28.1 77=4 122.4 ±26.6 77=4
2.27.3 63.3 ±73.1 n =5 45.4 ±44.6 77 =5 52.5 ± 52 n =5 46.1 ±41.3/7=4 52.7 ± 36.7 n =4
74.11.10 86.6 ± 58.8 n =6 56.5 ± 30.6 77=6 56.5 ±46.6 77 =6 39.0 ±21.8 77=5 53.3 ± 25.9 /7 =4
2.12.3 10.7 ±6.9n=6 5.3 ± 1.9 77=6 6.5 ± 3.0 77=6 6.5 ± 3.38 77= 5 6.8 ±2.7 77 =4
16.7E4 3.4 ±0.4 /7 =6 3.5 ±0.3 77=6 3.3 ± 0.5 n =6 4.1 ±0.6/7=5 5.135 ± 3.0 77=4
Table 5: Summary of raw MFI data
The table shows the mean average MFI recorded for each antibody, at each 
time point ± standard deviation and the number of experimental repeats 
represented by these data (n).
In each sample the MFI of the isotype controls and the negative 
control 16.7E4 did not exceed 10 (data not shown) at all time points. The 
data presented shows that CSFV significantly inhibits MFIC class I 
expression detected by PT-85 (blue) at 24 hpi (p = 0.009), 48 hpi (p = 0.009) 
and 72 hpi (p = 0.014). Overall, the decrease in MFIC class I expression 
progresses with viral infection. Flowever at 96 hpi, the magnitude of the 
decrease in MFIC class I expression is less than at earlier time points. The 
results using the antibody 74.11.10 show a similar trend; MHC class I 
expression appears to decrease, although large standard deviations 
prevented statistical significance being reached. Similarly, the mean 
percentage decrease in class I expression recorded with the antibody 2.27.3 
(yellow) shows a trend of down regulation. In this instance significance could 
not be achieved, presumably the large variations in standard deviation at 
each time point is responsible for this.
By contrast, the antibody 2.12.3 did not record an increase or 
decrease in SLA class I expression (results not shown) and the MFI of the 
negative control 16.7E4 remained below 10.
Figure 3.7 shows a series of representative histograms showing data 
from one repeat of this experiment. FACS profiles of isotype controls (black 
histograms), uninfected control cells (open black histograms) and CSFV 
infected Max cells are shown for each antibody and at each time point.
-118-
The interesting result from these experiments is that CSFV infection 
down-regulates SLA class I expression significantly and therefore these 
results describe a previously undocumented immune evasion strategy used 
by this virus. The exact identity of the alleles that are down-regulated 
following CSFV infection could not be determined, since the identity of the 
specific class I alleles recognised by the panel of antibodies used is not 
known.
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Figure 3.7: CSFV down regulates MHC class I expression on Max cells - 
representative histograms.
Max cells were infected with the Brescia strain of CSFV for 24, 48, 72 and 96 hpi (as 
indicated) Figure 6A: CSFV down-regulates MHC class I surface expression on Max 
cells. Cell surface MHC class I expression was measured by flow cytomertry using a 
panel on antibodies specific for MHC class I. This figure shows the individual results 
from each antibody recognising MHC class I and is a representation of a single 
experiment from figure 6A. Each graph shows an isotype control (solid black 
histogram), MHC class I on uninfected Max cells (open black histogram) and MHC 
class I on CSFV infected cells (open red histograms). This figure is continued 
overleaf.
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Figure 3.7: CSFV down regulates MHC class I expression on Max cells 
continued
3.4.1 Summary of results
This chapter has examined SLA class I expression on a number of 
porcine cell lines using the analytical tools currently available and has 
identified two porcine cell lines that express high constitutive levels of MHC 
class I which can be induced by IFN-a/-y: Max d/d kidney cell line and 
primary d/d PAECs. In addition, a cell line that lacks MHC class I expression 
has been identified, Shimozuma cells. SLA class I expression on PAECs 
from outbred and d/d animals was compared, demonstrating that SLA 
epitopes differ in their responses to IFN-ot/-y which underlines the importance 
of using inbred animals expressing a restricted set of SLA class I genes for 
SLA class I expression studies. In addition, SLA antibodies localised intra 
and extracellular SLA class I in PAECs and Max cells expressing high levels 
of MHC class I by immunofluorescence. This immunofluorescence protocol 
can be used to monitor gross changes in SLA class I expression on individual 
cells, such as IFN induction, in future studies. After having characterised 
MHC class I expression on Max cells, the effects of infection with CSFV on 
SLA class I expression were examined. CSFV infection caused a dramatic 
down-regulation in the constitutive levels of SLA class I cell surface 
expression measured by two antibodies. This represents a novel immune 
evasion strategy for this virus which has not previously been reported.
3.4 Discussion
3.4.2 General considerations for studying MHC class i
When interpreting experimental data from MHC class I expression 
studies a number of factors pertaining to the specificity of the SLA antibodies 
being used and the inherent nature of MHC class I polymorphisms and 
expression patterns must be considered. These will now be discussed in 
detail.
3.4.2.1 Antibody specificity
The specificity of the antibodies used in this study were originally 
defined by serology. To date, antibodies raised against SLA class I have 
identified and characterised 75 haplotypes (in all breeds tested), indicating 
that there is considerable variation between individuals in which and how 
many alleles are expressed (Lunney, 1994). Although serology is a cheap 
and reliable means of haplotyping pigs and defining the specificity of a 
particular antibody there are some limitations to consider. Firstly some 
haplotypes may appear to have the same specificity, but may in fact be 
subtly different. For example, if gene duplication arose recently the allelic 
series would look the same by serology but is actually quite distinct. 
Serology cannot differentiate these ‘pseudoalleles’ whereas molecular 
techniques such as RT-PCR, can. Alternatively, the same antibodies can be 
used to immunoprecipitate MHC class I which can then be differentiated by 
iso-electric focussing. Secondly, SLA haplotyping is based on the expression 
of classical SLA genes and does not consider non-classical expression.
The antibody PT-85 has the broadest specificity of all the antibodies 
used here, having specificity for MHC class I in a range of species with 
distant evolutionary relationships it can be described as a ‘pan-class I* 
antibody. It must therefore recognise a highly conserved epitope within the 
MHC class I molecule. The SLA-specific antibody 2.27.3 is serologically 
defined as poly-loci specific and recognises a common determinant shared 
among the pig haplotypes H04, H07, H08, H10, H12 and H14 (C. Renard, 
personal communication). By contrast, the antibodies 2.12.3 and 2.32.1 
have an exclusive specificity for the H04 (d/d) haplotype. This has been 
confirmed by recognition of mouse L cells transfected with the d/d cDNAs 
encoding PD1 (SLA-1) and PD14 (SLA-2) by these antibodies (Satz & 
Singer, 1984).
Consideration of regions of structural homology within SLA class I 
molecules is essential when defining antibody specificity. Antibodies raised 
against a group of polymorphic molecules with structural homology such as 
SLA class I may be reactive against both ‘public’ and ‘private’ epitopes. The 
antibodies available to study SLA class I were raised in mice so they could 
potentially be specific for any part of the SLA class I molecule. To put this 
point into context, highly conserved regions such as exon 4 are virtually 
identical in all class I molecules, including the non-classical SLA. Recent 
studies characterising non-classical SLA expression by RT-PCR have 
demonstrated that some non-classical genes, namely SLA-8, are ubiquitously 
expressed, although only a limited number of tissues were studied (Crew et 
al., 2004). Therefore, when interpreting the FACS data in this study it cannot
be assumed that the SLA antibodies raised against SLA class I have 
exclusive specificity for classical genes and do not recognise the exon 4 
region of this non-classical molecule.
3.4.2.2 Antibody affinity
The affinity of an antibody for an epitope and the concentration of 
antibody used for staining are also important considerations for FACS 
analysis. Use of high affinity antibodies at high concentrations is not only 
wasteful but may lead to non-specific binding. Use of low affinity antibodies 
at low concentrations will only allow a proportion of the total epitope density 
to be detected and therefore may not provide a truly accurate representation 
of the level of epitope expression. For these reasons, antibodies were 
titrated wherever possible in order to determine an appropriate working 
dilution for SLA class I detection, that is the concentration of antibody which 
gives good sensitivity with a high signabnoise ratio. The SLA class I specific 
antibodies were used undiluted. Higher concentrations may provide better 
sensitivity, to achieve this affinity purification would be necessary.
3.4.2.3 Tissue specific expression
In the human, it is well established that expression of classical MHC 
class I molecules is ubiquitous whereas the expression of non-classical 
genes is tissue specific (reviewed by van den Elsen et al., 2004). Where 
expressed, the basal level of expression of each class I molecule may also 
vary between tissues. In the pig this has been demonstrated for the classical 
gene PD1. PD1 mRNA was detected in all tissues examined, but the degree
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of expression varies between tissues (Singer et al., 1987). Expression is 
highest in mature lymphoid tissues such as the spleen and lymph nodes and 
peripheral blood lymphocytes whereas the thymus, kidney and testis express 
relatively low levels of PD1 mRNA. Comparison of two individuals revealed 
variable levels of PD1 expression in the heart and liver, although lymphocyte 
contamination could not be ruled out as the cause of this variation (Ehrlich et 
al., 1989). This is an important consideration when using primary cells, and 
ideally cells derived form several individuals should be compared in order to 
minimise the impact of individual variation upon results. Also, use of a panel 
of antibodies and a comparative analysis of MHC class I expression in a 
range of cells derived from different tissues would allow tissue specific 
expression to be explored more comprehensively.
The porcine non-ciassical genes SLA-6 and SLA-7 are also expressed 
in a tissue specific manner and the level of class I transcription varies 
between tissues (Crew et al., 2004). Most importantly for this study, SLA-7 is 
expressed in the kidney. This has implications for studies in Max cells where 
cross reactivity of SLA antibodies with the exon 4 region of SLA-7 is a 
possibility. As discussed above, constitutive expression of SLA-7 and SLA-8 
means that FACS profiles may represent both classical and non-classical 
gene expression. Ideally, future studies should combine serological and 
molecular techniques such as RT-PCR to study tissue specific expression 
and rule out cross reactivity of SLA antibodies.
The influences of non-genetic factors such as immune status, sub- 
clinical disease, diet, psychological and physiological stress on SLA class i 
expression are difficult to define, quantify and explain. However, these 
factors are particularly relevant in experiments using primary cells such as 
PAECs, since they have an impact on gene transcription and therefore SLA 
class I expression. These factors have the potential to contribute to 
differences in FACS profiles seen between individual pigs. Although primary 
cells do provide a realistic representation of MHC expression in vivo; a 
dynamic system where expression changes in response to invading 
pathogens which is influenced by the state of health of the animal, results 
using these cells can be difficult to explain. The use of cell lines derived 
from a single individual such as Max cells, can help rule out variation caused 
by these factors. Ideally, comparative studies using d/d PAECs from a large 
population of individuals would be used, in practise this is both financially and 
technically demanding.
Experimental manipulation of cell samples can also affect the density 
of SLA class I molecules expressed at the cell surface, which in turn 
influences antibody recognition. Minute differences in technical manipulation 
during sample preparation for FACS analysis may also affect SLA class I 
expression and contribute to the variations in levels of class I expressed 
between experiments observed using cells derived from the same individual.
3.4.2.4 Non-genetic factors
In summary, the SLA antibodies used in this study can be used to 
determine the haplotype and allelic series of an individual. However, they 
may not recognise individual class I molecules or differentiate between 
pseudoalleles and may recognise both classical and non-classical SLA class 
I. While these antibodies are important tools for serological analysis, they 
cannot be used for molecular identification of discrete SLA class I antigens. 
For these reasons it is important to use a panel of antibodies recognising 
SLA class I in order to have a clear and unbiased picture of patterns of SLA 
class I expression. It is also important to examine SLA class I expression on 
a series of cells originating from different tissues, so that tissue specific 
expression patterns are considered for both constitutive and cytokine- 
induced expression. For the reasons discussed above cells originating from 
both d/d inbred and outbred pigs of unknown haplotypes were chosen to 
compare SLA class I expression and emphasises the importance of using 
porcine cells derived from individuals of known haplotype wherever possible.
3.4.3 SLA class I expression in primary cells
SLA class I expression was examined on PAECs from two groups of 
pigs; large White ‘outbred’ minipigs of unknown haplotype and inbred NIH 
minipigs that express the d/d haplotype. Clearly, there will be variation 
between the alleles expressed constitutively by d/d and outbred individuals 
and this is reflected in the different FACS profiles seen using the same panel 
of antibodies for both types of PAEC in figure 3.1. In particular, no staining of
3.4.2.5 Summary of the limitations of SLA class I antibody use
SLA class I on outbred PAECs was observed with 2.12.3 antibody, 
suggesting that the SLA recognised by this antibody is either not present on 
outbred populations or not expressed by the individuals examined. The 
specificity of 2.12.3 antibody was defined by serology; it recognises an SLA 
determinant that is unique to d/d cells. The results in figure 3.1 therefore 
correlate with the serological definition of this antibody. Another important 
consideration when analysing cells from pigs of unknown haplotypes using a 
small panel of SLA antibodies is that the combined specificities of the 
antibodies being used may not be broad enough to recognise every single 
class I allele expressed. This is another argument which supports the use of 
cells derived from inbred animals of a known haplotype and antibodies with a 
defined specificity for a particular haplotype, such as d/d locus specific 
antibodies.
3.4.4 Interferon induction of SLA class I expression
The importance of increasing SLA class I expression in response to a 
viral infection has already been discussed. Stimulation of outbred PAECs 
with interferon induced a minimal increase in SLA class I expression 
compared to IFN-oc/y induction observed in d/d PAECs. Since it is well 
established that interferon is a potent inducer of MFIC class I expression, this 
observation could be explained by the specificities and concentrations of the 
antibodies used; it is possible that the increases in class I expression cannot 
be seen despite having used a panel of SLA class I antibodies at high 
concentrations. In future studies, the SLA antibodies could be further
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concentrated by using affinity columns and tested at a range of higher 
concentrations than used in this study. The physiological state of the cells 
would also affect SLA class I expression and impaired response to interferon 
may be a result of cell culture conditions or the health of the individual. It is 
conceivable that activated cells express a maximum amount of MHC class I 
which cannot be further induced by interferon. There are two pieces of 
evidence which indicate that outbred PAECs have not lost their ability to 
respond to IFN-a/y, firstly stimulation of PAECs with IFN-a induces an 
increase in IFN-a mRNA (Bensaude et al., 2004). Secondly, IFN-a strongly 
induced SLA class I expression on d/d PAECs, which have been subjected to 
the same cell culture conditions as outbred PAECs.
The most intriguing observation in the experiments using inbred 
PAECs stimulated with interferons was the dramatic increase in expression 
of the SLA recognised by the antibody 2.12.3. As previously stated, 2.12.3 
and 2.32.1 have specificity for the H04 haplotype and recognise both PD1 
(SLA-1) and PD14 (SLA-2) on mouse L cells stably transfected with these 
genes (Singer et al., 1987, Ehrlich et al., 1989). This indicated that both 
antibodies recognise common determinants of these SLA molecules. 
However, FACS profiles of IFN-a/y stimulated Max cells and inbred PAECs 
using these two antibodies were quite distinct, indicating that these two 
antibodies actually recognise different epitopes. On Max cells the SLA 
recognised by 2.32.1 is constitutively expressed whereas the epitope 
recognised by 2.12.3 is not. However, on d/d PAECs, 2.12.3 gave a weak 
positive signal on untreated cells that was dramatically induced by IFN-a,
further evidence that these two antibodies recognise distinct SLA gene 
products. The exact identity of which SLA gene products 2.12.3 and 2.32.1 
recognise recognises remains to be determined. What is certain is that 
whatever 2.12.3 antibody recognises, is very strongly induced by IFN-a/y. 
This is interesting in the context of immune response to pathogens and 
indicates an important allele for response to viral infection. This allele could 
be targeted in vaccination programmes and therefore it warrants further 
investigation. Unfortunately, attempts to isolate the SLA class I protein that is 
recognised by 2.12.3 were limited by the technical applications of this IgM 
antibody.
3.4.5 CSFV down-regulates MHC class I expression on porcine cells
Importantly, this study has demonstrated that infection with CSFV 
down-regulates constitutive SLA class I expression on Max cells by FACS. 
This could be a novel immune evasion strategy for CSFV. The decrease in 
SLA class I expression was only detected with PT85, 74.11.10 and 2.32.1, 
but not by 2.27.3, or 2.12.3. As previously discussed, allele-specific 
expression needs to be controlled by the virus in order to prevent both CTL 
and NK cell activity therefore targeting CTL specific MHC ligands/SLA class I 
alleles rather than those which are inhibitory receptors for NK cells would 
provide CSFV with a distinct advantage. The identity of the class I alleles 
recognised by the panel of antibodies used in this study remains to be 
elucidated, therefore specific alleles affected by CSFV infection could not be 
examined. Since, the exact functions of each porcine SLA class I allele,
particularly non-classical SLA class I are not fully understood at present, it is 
not possible to determine the implications of SLA allele specific MHC class I 
down-regulation at this time.
The epitope recognised by the antibody 2.12.3 was not up-regulated 
by viral infection. This is interesting and suggests that CSFV does not induce 
an IFN response. Figures 3.1 and 3.3 show that IFN-a strongly induces the 
expression of SLA class I molecule recognised by this antibody, therefore
2.12.3 can be used as a marker for measuring SLA class I responses to 
IFNs. During a viral infection, IFN-a transcription and synthesis is induced 
when members of the Toll Like receptor family of receptors recognise 
intermediates of viral replication (figure 1.7). Taking this into account, one 
would anticipate that CSFV would induce IFN-a secretion and stimulate an 
increase in SLA class I expression, which would be reflected by an increase 
in the allele recognised by 2.12.3. This hypothesis is supported by previous 
data which demonstrated that IFN-a secretion is inhibited in CSFV infected 
cells (Bensaude etal., 2004 & Larocca etal., 2005).
The next challenge is to elucidate the mechanism by which CSFV 
down-regulates MHC class I. Key questions to address are does this virus 
down-regulate SLA class I expression by disrupting MHC class I 
transcription, synthesis, assembly or transport and which viral proteins are 
involved. As discussed in the introduction, viruses can disrupt the MHC class 
I presentation pathway at many stages. In chapter 5 the effect of CSFV on 
SLA class I expression at the level of transcription will be examined.
3.4.6 Summary
In order to understand the mechanisms that regulate SLA class I 
expression in more detail, I chose to investigate SLA class I expression at the 
transcriptional level by studying SLA class I gene promoters and study the 
effects of cytokines, transcription factors and CSFV upon SLA promoter 
activity. The next chapter will describe how promoters regions of classical 
and non-classical SLA genes derived from the H01 haplotype pig were 
cloned into a luciferase reporter vector. Investigation of the transcriptional 
control of six SLA class I genes is described in Chapter 5.
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Chapter 4: Physical and Structural Characterisation of the 
SLA Ciass i Locus
4.1 Introduction
A series of overlapping Bacterial Artificial Chromosomes (BACs) that 
span the entire MHC class I locus of an HOI haplotype pig were produced 
and sequenced by the LREG laboratory at INRA, France in collaboration wit 
Genoscope, France (Velten et al., 1998; Rogel-Gaillard et al., 1999). 
Sequence analyses identified three classical class la genes (SLA 1, 2 and 3), 
three non-classical class lb genes (SLA-6, -7 and -8) and one class lc gene 
(MIC-2) with the correct intron/exon organisation and promoter elements that 
suggest that they encode functional SLA class I molecules (Chardon et al., 
2001; Renard et al., 2001). The first aim of this work was to identify which 
genes could be transcribed from these DNA sequences by functionally 
analysing the upstream promoter elements. The sequences upstream of the 
MHC class I gene coding regions of human, mouse and the pig PD1, PD7 
and PD14 class I genes contain interferon Sensitive Response Elements 
(ISRE), Enhancer A, NF-kB and SXY sites (Ehrlich et al., 1998). Analysis of 
the individual SLA class I gene promoter regions of the H01 pig identified the 
same conserved regulatory elements including; an ISRE containing putative 
IRF binding sites, an Enhancer A containing putative NF-kB binding sites and 
an SXY region (Chardon et al., 2001, Renard et al., 2001). Chapter 5 will 
determine which of these elements are functional in the pig and explore the 
interactions of these motifs with the relevant transcription factors.
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This chapter includes a summary of the physical information obtained 
from DNA sequence analysis, including alignment of pig and human HLA 
promoters, and an alignment of the promoter elements for seven of the 
classical and non-classical SLA class I genes. It also describes the cloning 
strategy used to express SLA class I promoters in luciferase reporter 
plasmids to analyse their transcriptional activity.
4.2 Description of the porcine MHC class I locus and regulatory 
promoter elements.
Figure 4.1 A shows a diagram of the major histocompatibility complex 
(SLA) of the pig located on chromosome 7. It has been divided into three 
regions according to gene content; class II, class III and class I regions. The 
position of the centromere is indicated by a red circle. The regions 
containing postulated open reading frames (ORFS) for SLA class I are shown 
in blue, SLA class II genes are shown in yellow and other functional genes of 
interest are shown in white. A genomic library of BACs spanning the entire 
class I region of the Large White haplotype H01 was produced and a BAC 
contig spanning the entire class I region was built. The BAC clones 
corresponding to the minimum tiling path were sequenced (Chardon et al., 
2001, Renard et al., 2001). Three BACs were identified which, among other 
genes, collectively contain all of the SLA class I genes.
Figure 4.1: Physical structure of SLA promoter regions on chromosome 7 
and identification of SLA Class I genes from Bacterial Artificial 
Chromosomes (BACs).
A: The MHC class I locus of the pig is located on chromosome 7 of the pig and 
spans approximately 2 Mega bases (Velten et al., 1998). The class I region 
contains SLA class la, lb and Ic genes, shown in blue. The class II region 
contains SLA class II genes, shown in yellow. Other functional genes of interest 
are depicted as white boxes.
B. The gene content of three BACs which include all of the SLA class I genes is 
shown. Functional genes are shown in blue, pseudogenes are shown as 
hatched boxes and the direction of transcription is designated by the arrows. 
BAC 493A7 contains the non-classical class lb genes SLA-6, -7 -8 and the 
class Ic gene MIC-2. BAC 490B10 contains the classical class la genes SLA-2 
and -3, the putative class la gene SLA-5 and three pseudogenes SLA-11, -4 
and -9. BAC 207G8 contains SLA-1.
C: BAC sequence data were used to design primers for the amplification of full 
length promoter regions of SLA-1, -2, -3, -6, -7, -8 and MIC-2 genes (red 
circles). The promoter regions amplified and the nucleotide positions of primers 
is shown with respect to their positions on each BAC (red rectangles).
D: Alignment of SLA promoter regions reveals a series of conserved regulatory 
domains in class la and lb genes including a distal domain containing enhancer 
and silencer sites, a proximal domain containing a region homologous to a 
functional motif within the mouse H-2k gene, a proximal enhancer, two putative 
Sp1 binding sites, Enhancer A and an interferon stimulated response element 
(ISRE) (Chardon et al., 2001; Renard et al., 2001). Three transactivator 
elements common to MHC class I, class II and b2-microglobulin promoters, w, 
x1 and y are located within the proximal region. A series of proximal or “core” 
elements including CAT and TATA boxes and a CAP binding motif are also 
present.
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Figure 4.1 B shows the content and physical organisation of the genes 
identified within each BAC (accession numbers for sequence data are 
indicated). Individual genes are shown as blue arrows and hatched arrows 
indicate pseudogenes. The orientation of each gene and proposed direction 
of transcription is indicated by the direction of the arrow. BAC 207G8 
contains the class la gene SLA-1. BAC 490B10 contains the class la genes 
SLA-2 and SLA-3, the putative class la gene SLA-5 and the pseudogenes 
SLA-4, -9 and -11. BAC 493A6 contains the class lb genes SLA-6, -7 and -8 
and the class Ic gene MIC-2.
Figure 4.1 C shows the nucleotide positions, with respect to each 
BAC, that were selected for cloning out full length SLA class I promoters from 
the distal enhancer silencer sites to the translation initiation sites identified 
previously (Chardon et al., 2001, Renard et al., 2001). Figure 4.1 D shows 
an alignment of the promoter regions of SLA class la and lb and indicates the 
key regulatory domains thought to be implicated in the regulation of SLA 
class I expression. SINE elements within the promoter regions of SLA-2 and 
SLA-3 have been excluded from this alignment. When compared to human 
and mouse MHC class I the DNA sequences of the seven SLA class I genes 
revealed conserved regulatory domains, highlighted in red. A series of 
regulatory domains were identified within the 5’ flanking regions of SLA class 
I genes including several distal enhancer silencer sites, a region homologous 
to that found in mouse H-2k and an enhancer. In addition, a proximal domain 
was identified containing functional motifs implicated in cytokine-indirced 
regulation of HLA expression including two putative Sp1 binding sites, an
Enhancer A region containing putative binding sites for NF-kB family 
transcription factors and an ISRE region which may bind IRF-1 and IRF-2. A 
class I transactivator region containing W/S, X and Y elements was deduced 
from comparison of SLA promoters with other vertebrate class I and class II 
promoter sequences that have already been characterised (van den Elsen et 
al., 1998). In humans, the S, X1, X2 and Y domains bind RFX, CREB and 
NF-Y respectively and control constitutive FILA class I expression. CIITA 
acts as a co-activator of transcription, interacting with RFX, CREB and NF-Y 
bound to SXY motifs and drives FILA class I expression in response to IFN-y. 
A CAT box, TATA box and CAP binding domain were also identified. A 
detailed comparison of individual SLA class I promoter sequences reveals 
locus-specific differences in promoter elements that may be responsible for 
differential levels of constitutive and cytokine-induced expression of the 
individual SLA class I genes. The functional motifs within SLA-1, -2 and -3 
promoters are highly conserved whereas those of non-classical promoters 
contain some nucleotide differences which may affect their ability to bind 
transcription factors. For example, since the SLA-8 promoter lacks an ISRE, 
type I IFN may not stimulate the transcription of this gene.
In addition to the regulatory motifs described above, putative STAT 
binding motifs were identified in the promoter regions of SLA-1, -2, -3 and - 6. 
These previously undescribed motifs and their position with respect to the 
transcriptional initiation site (ATG) are listed in table 6.
Promoter M otif sequence Position
SLA-1 TTACTGGAA -952
SLA-2 TTACTTCAA -501
SLA-3 TTACTGGAA -1268
SLA-5 TTCCTGGAA -1233
SLA-6 TTCAGGGAA -327
SLA-7
SLA-8
MIC-2
Table 6: Putative STAT binding motifs in SLA class I promoters
Analysis of promoter sequences using TFSEARCH software reveals putative 
STAT binding sites within the promoters of SLA-1, -2, -3, -5 and -6. The table 
shows the sequence of each STAT motif and the location within each promoter 
region with respect to the ATG. These motifs have not been previously 
described or tested experimentally.
/
The functions of promoter regulatory domains and the specific 
sequences that bind transcription factors within these domains have been 
studied in detail for human MHC class I genes (summarised in figure 1.8). 
The information from these human studies can be used as a comparative 
model for studying the molecular regulation of SLA class I expression. In 
figure 4.2, the promoter region of SLA-1 is aligned with the promoter regions 
of HLA-A, -B and -C  and a consensus sites for each regulatory element is 
shown. Since SLA-1, -2 and -3 share highly homologous sequences in 
Enhancer A, ISRE and SXY domains only SLA-1 is shown here.
4.3 Cloning of SLA class I promoter regions
Sequence data were used to design primers for the amplification of full 
length SLA class I promoter regions from the 5’ distal enhancer silencer sites 
to the 3’ ATG from BAC DNA. Promoter regions of approximately 1000 
nucleotides in length were cloned into the luciferase reporter vector pGL3- 
basic (Promega), listed in table 7.
The DNA containing each SLA promoter was subcloned into 
pcDNA3.1A/5-His/TOPO (Invitrogen), excised, then ligated into the promoter- 
less reporter vector pGL3-basic upstream of the luciferase gene. Plasmids 
were then analysed by digestion with Nhe\ and Hind\\\ followed by gel 
electrophoresis to re-confirm the size of promoter inserts (figure 4.3 and table 
7). The sequences of SLA promoter inserts within pGL3-basic were 
confirmed by DNA sequencing.
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Figure 4.2: Comparison of porcine SLA-1 promoter sequence with human 
HLA-A1, -B7 and -Cw7 alleles.
This figure shows an alignment of the promoter region of SLA-1 with three 
common human classical HLA class I alleles. The 5’ flanking sequence of SLA 
class la share homology with human class I a genes within regions containing 
functional motifs including enhancer A, ISRE, w/s, x and y domains. Purine and 
pyrimidine residues are shown in coloured boxes: argenine (yellow), thymidine 
(red), guanine (green) and cystine (blue). The functions of these promoter 
domains have been characterised for human class I genes but not for H01 SLA 
class I genes. Consensus sites for each motif are indicated below each section 
of the alignment.
Target gene Anticipated PCR product size
SLA-1 1069
SLA-2 1330
SLA-3 1402
SLA-6 988
SLA-7 997
SLA-8 962
MIC-2 1228
Table 7: Anticipated sizes of SLA class I gene promoter regions to be 
cloned into pGL3-basic
Figure 4.3: Analysis of DNA amplified from BACs and cloned into pGL3 
basic.
Promoter DNA was cloned into pGL3 basic and the resulting plasmids were 
digested with Hind\\\ and Nhe\ and run on an analytical agarose gel to confirm 
molecular weight of inserts. The predicted size of the promoter regions of SLA- 
1, -2, -3, -6, -7 and MIC-2 genes amplified from BACS by PCR in table 7 
corresponds with the sizes of promoter regions cloned into pGL3-basic. These 
results were also confirmed by sequencing.
All SLA promoter constructs were sequenced with both pGL3-basic 
vector-specific and SLA sequence specific primers to confirm the presence of 
SLA promoter sequences upstream of the luciferase gene. Two clones of 
each construct were sequenced four times and compared to the reference 
BAC sequences (see Figure 4.1 C for accession numbers). The promoters of 
SLA-1, -2, -3, -6, -7, and MIC-2 genes were successfully ligated into pGL3- 
basic. Cloning of SLA-8 was unsuccessful and therefore this promoter is 
excluded from this study. Sequence data for pGL3-SLA-1, -6, -7 and MIC-2 
matched the BAC reference sequences with 100 % identity. Analysis of 
sequence data for SLA-2 and SLA-3 revealed several differences to the 
published sequence, these are reported in figure 4.4. Nucleotides that are at 
variance with the published sequence are shown in bold type. Nucleotide 
positions are given with reference to the cloned region of SLA-1 and -2 
promoters (refer to figure 1 C for address on BAC). None of the base 
changes reported here are within the Enhancer A (blue), ISRE (red), S 
(yellow), X (green) or Y (orange) regions of the SLA-2 and SLA-3 promoters 
therefore are not regarded to be of significance for the experiments described 
in Chapter 5.
4.4.1 Summary of results
This chapter has described the production of reporter plasmids 
containing the whole of the regulatory region for six SLA class I genes, 
including classical genes SLA-1, -2 and -3, non-classical 1b genes SLA-6, 
and -7 and the class Ic gene MIC-2. Evidence from restriction digests and
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Figure 4.4: Sequence analysis of SLA promoters
Sequencing of SLA-2 and SLA-3 constructs revealed several modifications 
to the published sequences within BAC 490B10. Two base changes, one 
insertion and one deletion in the sequence of the SLA-2 promoter and one 
base change in the SLA-3 promoter are shown in bold. Importantly, none 
of the base changes are located within the enhancer A, ISRE or SXY 
promoter modules.
DNA sequencing confirmed that SLA promoter regions were cloned 
into each reporter construct.
4.4.2 The sequences of the SLA-2 and SLA-3 promoter differ to the 
published sequences.
Comparison of our sequence data with the published sequence data 
identified several differences in the sequences of SLA-2 and SLA-3. The 
original BAC sequence data provided by Chardon et al (2001) and Renard et 
al (2001) were generated from sequencing of each BAC clone at least 10 
times. BAC DNA is considered as very stable and it is therefore unlikely that 
the base changes reported here arose during manipulation and preparation 
of BAC DNA or errors introduced by the pfu polymerase used for PCR 
amplification. Crucially, none of the base changes reported here are located 
within the regulatory domains of the promoter that will be studied here and it 
is anticipated that these changes will not affect promoter activity or be of 
consideration for the functional studies performed in chapter 5.
4.4.3 Functional analysis of SLA class I promoters from the H01 pig
The BAC sequences used to generate SLA promoter reporter 
constructs were derived from a male, Large White pig expressing the H01 
haplotype. At the time this study commenced, little was known about which 
SLA class I genes are expressed by this haplotype. In the recent paper by 
Crew et al (2004), the expression of the non-classical genes has been
clarified. What remains unclear is how expression of SLA class I genes is 
regulated at the molecular level. Variations in the promoter regions of SLA 
genes affect levels of constitutive expression; this has been demonstrated in 
the d/d pig where variation in PD7 and PD14 expression may be explained 
by base changes in the enhancer region (Ehrlich et al., 1998). In addition, 
nucleotide variations in promoter regions of SLA class I genes of different 
haplotypes may effect regulation through transcription factor binding. The 
response of the SLA genes of the H01 pig to cytokines and transcription 
factors is unknown. Since the promoter regions of HLA class I have been 
well characterised, these human genes can be used as a model for the pig 
class I genes. In the next chapter I will determine the constitutive activities of 
SLA class I promoters and investigate the functional activity of each SLA 
class I promoter in respect to responses to cytokines, transcription factors 
and viral infection.
Chapter 5: Transcriptional regulation o f classical and non- 
classical SLA class I genes.
5.1 Introduction
This chapter will investigate the mechanisms of regulation of SLA 
class I gene expression using the SLA class I promoters cloned into reporter 
plasmid described in the previous chapter. Key questions to address are: 
which promoters are constitutively active? and which SLA promoters are 
induced by pro-inflammatory cytokines? Induction by cytokines will be 
examined at the molecular level by examining promoter responses to 
transcription factors that are induced by cytokines and predicted to interact 
with the ISRE, Enhancer A and SXY core regulatory motifs within SLA class I 
promoters. In addition, the effects of CSFV infection on SLA gene 
expression will be investigated. In chapter 3 it was demonstrated that CSFV 
down-regulates the expression of SLA class I molecules at the cell surface. 
In this chapter, SLA promoter constructs will be used to determine if CSFV 
targets SLA class I at the level of gene transcription and which SLA class I 
genes are involved.
5.2 Constitutive activity of classical and non-classical SLA class I 
promoters in porcine cells
To determine the constitutive activity of SLA-1, -2, -3, 6, -7 and MIC-2 
promoters in porcine cells in culture, classical and non-classical promoters 
were cloned in front of a luciferase reporter gene (as described in chapter 4).
They were transiently transfected into the porcine Max ceil line isolated from 
an inbred NIH minipig expressing the d/d haplotype (described in chapter 3). 
As a control for transfection efficiency, Max cells were co-transfected with the 
plasmid pJATLacZ, a p-galactosidase reporter gene under the control of the 
rat p-actin promoter (Didcock et al., 1999). Normalised luciferase activities 
were calculated for each sample as shown below, this calculation was used 
in all subsequent transfection experiments unless otherwise stated.
Normalised LUC = luciferase reading
(P-gal reading - background)
The constitutive activities of SLA class I promoters 48 hours post 
transfection of Max cells is shown in Figure 5.1. The data shown here 
represent the mean average RLU from three repeats and is are qualitative 
representation of the trends observed throughout this study. The trend 
observed was that SLA-1 was most active of the three classical SLA 
promoters, SLA-2 had less activity and SLA-3 activity was the lowest of the 
three classical genes. Of the non-classical promoters, SLA-7 was most 
active, and in this ceil type was always higher than SLA-1. In this example 
SLA-7 activity is approximately three times that observed for SLA-1. 
Constitutive SLA-6 activity was also high, to a similar magnitude as SLA-1. 
MIC-2 has a constitutive activity comparable to SLA2.
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Figure 5.1: Constitutive activity of SLA class I promoters in porcine cells
Max cells were transfected with the SLA class I promoter-driven luciferase 
reporter plasmids pGL3-SLA-1, -2, -3, -6, -7 -8  or -MIC-2 and co-transfected 
with the |3-galactosidase control pJATLacZ for normalisation. After 48 hrs, 
luciferase and p-galactosidase assays were performed. Luciferase readings 
were normalised with |3-galactosidase readings to obtain normalised relative 
light units (RLU). This graph shows the mean average normalised RLU in 
untreated cells for each SLA promoter construct from a single experiment 
containing three repeats. The trend observed is representative of that 
observed throughout this study. Of the classical SLA promoters, SLA-1 was 
the most active, followed by SLA-2 and SLA-3. The non-classical SLA-7 
promoter was the most active of all promoters tested. SLA-6 was also strongly 
active. The MIC-2 promoter is constitutively active, with an activity comparable 
to SLA-2.
5.3.1 Regulation by interferons
In order to determine whether the ISRE and putative STAT binding 
motifs identified within the promoter regions of SLA class I genes are 
functional, the responses of SLA class I promoter reporters to stimulation 
with porcine interferon alpha and gamma were examined. First it was 
necessary to set up a series of controls. The reporter vector pGL3-control, 
which contains the firefly luciferase gene under control of the SV40 promoter, 
was used as a positive control for the luciferase assay. The reporter plasmid 
pISRE contains 4 copies of the ISRE consensus sequence 
(AGGAAATAGAAACTG) arranged in tandem upstream of the firefly 
luciferase reporter gene of a ptkA(-39)lucter plasmid (King & Goodbourn, 
1998, Reid et al., 1989). This plasmid was used as a positive control to 
monitor cellular responses to IFN-a. The reporter plasmid pGAS contains 2 
copies of the IRF-1 GAS consensus sequence (TTTCCCCGAAA) arranged in 
tandem upstream of the firefly luciferase reporter gene of the ptkA(-39)lucter 
plasmid (King & Goodbourn, 1994, King & Goodbourn, 1998). This plasmid 
was used as a positive control for IFN-y activation. In control experiments, 
Max cells were transfected with pISRE or pGAS and co-transfected with 
pJATLac for 32 hours, followed by treatment with pIFN-a or pIFN-y for 16 
hours. Cell lysates were analysed for luciferase and p-gal activity, and 
luciferase was normalised against p-gal as described above and normalised 
p-galactosidase activity was calculated. Statistical significance was 
evaluated for each condition using Wilcoxon signed ranked tests on paired 
raw data.
-151 -
Stimulation of Max cells transfected with pISRE with IFNa and cells 
transfected with pGAS with IFN-y caused a 2.1- and 3.2-fold increase in 
luciferase synthesis respectively (Figure 5.2 A i and ii). Interestingly, there 
was a significant decrease in pGL3-control plasmid activity when treated with 
IFN-a (Figure 5.2A iii) (p=0.028). The addition of IFN-y also caused a 
significant decrease in luciferase production (0.6) by pGL3-control (p=0.028).
The classical SLA class I promoter constructs pGL3-SLA-1, -2 and -3 
were transiently transfected into Max cells together with the control 
pJATLacZ and stimulated with IFN-a or IFN-y for 16 hours. The normalised 
fold inductions of luciferase activity as a consequence of IFN-a and IFN-y 
stimulation are shown in Figure 5.2 (i) and (ii) respectively. The classical 
SLA promoters SLA-1, -2 and -3 are more sensitive to stimulation with IFN-y 
than IFN -a. IFN -a induced the activity of the SLA-1 promoter by mean fold 
induction of 1.6, a value which is close to statistical significance (p=0.068). 
Induction of the SLA-2 promoter by IFN-a is negligible, a mean fold induction 
of 1.1 is reported here (p=0.068).
IFN-y increased SLA-1 promoter activity by 4.1 fold (p=0.015). SLA-2 
and -3 also appear to be induced by IFN-y, a mean fold induction of 2.5 and 
2.0 was observed and these data are approaching significance (p=0.068 and
The responses of the non-classical SLA promoters of SLA-6, -7 and 
MIC-2 genes to IFN-a and IFN-y were investigated by transient transfection
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Figure 5.2: Effect of interferon stimulation on classical SLA class I 
promoters.
Max cells were transfected with pJATLacZ and SLA promoter luciferase 
reporter plasmids (SLA-1, -2 and -3 ) or the control plasmids pISRE, pGAS or 
pGL3-control for 32 hours. Transfected cells were incubated with IFN-a or IFN- 
y for a further 16 hrs. These graphs show the mean normalised fold induction ± 
standard deviation of the mean of normalised luciferase following IFN 
stimulation compared with untreated controls for each condition and plasmid 
tested. Wilcoxon signed ranked tests were performed on paired raw data. 
Statistically significant p values are marked with asterisks (p=<0.05). The 
number of repeats (/?) is indicated below each graph. Panel A shows the 
results for the control plasmids. In (i), the positive control for IFN-a activity, 
pISRE is induced by IFN-a, in (ii), the positive control for IFN-y activity, pGAS is 
induced by IFN-y and in (iii) the positive control pGL3-control is repressed by 
IFN-a and IFN-y. In panel B (i), IFN-a appears to induce SLA-1 promoter 
activity. Induction of SLA-2 is negligible. In B (ii), IFN-y significantly induces 
SLA-1 activity and also appears to induce SLA-2 and SLA-3 activity.
of Max cells with the promoter constructs pGL3-SLA-6, pGL3-SLA-7 or 
pGL3-MIC-2 for 32 hours. Cells were then treated with pIFN-a or piFN-y for 
16 hours as described above. Promoter responses to IFN-a and IFN-y 
stimulation are shown in figure 5.3 [(i) and (ii) respectively]. The SLA-6 
promoter is neither induced nor repressed by IFN-a or IFN-^y. For SLA-7, a 
significant repression was observed with IFN-a (p=0.021) but IFN-y does not 
affect the transcription of this gene. Finally, MIC-2 promoter activity appears 
not to be repressed by IFN-a or -y although statistical significance could not 
be measured these data due to the small sample size.
Pro-inflammatory cytokine such as TNF-a and interleukins have been 
shown to up-regulate expression of MHC class I genes in the human (Israel 
et al., 1989, Johnson, 2003). In order to determine whether TNF-a induces 
SLA class I expression, the classical SLA class I promoter construct pGL3- 
SLA-1 and the non-classical promoter construct pGL3-SLA-7 were transiently 
transfected into Max cells together with the normalisation control pJATLacZ 
for 32 hours then stimulated with human TNF-a for 16 hours. The reporter 
vector pGL3-control was used as a positive control for luciferase activity as 
described before. Statistical significance was calculated using Wilcoxons 
signed ranked tests on paired raw data. In figure 5.4a (yellow bars), SLA-1 
activity increased by a mean fold induction of 1.9. A small, but significant fold 
induction (1.3) of the SLA-7 promoter was also observed (p= 0.008) (figure 
5.4c yellow bar). The luciferase activity of the control plasmid pGL3-control 
was not affected by TNF-a (figure 5.4c, yellow bar).
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Figure 5.3: Effect of interferon stimulation on non-classical SLA class I 
promoters.
Max cells were transfected with pJATLacZ and SLA promoter luciferase 
reporter plasmids or the control plasmids pISRE, pGAS or pGL3-control for 32 
hours then incubated with pIFN-a, pIFN-y or media alone for a further 16 hrs. 
The plasmids pISRE, pGAS and pGL3 control were used as controls (refer to 
figure 2). Graphs show the average fold induction ± standard deviation of 
normalised luciferase following pIFN-a (red) and pIFN-y (green) stimulation 
compared with unstimulated controls for each condition and plasmid tested. 
The number of repeats (n) is indicated below each graph. Wilcoxon signed 
ranked tests were performed on paired raw data and asterisks indicate 
statistically significant data (p=<0.05). The SLA-6 promoter was not affected 
by IFN treatment. SLA-7 is repressed by IFN-a but is not affected by IFN-y. 
The MIC-2 promoter was not affected by IFNs (statistical test not performed).
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Figure 5.4: Stimulation of SLA-1 and SLA-7 promoters with TNF-a and 
co-stimulation with IFN-a/-y and TNF-a
Max cells were transfected with pJATLacZ and pGL3-SLA-1 or pGL3-SLA-7 
promoter reporter plasmids or the control plasmid pGL3-control for 32 hours. 
Transfected cells were then incubated with (i) TNF-a (yellow bars), (ii) TNF-a 
plus IFN-a (orange bars) or (iii) TNF-a plus IFN-y (blue bars) for a further 16 
hrs. Graphs show the average fold induction ± standard deviation of 
normalised luciferase following cytokine stimulation compared with untreated 
controls for each condition and plasmid tested. The number of repeats (n) and 
standard deviation (SD) from the mean fold induction is indicated below each 
graph. Wilcoxon signed ranked paired tests were performed on raw RLU data, 
asterisks indicate statistical significance (p=<0.05).
Previous studies have shown that co-stimulation with TNF-a and IFN- 
a  or IFN-y synergistically increase HLA class I promoters (Drew et al., 1995b, 
Johnson, 2003). Therefore, the synergistic induction of SLA class I 
expression by TN F-a and IFNs was investigated using the classical promoter 
construct pGL3-SLA-1 and the non-classical promoter construct pGL3-SLA- 
7. Max cells were transiently transfected with pGL3-SLA-1 or pGL3-SLA-7 
and pJATLacZ for 32 hrs then treated with a combination of TNF-a and IFN- 
a or IFN~-y for 16 hours, as in previous experiments, pGL3-basic was used as 
a negative control for cellular responses to IFN-a/y and TNF-a. Mean fold 
inductions for each reporter plasmid are shown in figure 5.4. As above, 
statistical significance was determined using Wilcoxons signed ranked tests 
on paired raw data.
In control experiments, TNF-a did not affect luciferase production in 
cells transfected with the control pGL3-control (figure 5.4a yellow bar). 
Combined treatment with TNF-a and IFN-a represses luciferase activity of 
pGL3 compared with the untreated control and compared with TNF-a alone 
(p=0.028), shown in figure 5.4a (orange bar) as a fold induction of 0.3. IFN-y 
also represses pGL3 control, although to lesser extent than IFN-a, shown in 
figure 5.4a as a fold induction of 0.6 (p-0.028).
The data presented in figure 5.4b show a trend indicative of SLA-1 
induction by TNF-a. A mean fold induction of 1.9 is reported although in this 
experiment, these data approach, but do not reach significance (p=0.068).
Co-stimulation of SLA-1 with TNF-a and IFN-a does not cause a synergistic 
induction of the SLA-1 promoter compared with TNF-a alone (figure 5.4b, 
orange bar). Co-stimulation of SLA-1 promoter with TNF-a and IFN-y 
resulted in a mean fold induction of 4.4 which was higher than that reported 
for IFN-y alone (4.1) or TNF-a alone (2.0). This observation could not be 
confirmed statistically (p=0.066) and therefore may reflect the variation in 
induction by IFN-y, which is mirrored in figure 5.2b (iii), rather than synergistic 
induction by these two cytokines.
5.4 Regulation of SLA promoters by transcription factors
In order to determine which promoter elements are involved in 
transcriptional regulation of SLA class I in response to cytokines at the 
molecular level, SLA class I promoter constructs were co-transfected into 
Max cells with a number of transcription factors that are involved in the 
interferon and NF-k B signal transduction pathways. Many of these 
transcription factors have been shown to bind specific promoter motifs of 
HLA class I promoters and induce transcription of these genes. The 
regulation of three core promoter motifs within SLA class I promoters: ISRE, 
Enhancer A and SXY will now be considered.
5.4.1 The interferon-stimulated response element (ISRE)
The previous experiments showed that classical SLA class I 
promoters were regulated by interferon. Interferon alpha and gamma induce 
the expression of members of the interferon regulatory factor family (IRFs)
through the JAK/STAT pathway of signal transduction. IRFs then bind to the 
consensus sequence G/A G/C TTTC within ISRE elements of interferon 
sensitive genes, including human MFIC class I promoters and modulates 
expression of these genes.
ISRE were found within all SLA class I promoters with the exception 
of MIC-2 and SLA-8 (Chardon et al., 2001, Renard et al., 2001). Figure 5.5 
shows an analysis of the nucleotide sequences of the ISRE elements of SLA- 
1, -2, -3, -6, and -7 and a comparison with FILA-A, -B, -C, -E, -F and -G. The 
ISREs of SLA-1, -2 and -3 are identical to the ISRE of FILA-A1. It is therefore 
likely that the ISRE motifs of these SLA promoters will bind and respond to 
IRFs. By contrast, the sequences of ISRE in non-classical SLA-6 and SLA-7 
promoters not only differ from classical HLA and SLA class I, but also from 
the three human non-classicai genes, HLA- E, -F, and -G. The ISRE of SLA- 
6 contains an insertion of 2 nucleotides that may disrupt transcription factor 
binding or affect the spatial arrangement of transcription factor complex 
binding. Overall, the ISRE of SLA-7 is very similar to that of classical SLA 
and HLA. However, there are three nucleotide variations up- and down­
stream of the consensus IRF binding motif which may have an impact on 
transcription factor binding.
In humans, IRF-1 is a transcriptional activator of MHC class I whereas 
IRF-2 functions primarily as a transcriptional repressor (Reis et al., 1992, 
Drew et al., 1995a). To determine the effect of IRF-1 and -2 on SLA class I 
promoters experimentally, Max cells transiently transfected with the promoter
SLA-6
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Figure 5.5: Analysis of ISRE sequences from MHC class I promoters
Nucleotide sequences of ISRE regions from classical and non-classical SLA and 
HLA class I were aligned to highlight similarities and differences between human 
and porcine classical and non-classical genes.
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Figure 5.6A and B: Effect of IRF-1 and IRF-2 on SLA class I promoters
Max cells transfected for 48 hrs with SLA promoter constructs or a positive 
control reporter for IRF-1 activity and co-transfected with IRF-1 (A) or IRF-2 (B) 
expression vectors. Graphs A and B show fold induction of normalised 
luciferase values ± standard deviation (SD) when compared to a negative 
control where plRF-1/IRF-2 was substituted with pcDNA3.1. Statistical 
significance was calculated using Wilcoxon signed ranked tests on paired raw 
normalised luciferase data sets. Asterisks show significant data (p=<0.05).
c T T C I c c
c T T C T C c
c T T c T C c
c T T c T c c
c 1 T c T c c
c T T c T c c
reporter constructs pGL3-SLA-1, -3, -7, or -M IC-2 were co-transfected for 48 
hours with an IRF-1 expression plasmid (pEFPIink2-IRF-1) or an IRF-2 
expression plasmid (pEFPIink.2-IRF-2) or with the negative control backbone 
plasmid pEFPIink2. In all cases cells were also transfected with the p- 
galactosidase reporter plasmid pJATLacZ for normalisation. A control 
reporter p[(AAGTGA)4]5tkA(~39)]lucter was used to monitor IRF-1 activity. 
This plasmid contains a luciferase gene under the control of a synthetic 
promoter containing the herpes simplex virus thymidine kinase TATA box 
and 5 tandem repeats of an IRF-1/2 binding motif. Normalised luciferase 
values were calculated for each sample as above and statistical significance 
was assessed using Wilcoxon signed ranked tests on paired data. For 
simplicity, fold inductions were calculated by comparing mock co-transfected 
and IRF-1 co-transfected normalised luciferase data and the mean fold 
induction for each SLA promoter is shown in figure 5.6A.
Co-transfection of IRF-1 with the positive control vector HEX-4 results 
in a significant increase in transcription of the luciferase gene (p=0.043). In 
figure 5.6a, transcriptional activity of the SLA-1 promoter is induced by IRF-1 
(p=0.028), a mean fold induction of 1.6 is reported here. Induction of SLA-3 
by IRF-1 does not reach significance despite a mean fold induction of 1.5, 
perhaps due to the considerable variation in induction levels causing a 
substantial standard deviation. Interestingly, a 1.4 fold induction of the non- 
classical SLA-7 promoter by IRF-1 was observed (p = 0.028). Preliminary 
data for the MIC-2 promoter suggests that transcription of this gene is not
affected by IRF-1 although statistical analysis could not be performed on this 
small number of data points.
Co-transfection with the IRF-2 cDNA caused a variety of effects on 
classical SLA class I promoters (Figure 5.6B). Interestingly, and rather 
unexpectedly, a mean fold induction of 1.6 suggests that SLA-1 is weakly 
induced by IRF-2, these data are approaching significance (p=0.068). IRF-2 
co-transfection caused a fold induction of 1.1 in SLA-2 promoter activity, 
suggesting that IRF-2 does not repress SLA-2 promoter activity. The SLA-3 
promoter however was repressed by IRF-2. Transfection with IRF-2 did not 
affect SLA-7 or MIC-2 promoters.
Next, the effect of expression of IRF-3 on SLA class I promoters was 
investigated. Activated IRF-3 binds in a homodimeric complex to the same 
consensus sites as IRF-1 and -2. Max cells were transiently transfected with 
pGL3-SLA-1, -2 and -7 and co-transfected with an IRF-3 expression vector 
and the p-galactosidase control pJATLacZ for normalisation for 48 hrs. 
Normalised fold induction of SLA promoters in samples where IRF-3 was 
expressed were calculated by comparison with samples transfected with 
pcDNA3.1 control vector. In figure 5.7, IRF-3 induces SLA-1 promoter 
activity by nearly 3-fold (p=0.028). Interestingly, IRF-3 had no significant 
effect on SLA-2 or SLA-7 promoters despite both these promoters containing 
an ISRE and a reasonable sample size. This indicates that IRF-3 is a more 
important transcription factor for gene induction from SLA-1.
-163-
Fold induction of normalised luciferase readings from Max cells transfected for 
48 hrs with SLA promoter constructs, IRF-3 and pJATLacZ. The standard 
deviation (SD) and number of repeats (n) is indicated for each experiment. 
Statistical significance of inductions was calculated using Wilcoxon signed 
ranked tests on paired raw normalised luciferase data sets, significant data 
(p=<0.05) are marked with an asterisk.
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Figure 5.7: Effect of IRF-3 expression on SLA class I promoters
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Figure 5.8: Effect of IRF-7 expression on SLA class I promoters
Fold induction of normalised luciferase readings from Max cells transfected for 
48 hrs with SLA promoter constructs, IRF-3 and pJATLacZ. The standard 
deviation (SD) and number of repeats (n) is indicated for each experiment. 
Statistical significance of inductions was calculated using Wilcoxon signed 
ranked tests on paired raw normalised luciferase data sets, significant data 
(p=<0.05) are marked with an asterisk.
The effect of IRF-7 on SLA-1, -2, -7 and MIC-2 promoters was 
investigated next. Max cells were transfected with SLA promoter constructs, 
the control pJATLacZ and an IRF-7 expression vector plRF-7-GFP. 
Normalised fold inductions were calculated as before, comparing luciferase 
output from cells transfected with and without plRF-7-GFP. Figure 5.8 shows 
a trend that IRF-7 induces SLA-1 by a mean fold induction of 1.9 and SLA-2 
by a mean fold induction of 2.3, but these observations could not be 
confirmed by statistical analysis. The non-classical SLA-7 promoter and the 
MIC-2 promoter were not induced by IRF-7.
The effect of IRF-9 expression on SLA class I promoters was 
determined in a similar fashion. IRF-9 stimulates transcription of ISGs only 
as part of a complex with STAT1 and STAT2. Therefore, a constitutively 
active IRF-9 fusion protein that combines IRF-9 with the transactivator 
domain of the HSV1 VP16 protein was co-transfected into Max cells with the 
promoter constructs SLA-1, SLA-7 or MIC-2 and pJatLacZ for normalisation. 
As in previous experiments, normalised fold inductions were calculated for 
each condition and statistical significance was calculated using Wilcoxon 
signed ranked tests on pairs of normalised luciferase data. In the experiment 
shown in figure 5.9, co-expression of IRF-9 induces SLA-1 promoter activity 
(p=0.043), a mean fold induction of 2.9 was observed. SLA-7 appears to be 
weakly induced by IRF-9, significance was not reached using these data. 
Preliminary indications suggest that IRF-9 has no effect on MIC-2, a larger 
pool of data is required to confirm this.
Figure 5.9: Effect of IRF-9 expression on SLA class I promoters
Fold induction of normalised luciferase readings from Max cells transfected for 
48 hrs with SLA promoter constructs, plRF-9vp16 and pJATLacZ. The standard 
deviation (SD) and number of repeats (n) is indicated for each experiment. 
Statistical significance of inductions was calculated using Wilcoxon signed 
ranked tests on paired raw normalised luciferase data sets, significant data 
(p=<0.05) are marked with an asterisk.
5.4.2 Enhancer A region (NF-kB consensus site)
Putative NF-kB binding sites have been identified in silico within the 
Enhancer A regions of all SLA class I promoters with the exception of MIC-2 
(Chardon et al., 2001, Renard et al., 2001); the functions of these regions 
have not been tested experimentally previously. An alignment of Enhancer A 
consensus from human and porcine class I promoters is shown in figure 
5.10. The nucleotide sequences of Enhancer A regions of classical SLA 
promoters are identical and highly homologous to human classical Enhancer 
A sequences. Non-classical Enhancer A sequences of SLA-6 and SLA-8 
promoters are identical, share overall homology with their human 
counterparts and only differ from classical SLA Enhancer A sequences by a 
single trnucleotide. The Enhancer A region of SLA-7 lacks two nucleotides, 
this may affect the binding of NF-kB subunits.
The effect of co-expression of NF-kB p65 and p50 on SLA class I 
promoters was investigated. Max ceils were transiently transfected for 48 
hours with the promoter reporter constructs pGL3-SLA-1, -2, -3, -6, -7, or -  
MIC-2 and pJATLacZ for normalisation. For NF-kB studies, these cells were 
also co-transfected with a NF-kB p65 expression vector. A control reporter 
plasmid p6icB containing 6 tandem repeats of a consensus kB binding 
sequence upstream of the firefly luciferase gene was used as a positive 
control to monitor NF-kB p65 activity. For NF-kB p50 studies cells were co­
transfected with p50 expression vector or pcDNA3.1. In each experiment 
normalised fold inductions were calculated as before and statistical
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Figure 10: Analysis of Enhancer A sequences from MHC class I promoters
Nucleotide sequences of Enhancer A regions from classical and non-classical 
SLA and HLA class I were aligned. Human and porcine enhancer a sequences 
are highly conserved and share considerable homology between species.
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Figure 5.11 A and B: Effect of NF-kB p65 and p50 on SLA class I 
promoters
Max cells transfected for 48 hrs with pJAT-LacZ and SLA promoter constructs or 
a p6kB reporter and co-transfected with p65 (A) or p50 (B) expression vectors. 
Graphs show fold induction of normalised luciferase values compared to a 
negative control where p50/p65 was substituted with pcDNA3.1 Statistical 
significance was calculated using Wilcoxon signed ranked tests on paired raw 
data sets, significant data (p=<0.05) are marked with an asterisk.
significance of inductions was calculated using Wilcoxon signed ranked tests 
on paired raw normalised luciferase data sets.
Figure 5.11 A shows that the positive control, 6kB is induced by co­
transfection with NF-kB p65. The classical SLA promoters SLA-1, appears to 
be induced by NF-kB p65, although this could not be proven statistically 
using this data set. SLA-2 is induced by p65 (p=0.042), a mean fold 
induction of 3.2 was observed. Data presented for SLA-3 is approaching 
significance (p=0.068) indicating that SLA-3 is also induced by p65, an 
average fold induction of 3.2 suggests a similar magnitude of induction to that 
of SLA-2 despite having identical Enhancer A nucleotide sequences. A 
larger standard deviation and smaller sample size is likely to account for the 
lack of statistical significance. Previous results from this thesis showed that 
SLA-1 promoter activity is induced by TN F-a  (see section 5.3.2), the 
induction of classical SLA promoters by NF-kB p65 correlates with these 
results. Therefore it can be confirmed that the putative Enhancer A 
sequences identified within classical SLA promoters are functional and, like 
FiLA class I promoters, are regulated by NF-kB p65. In contrast to classical 
SLA class I the non-classical promoters were not induced by NF-kB p65 
despite having similar Enhancer A sequences to those reported in classical 
and FILA class I promoters. A weak induction of SLA-7 activity by TNF-a 
was observed, this was also seen in some, but not ail of the samples tested 
NF-kB p50 caused different effects on each classical SLA class I promoter 
tested. It was not possible to show any statistically significant decrease or
-169-
increase in promoter activity correlating with p50 co-transfection. Trends 
emerging from this data are that p50 may induce SLA-2 and repress SLA-3 
but does not effect SLA-1. Since the Enhancer A sequences of these 
promoters are identical, there may be other factors that influence NF-icB p50 
regulation of classical SLA class I genes. The non-classical SLA-6 and -7  
and MIC-2 promoters appear to be repressed by p50.
5.4.3 S, X and Y elements within SLA class I promoters
In the human, S, X and Y elements are important in both constitutive 
and IFN-y induced transactivation of HLA class I gene expression mediated 
by CIITA. CIITA acts as a co-activator of transcription, it does not bind DNA 
directly but mediates gene transcription by interacting with RFX, CREB and 
NF-Y complexes bound to promoter elements X1, X2 (site a) and Y 
respectively (Martin et al., 1997). In the pig, S, X and Y boxes have been 
identified within classical class la and non-classical class lb promoters but 
appear to be absent within the class Ic promoter MIC-2 (Chardon et al., 2001, 
Renard et a/., 2001). The effect of CIITA on SXY regulatory domains in SLA 
class I genes has not been investigated previously. An alignment of human 
and porcine S, X, and Y motifs within classical and non-classical promoters is 
shown in figure 5.12. Consideration of the sequences of S, X and Y 
regulatory domains may help explanation any differences in CIITA co­
activation between promoters.
Classical SLA S motifs are conserved, identical to HLA-C and differ 
from HLA-A and -B  by a single base. Classical X motifs differ from each
other by a single base only and share overall homology to HLA class I S 
motifs. The Y motifs of SLA-1 and -2  are identical, and differ from those of 
classical HLA by a single base. The S regions of the non-classical SLA 
promoters are less conserved than in classical SLA genes. The SLA-6 S 
motif is identical to that of HLA-E and -G  and the S motif of SLA-8 differs 
from HLA-F and -G by a single base. The S box of SLA-7 is most divergent. 
Comparison of the non-classical X motifs with those of non-classical HLA 
reveals a series of conserved residues, with single base variations at 
numerous point in the sequences. The effect of these differences upon 
transcription factor binding remains to be established. By contrast, the Y 
motifs of the non-classical SLA are all identical to that of HLA-F.
The effect of co-expression of CIITA on SLA class I promoters was 
investigated. The promoter reporter constructs pGL3-SLA-1, -2, -3, -6, -7, 
and -M IC-2 were co-transfected into Max cells with pJATLacZ and a CIITA 
expression vector or pcDNA3.1 for 48 hours. Normalised luciferase values 
and fold inductions were calculated as standard and statistical significance 
was calculated using Wilcoxon signed ranked tests on paired raw data sets 
(figure 5.13).
The classical SLA promoter SLA-1 is induced by co-transfection with CIITA 
(p = 0.008) and a strong fold induction of 4.9 was observed. Similarly, CIITA 
also appears to induce SLA -2 and -3 , and p values on these data approach 
significance (p=0.043 and 0.043 respectively). Chapter 3 of this thesis 
showed that classical SLA promoter activity was induced by IFN-a. The
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Figure 5.12: Analysis of S, X and Y domain sequences from MHC class I 
promoters
Nucleotide sequences of SXY regions from classical and non-classical SLA 
and HLA class I were aligned to highlight similarities and differences between 
human and porcine classical and non-classical genes.
Figure 5.13: Effect of CIITA on SLA class I promoters
Normalised fold induction of SLA promoter activity in Max cells following 
expression CIITA for 48 hrs. CIITA induces classical but not non-classical 
SLA promoter activity. The standard deviation (SD) and number of repeats 
(n) indicated below each data set. Statistical significance was calculated 
using Wilcoxon signed ranked tests on paired raw data sets. Asterisks 
indicate significant data (p=<0.05).
induction of classical SLA promoters by CIITA, which is induced by IFN-y, 
provides supporting evidence for these results. These experiments confirm 
that the putative S, X, and Y regulatory modules identified within classical 
SLA promoters are functional and, as with human classical promoters, are 
regulated by CIITA.
CIITA expression did not induce the non-classical SLA promoters. For 
the SLA-6 promoter, this correlates with the lack of promoter response to 
IFN-y stimulation reported here and may reflect differences in the sequence 
of the S, X, Y module, particularly in the X2/site-a region. In contrast SLAY 
promoter activity is repressed by CIITA (p=0.028) but not by IFN-y, sequence 
differences in the S and X regions of SLAY may provide a partial explanation 
for the lack of CIITA activation. Our preliminary observations indicate that 
both CIITA and IFN-y repress MIC-2 promoter activity. Since the MIC-2 
promoter does not contain S, X or Y regulatory domains this comes as no 
surprise.
5.5 Viral disruption of SLA class I promoters
5.5.1 CSFV down-regulates the constitutive activity of SLA ciass I 
promoters.
Results from this thesis have shown that infection with CSFV down 
regulates ceil surface MHC class I expression on porcine cells (see section 
3.3.2). Since modulation of gene transcription at the level of the promoter is 
a common strategy used by viruses to control the expression of host cell
genes, the activity of SLA class ! promoter constructs in CSFV-infected cells 
was investigated. Max cells were infected with CSFV Brescia for 24 hrs. 
CSFV-infected and uninfected Max cells were transiently transfected for 48 
hrs with pGL3-SLA-1, -2, -7, or pGL3-control. After a total infection time of 
72 hpi, cells were harvested and luciferase activity was measured. Previous 
experiments showed that the constitutive p-galactosidase activity of 
pJATLacZ was down regulated during CSFV infection and for this reason, 
luciferase values were not normalised against p-galactosidase activity in 
these experiments. Constitutive SLA promoter activities in uninfected and 
CSFV infected Max cells are shown in figure 5.14. At 72 hpi, the basal 
activity of SLA-1 is significantly down-regulated (p=0.028). In addition, the 
data show a trend that constitutive activity of the classical promoter SLA-2 is 
reduced. The basal activity of the non-classical promoters SLA-6 and SLA-7 
also appear to be decreased and these data are approaching significance 
(p=0.068 for both). In addition, data from these experiments shows a 
decrease in the constitutive luciferase activity of pGL3-control suggesting that 
CSFV causes a more generalised disruption of transcription.
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Figure 5.14: CSFV down regulates constitutive classical and non- 
classical SLA class I promoter activity.
Max cells were mock infected or infected with the Brescia strain of CSFV for 24 
hrs. Cells were then transiently transfected for a further 48 hrs with pGL3-SLA- 
1, pGL3-SLA-2, pGL3-SLA-3, pJATLacZ or the positive control pGL3-control 
(luciferase synthesis driven by the SV40 promoter). Total time for CSFV 
infection was 72 hrs. This graph shows the luciferase activity of SLA-1, -2, -6, - 
7 promoters and pGL3-control in CSFV infected cells, shown as percentage 
expression compared with the equivalent uninfected controls. Normalised RLU 
were not used as CSFV down-regulated p-galactosidase expression by 
pJATLacZ (data not shown). Statistical significance was calculated for data 
(where n->2) using Wilcoxon signed ranked tests on paired raw luciferase 
data. Significant data (p=<0.05) are marked with an asterisk.
5.6 Discussion
5.6.1 Summary of results
The results described above have characterised the responses of 
classical and non-classical SLA class I promoters to cytokines and 
transcription factors. This chapter has shown that all the classical SLA and 
non-classical SLA promoters are constitutively expressed and that there are 
locus-specific responses to cytokines and transcription factors. Table 8 
shows a summary of the expected results and table 9 shows the overall 
results according to SLA gene. In addition, the key regions of SLA class I 
promoters responsible for transcriptional regulation of SLA class I genes 
have been analysed in detail and conclusions about their function wiii now be 
discussed. First some general but important considerations that should be 
taken into consideration when interpreting the results reported here will be 
discussed.
Table 8: Summary of the expected results
Condition Classical SLA Non-classical SLA
Constitutive +++ variable/tissue specific
IFN-a ++++ variable inductions
IFN-y ++++ variable inductions
TNF-a +++ variable inductions
TNF-a + iFN-a +++++ variable inductions
TNF-a + IFN-y +++++ variable inductions
IRF-1 ++++ variable inductions
IRF-2 ++++ variable inductions
IRF-3 ++++ variable inductions
IRF-7 ++++ variable inductions
IRF-9 ++++ variable inductions
p65 ++++ variable inductions
p50 - repression
CIITA ++++ unknown
Table 9: Summary of the SLA promoter response results
Promoter response to stimulus
Condition SLA-1 SLA-2 SLA-3 SLA-6 SLA-7 MIC-2
Constitutive +++ ++ + +++ ++++ ++
IFN-a ++ 0 nd 0 - -
IFN-y ++++ ++ ++ 0 0 -
TNF-a ++ nd nd nd + nd
TNF-a +
IFN-a ++ nd nd nd - nd
TNF-a +
IFN-y H—|- 4 1' nd nd nd - nd
IRF-1 + nd + nd + 0
IRF-2 + 0 - nd 0 0
IRF-3 +++ 0 nd nd 0 nd
IRF-7 ++ ++ nd nd 0 -
IRF-9 +++ nd nd nd + 0
p65 ++ +++ +++ - 0 -
p50 0 + - - - -
CIITA +++++ +++++ +++ 0 - -
5.6.2 General considerations
The experiments described above required the transient transfection 
of cells with up to 4 plasmids, this presents a series of potential technical 
limitations. Amine transfection reagents are toxic to cells and may affect 
gene expression. Transient nucleic acid transfection has been shown to 
induce PKR and RNase L activity and suppress gene expression from viral 
and non-viral based vectors (Kaufman & Murtha, 1987, Terenzi et al., 1999) 
and in these studies transfection may affect the expression of co-transfected 
expression construct genes and reporter genes. In addition there may be 
competition between plasmids for cellular transcription factors, this may 
disrupt the expression of co-transfected genes. In future studies, the use of 
ceils stably transfected with SLA class I promoters or may help to minimise
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the effects of these factors and have the added advantage that SLA 
promoters can be studied in a chromatised environment.
The magnitudes of SLA class I promoter inductions following cytokine 
treatment and expression of transcription factors were considerably lower 
than those reported in similar studies using human class I promoters (Gobin 
et al., 1998, 1999). There may be several explanations for this, the most 
likely being that this study used long promoter regions that contain a number 
of silencer and enhancer motifs whose impact upon promoter activity and 
gene expression is not fully understood. Human studies used truncated 
promoter regions containing motifs such as Enhancer A or ISRE in isolation 
upstream of a reporter gene; similar reporter constructs should be used in 
future studies of SLA class I promoters. In addition, studies of HLA class I 
promoters were compared in a number of cell lines. As discussed previously, 
only a limited number of porcine cell lines are available. Studies carried out 
by the Singer lab demonstrated that the mechanisms controlling the 
regulation of PD1 are conserved in mouse and pig (Ehrlich et al., 1989; Frels 
et al., 1985), therefore murine cell lines could be an acceptable alternative for 
future SLA class I promoter studies.
5.6.3 Constitutive activity of SLA promoters in porcine cells
It is important to understand the constitutive activities of SLA class I 
promoters in order to benchmark changes in activity that take place when 
induction occurs. Class I promoters that are constitutively expressed at high
levels are probably most important in peptide presentation and as inhibitory 
receptors to prevent NK cell activation. The consistent trend observed for 
constitutive expression was: SLA-7 had the highest constitutive activity
followed by SLA-1 and SLA-6 and then SLA-2 and MIC-2, SLA-3 had the 
lowest constitutive activity. Constitutive activity of the classical gene 
promoters is consistent with characteristic ubiquitous expression that is 
associated with classical genes. Despite sharing highly homologous 
promoter sequences, there is locus specific variation in the constitutive 
activities of the classical SLA class I genes. Differences in constitutive 
activity may arise from binding of different transcription factor and regulatory 
promoter domains outside of the regions studied in this thesis such as distal 
enhancer and silencer sites, which may account for the differences observed. 
A comparison of the transcription factor binding profiles of each classical 
gene in resting cells could be used to explore this theory. It is noteworthy 
that in the H01 haplotype, an interspersed repeat or "SINE" separates the 
enhancer from silencer of SLA-2 and lengthens the promoter of SLA 3 
(Renard et al., 2001). The fact that SINE is absent from the SLA-1 promoter 
may explain why this gene is more constitutively active than the others. It is 
possible that the SINE changes the configuration of the DNA and hinders 
transcription. Not only does the location of the SINE vary from loci to loci, but 
also from haplotype to haplotype as described for the H04 (d/d) pig (Maguire 
etal, 1990).
Given that mRNA levels of PD1 expression have been shown to differ 
dramatically between tissues, it is almost certain that the levels of constitutive
activity of H01 classical genes would differ among tissues; SLA-1 may not 
always be the most highly expressed. It would therefore be interesting to 
compare the constitutive activity of these promoters in cells derived from 
several different tissues; in particular comparison of non-immune and 
immune tissues such as the spleen, thymus and lymph nodes would be 
useful. Unfortunately, only a number of porcine cell lines are available, cell 
lines of defined haplotypes are particularly rare and transfection of primary 
cell lines is technically challenging. Analysis of classical gene expression 
using quantitative RT-PCR on a range of cell types would compliment 
promoter studies.
Strong constitutive activity of the promoters of the non-classical genes 
SLA-6 and SLA-7 was observed and these results correspond with the 
constitutive mRNA expression of these genes reported in the kidney (Crew et 
al., 2004). In the light of this recent data, it would be interesting to compare 
constitutive expression of these promoters in other tissues including those 
found to be negative for mRNA expression of SLA-6 and SLA-7. One 
pertinent question that remains is what is the functional equivalent of HLA-G 
in the pig? To address this, a study of expression of non-classical genes in 
cells at the materno-foetal interface is required.
5.6.4 Interferon induces classical SLA class I promoter activity
Induction of classical MHC class I by type I and II IFNs has been well 
documented. The data presented here indicate that IFN-a and IFN-y also
induce classical SLA class I promoter activity and, although the data 
presented approach significance, induction of these genes by IFNs could not 
be proven. One exception is SLA-1, which was significantly induced by IFN-
Y-
The experimental use of IFNs is complicated by the inherent function 
of these cytokines as mediators of anti-viral responses, which have been well 
documented. Type I and II IFNs induce the RNA-dependent protein kinase 
(PKR) activity; this enzyme phosphorylates the a subunit of the eukaryotic 
initiation factor e!F2, leading to an inhibition of protein translation. In the 
experimental system used in this study there is evidence that inhibition of 
translation is taking place; luciferase activity of the SV40 driven luciferase 
gene (pGL3-contro! vector), which should be constitutively active, was 
repressed in IFN-a/-y treated cells. IFN-a is a weaker inducer of PKR (S. 
Goodbourn, personal communication) and accordingly, the decrease in 
constitutive luciferase activity of SV40-luciferase was less than that observed 
with IFN-y. Induction of PKR is therefore a plausible explanation for the lack 
of, or low levels of IFN-a induction seen for classical SLA class I promoters 
and the variation in inductions that prevents this data from reaching statistical 
significance. In future studies, inhibition of elF2a could be monitored by 
western blot.
IFN-y strongly induces SLA-1 promoter activity and appears to induce 
SLA-2 and SLA-3 albeit to a lower magnitude. This correlates to the
presence of a putative STAT binding site in each classical promoter. The 
fold inductions following IFN-y treatment presented for SLA-2 and SLA-3 are 
smaller than those presented for SLA-1, which may explain why these data 
approach, but do not reach significance. Comparison of the mean fold 
inductions caused by each IFN species shows that IFN-y induces SLA 
promoter activity more strongly than IFN-a. Both IFN-a and -y  induce the 
expression of families of transcription factors such as the IRFs which have 
the capacity to bind ISRE of SLA class I promoters and induce transcription. 
In addition, IFN-y induces class I expression via the transcription factor 
CIITA, which interacts with the SXY motifs. Induction of transcription factors 
which bind distinct regions of the class I promoter may confer IFN-y with an 
added potency for MHC class I induction. Interestingly, IFN-y also caused a 
significant decrease in luciferase production in control experiments using the 
pGL3-control vector and this decrease is less than that observed with IFN-a. 
Taking this into consideration, IFN-y could be a more potent inducer of class I 
in this system than IFN-a because it is a weaker inducer of PKR activity than 
IFN-a. A combination of increased potency and weaker induction of PKR are 
likely to be accountable for the differences in IFN-y and IFN-a fold inductions 
reported here. Experimental quantification of PKR activity would be required 
to exemplify this theory.
Overall these results suggest that there are locus specific differences 
in iFN-a responses of classical SLA class I genes. Since the classical SLA 
promoters contain consensus ISRE sites one can assume that in common
with humans, this region is functional and responsible for interferon-mediated 
regulation of classical SLA expression.
5.6.5 Non-classical promoter activity was not induced by IFNs
This study demonstrated that the promoters of the non-classical genes 
SLA-6 and -7 and the promoter of the class I c gene MIC-2 did not respond to 
IFN-a or -y. This is in contrast to human studies where IFN-y induced FILA-E 
and FILA-F (Gobin & van den Elsen, 2000) and therefore SLA class lb genes 
are either not regulated by IFN-a/yor inductions by these IFNs could not be 
detected using this experimental method. As discussed above it is possible 
that induction of PKR and RNAse L has masked the effect of IFN-a/y. For 
clarification, these experiments should be repeated using truncated 
promoters containing only the putative ISRE elements in parallel with 
measuring mRNA expression by quantitative RT-PCR in IFN-a/y treated 
cells. In these studies the SLA-8 promoter fused to a luciferase reporter 
gene would be useful as a negative control because SLA-8 it lacks an ISRE 
and is therefore not predicted to respond to IFNs.
In this study IFN-y did not induce non-classical SLA promoters. In 
silico analysis of SLA-6, -7 and -8  promoters identified a single putative 
STAT binding site within the promoter region of SLA-6, this site requires 
further characterisation to confirm its function in SLA-6. No equivalent site 
was found in the promoters of SLA-7 and SLA-8; the lack of a STAT binding
motif may explain the lack of response to IFN-y observed with these two 
promoters.
5.6.6 Regulation of SLA class I promoters by Interferon Regulatory 
Factors
IFN-a/y mediated induction of SLA class I expression was explored in 
more detail by analysing promoter responses to co-transfection with 
members of the IRF family of transcription factors. As discussed previously, 
these transcription factors are induced by IFNs and bind to consensus 
sequences within the ISRE of IFN-sensitive genes. Binding of IRFs to the 
ISRE regions of classical HLA class I gene has been described previously 
(Girdlestone et al., 1993, Lefebvre et al., 2001, Massa & Wu, 1995). In silico 
analysis of the ISRE of SLA-1, -2 and -3 promoters revealed consensus 
sequences for IRF transcription factor binding (Chardon et al., 2001; Renard 
et al., 2001) and therefore, in common with their human counterparts, the 
ISRE of classical SLA genes should bind and be induced by IRFs. Co­
transfection of the SLA-1 promoter with an IRF-1 expression vector results in 
an induction of SLA-1 driven luciferase production demonstrating that the 
ISRE of SLA-1 is functional and is induced by IRF-1. Similar studies using 
SLA-3 suggest that the ISRE of this promoter is also functional and induced 
by IRF-1 and these data approach significance.
The nucleotide sequence of the ISRE of SLAY differs from that of 
SLA-1 and HLA-A at two points; there is a C to G inversion and a C to T
insertion within in the 5’ region. It was predicted that these nucleotide 
differences might have an adverse effect upon IRF binding and prevent 
transcriptional induction of this gene by these transcription factors. However, 
co-transfection of SLA-7 with IRF-1 caused an increase in SLA-7 promoter 
activity, this was in contrast to experiments with IFN-a/y where no induction 
of SLA-7 was observed. As discussed above, induction of PKR may mask 
the effects of IFN-a/y.
The nucleotide sequence of the ISRE region of the SLA-6 promoter 
also differs from those of classical and HLA class I genes and contains an 
insertion of two nucleotides. In future experiments, this promoter would be 
tested using the same experimental model to determine the effects of this 
insertion on IRF binding and responses to IFN-a.
In order to further examine the interaction of IRF transcription factors 
with the ISRE of SLA class I genes, the effect of IRF-2, -3, -7 and -9  was 
investigated. All these IRFs bind to the same DNA sequence and with the 
exception of IRF-2, these transcription factors are known transcriptional 
activators of ISG’s. Accordingly, SLA-1 is induced by IRF-3 and IRF-9 and 
may be induced by IRF-7. SLA-2 was not induced by IRF-3 but appears to 
be induced by IRF-7 although significance was not reached by these data, 
perhaps due to the small sample size tested. SLA-7 was not induced by IRF- 
3 or IRF-7 but was, in some cases, induced by IRF-9, although these data 
did not reach significance. This is in contrast to IRF-1, which did induce SLA-
7.
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Overall, IRF-3 and IRF-7 did not behave as anticipated, they should 
have induced classical SLA class I transcription. One possible explanation is 
that IRF-3 and IRF-7 need to be activated in order to translocate to the 
nucleus and exert their effects on gene transcription. Co-transfection of 
these transcription factors alone may not be sufficient for their activation. 
Previous studies have shown that transfection of IRF-3 and IRF-7 cDNAs 
induced IFNa4 and a6 promoter activity, induction of these promoters was 
much stronger when cells were infected with virus (Marie et al., 1998). 
Therefore it is likely that activation of IRF-3 and IRF-7 by viral infection or 
stimulation with IFNs or synthetic dsRNA would substantially increase SLA 
promoter responses to these transcription factors. In this study a 
constitutiveiy active form of IRF-9 was used, and accordingly SLA-1 was 
significantly induced.
IRF-2 is a usually a transcriptional repressor of ISG’s therefore it was 
predicted that IRF-2 would repress SLA class I promoter activity. With the 
exception of SLA-3, however, there were no clear trends of transcriptional 
repression and rather unexpectedly, IRF-2 appeared to induce SLA-1 
promoter activity. These experiments produced variable results and 
contained small sample sizes, this is reflected by considerable variation in 
the results obtained from these experiments and accordingly, statistical 
significance was not reached for any of the classical promoters studied
These results have described the gross effect of cytokines and TFs on 
full length SLA class I promoters, which have been related to putative
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regulatory motifs identified within promoter regions. Future experiments 
should use truncated SLA promoters lacking upstream silencer elements and 
containing only the ISRE region. In addition, binding of IRFs to the ISRE 
should be confirmed using band shift assays and northern blots.
5.6.7 Transcriptional regulation by TNF-a and NF-kB
TNF -a induces activation of NF-kB species which bind to kB motifs 
located within Enhancer A promoter regions and induce transcription of MHC 
class I genes (Gobin et al., 1998, Johnson, 2003). In this study, TNF-a 
appears to induce SLA-1 promoter activity and is shown to induce the SLA-7 
promoter significantly, suggesting that the Enhancer A regions of these 
genes, which share homology to the consensus sequence found in human 
HLA class I promoters, are functional. Results from co-transfection of 
classical SLA promoters with NF-kB p65 studies also indicated that the 
Enhancer A regions of these genes are functional. A significant induction of 
SLA-2 was obtained following co-transfection of p65, but large standard 
deviation prevented significance being reached in similar experiments using 
SLA-1 and SLA-3. Given that the sequences of the Enhancer A region of all 
three classical SLA are identical, it can be assumed that they are functional 
on the basis of the data presented.
In humans, TNF-a has been shown to synergistically induce MHC 
class I with IFN-a and -y, mediated by co-operation of IRF-1 and NF-kB p65 
at the promoter level (Drew et al., 1995b, Johnson, 2003). In this study, no
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clear synergistic inductions of SLA class I genes were observed using these 
cytokines. As discussed above, induction of PKR and RNase L by 
interferons may mask synergistic activation.
5.6.8 CIITA induces classical SLA class I promoter activity
CIITA is a transcriptional activator of HLA class I and class II genes 
and mediates this effect via co-operative binding of RFX/CREB/NFY which 
are bound to the SXY region of these promoters. Until now, the effect of 
CIITA on SLA class I had not been examined, these data showed that CIITA 
is a transcriptional activator of classical SLA class I genes. Interestingly, the 
non-classical genes SLA-6 and SLA-7 were not induced by this transcription 
factor. The nucleotide sequences of the S and X1 regions of the SLA-7 
promoter are noticeably different; this probably affects binding of RFX and 
CREB and in turn, may explain the lack of CIITA induction observed. 
Similarly, the X1 and X2 regions of the SLA-6 promoter contain nucleotide 
sequences that are divergent from those of classical SLA which may disrupt 
CREB binding and prevent trans-activation by CIITA. To confirm that this is 
the case, the SXY regions of SLA-6 and -7  should be examined in isolation 
to determine which transcription factors bind them and compared with 
classical SLA promoters. MIC-2 was not induced by CIITA, this was as 
expected since this promoter does not contain an SXY box.
-188-
5.6.9 Regulation of MIC-2 expression
The regulation of the MIC-2 promoter requires separate consideration
since in the experiments using the MIC-2 promoter reporter described in this
chapter, none of the cytokines or transcription factors used caused an
increase in MIC-2 promoter activity. The porcine MIC-2 promoter contains a
region that resembles the heat shock element (HSE) found in human MIC
promoters, in humans this region directs transcription of the MIC-A and M1C-
B genes in response to heat stress at 42 °C. In the pig, MIC-2 expression
has been shown to be up-regulated in response to heat shock but this
observation was not confirmed by promoter analysis (Garcia-Borges et al.,
\
2005). Our attempts to repeat these heat shock experiments in Max cells 
using the MIC-2 promoter reporter construct did not detect an increase in 
MIC-2 promoter activity (data not shown). The MIC-2 promoter used in this 
study contained the sequence originally identified by Chardon et al (2001) 
which was identified by comparison of porcine MIC-2 exons with those of the 
human MIC genes. When the inter-genetic sequences were compared they 
could not be aligned with the exception of a 1.2kb region upstream of the 
MIC-2 coding sequence. Since this was the only conserved region found, it 
was presumed to be important for regulation of the MIC-2 gene. In this study 
this putative promoter was constitutively active but failed to respond to any of 
the transcriptional activators tested and therefore, it is likely that this region is 
not the MIC-2 promoter but does contain a regulatory sequence with the 
capacity to direct the transcription of the luciferase reporter gene. A second,
putative promoter region has been identified which is positioned several kilo 
bases upstream of the MIC-2 promoter sequence predicted by Chardon et al 
(Mark Crew, unpublished data). Whether this sequence actually represents 
the true MIC-2 promoter remains to be established.
5.6.10 CSFV down-regulates basal SLA class I promoter activity
Down-regulation of SLA class I expression by CSFV is a novel 
immune evasion strategy that has not been described previously for this 
virus. In order to determine if this down-regulation represents a block in SLA 
class I gene transcription, the effect of CSFV upon SLA class I promoter 
activity was examined.. This study has shown that CSFV significantly 
decreases the constitutive activity of SLA-1 and a trend which strongly 
suggests that CSFV down-regulates the activity of SLA-2, SLA-6 and SLA-7 
promoters. In addition, a decrease in the basal activities of the luciferase and 
(3-galactosidase control vectors appears to be caused by CSFV. Both these 
vectors are under the control of a constitutively active promoter and the level 
of their expression should not change during viral infection unless viral 
infection disrupts the availability of transcription factors or host cell 
transcriptional machinery, suggesting that CSFV disrupts host cel! 
transcription at a global level early during infection.
Host cell shutoff and cessation of host cell transcription is a 
mechanism that some viruses employ, CSFV however, causes a persistent 
infection and does not cause cell death in culture, therefore these
observations cannot be explained by host-cell shut off. Instead, it is possible 
that CSFV targets several transcription factors involved in transcription. This 
is currently being investigated in this laboratory and preliminary experiments 
have shown that both NF-kB p65 and TFIIB are down regulated during CSFV 
infection. In a previous study by this laboratory, CSFV was shown to prevent 
IRF-3 binding to the IFN -a promoter, resulting in inhibition of IFN-a synthesis 
(Larocca et al., 2005). Alternatively, CSFV may disrupt components of the 
host cell transcriptional machinery such as RNA polymerase activity.
The next question to address is which viral proteins are responsible for 
blocking SLA class I transcription. Stable cell lines that express individual 
CSFV proteins including E0 and Erns are available and a Max cell line stably 
transfected with Npro was produced as part of this study. These cells were 
analysed by FACS and transfection with SLA class I promoters; unfortunately 
no effect on SLA class I expression/transcription could be attributed to a 
single viral protein at this early stage (results therefore were not included in 
this thesis). It is important that this work continues, as understanding the 
viral proteins and mechanism responsible for SLA class I down-regulation will 
allow a greater understanding of the molecular pathogenesis of CSFV and 
may lead to the identification of therapeutic points of intervention.
5.6.11 Summary and future perspectives
Taking the results and discussion from this study into consideration, a 
model of the current understanding of the transcriptional regulation of
classical and non-classical SLA class I genes is presented (figure 5.15). In 
this figure, statistically significant results from this thesis are shown as 
coloured shapes, results that showed a trend of induction, approach 
significance and can be justified by similar studies in human are indicated by 
grey shapes. In summary, the transcriptional regulation of SLA class I genes 
in response to cytokines is controlled by four key promoter domains; a 
putative STAT binding motif which mediates responses to IFN-y, the 
Enhancer A region containing two kB binding motifs that mediate responses 
to TNF-a upon binding of NF-kB subunits, the ISRE which contains IRF 
binding motifs and mediates responses to type I IFN and the SXY domain, 
which is predicted to be bound by a multiprotein complex containing RFX, 
CREB and NF-Y and is transactivated by CIITA. Locus specific responses to 
cytokines and transcription factors can be attributed, in part, to sequence 
variation within these four key domains.
The sequences of these promoter domains in classical SLA class I 
share homology with each other as well as their human counterparts and 
accordingly, these promoters are responsive to IFN-y, NF-kB, IRFs and 
CIITA. Responses to TNF-a and NF-kB are presumed from trends indicated 
by the data presented. Given that SLA-2 and -3  contain STAT binding sites, 
that cell surface SLA class I substantially increases following IFN-y treatment, 
that human MFIC class I promoters containing STAT binding motifs respond 
to IFN-y and that trends of IFN-y induction were observed in SLA-2 and -3  
promoter studies, it is presumed that these motifs are functional. Further
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Figure 5.15: Model of the transcriptional regulation of SLA class I genes
Classical and non-classical gene expression was investigated at the molecular 
level using promoter regions upstream of three classical class I genes SLA-1, -2 
and -3, two non-classical genes SLA 6 and -7 and the MHC class I chain related 
gene MIC-2, cloned up stream of a luciferase reporter. Four core promoter 
regions are shown: STAT binding motif, Enhancer A, ISRE and SXY. This figure 
summarises the results of this thesis and shows the transcription factors that 
drive SLA class I transcription in response to cytokine stimulation and the motifs 
which they interact with. Coloured shapes show statistically proven responses 
from this study, grey shapes show indicative trends of induction requiring further 
validation.
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validation of this model could be achieved using promoters that have been 
dissected into individual regions and tested individually. These reagents 
could be used to determine the response of individual promoter elements to 
transcription factor and cytokine stimulation as well as to determine the 
physical binding of transcription factors to isolated DNA sequences. Finally, 
if time and money were of no object, these investigations should be repeated 
using cell lines stably transfected with each SLA class I promoter, in order to 
examine promoter responses in a chromatised environment.
Chapter 6. Conclusion
The porcine immune system has attracted a considerable amount of 
interest over the last decade due to the economic importance of this species 
in the food industry as well as the potential for pigs to provide solid organ and 
cell replacements for humans. The genes encoded in the major 
histocompatibility complex are central to both of these interests as 
transplantation antigens and as mediators of immune responses. Therefore, 
a greater understanding of their functions and how these genes are regulated 
is important to establish. The aim of this project was to obtain a more 
detailed understanding of how SLA class I gene expression is regulated. 
Given the importance of MHC class I in the immune response, selective 
pressure has maintained MHC class I function throughout evolution. The 
structure of MHC molecules is vital for correct function of the MHC genes and 
accordingly, have remained highly conserved. The expression of these 
genes, however, is variable. Since the majority of variation lies within the 
promoter region a greater understanding of how the SLA promoter operates 
is the key to understanding SLA class I expression and therefore in this 
project, the regulation of SLA class I promoters were studied in detail.
I have demonstrated that IFN-a and -y increase cell surface SLA class 
I expression on d/d PAECs and Max cells, in particular, one allele or group of 
alleles were identified that are particularly sensitive to stimulation with IFN-a 
and -y which justifies further investigation. The tools for analysing SLA class 
I are few in number. Additional limitations are that the identities of the alleles
recognised by each antibody is not known and cell lines available from 
animals that express a restricted set of SLA class are not readily available. 
Furthermore, while primary cells provide a more accurate representation of 
in vivo SLA class I expression than transformed cell lines, there is continued 
emphasis on reducing the use of animals for experimentation (for example 
the 3R’s initiative). As such, Max cells provide an attractive alternative to 
primary cells for studies of the regulation of SLA class I expression. In order 
to fully understand cell surface SLA class I expression more analytical tools 
are required. Stable transfection of cell lines with individual SLA class i 
genes could be used to characterise existing SLA class I antibodies and to 
study expression of SLA class I genes in isolation in a chromatised 
environment and in response to cytokine stimulation. In addition, these cell 
lines could be used to determine the nature of the peptides bound by each 
class I molecule, this would be particularly interesting for non-classical SLA, 
vaccine design and tetramer production. A second possibility would be to 
raise new antibodies against short fragments of SLA class I proteins specific 
to each class I protein, but this is complicated by the high homology of SLA 
class I alleles. Finally, as none of the existing antibodies available are able 
to detect class I MHC by Western blotting, generation of an antibody with this 
capability would be a valuable reagent for studying SLA class I protein 
expression in the future.
RT-PCR is commonly used to study gene expression at the mRNA level 
and has been used by other groups to study SLA class I expression (see 
Crew et al., 2004). An extensive collection of tissue samples derived from
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d/d pigs were collected as part of this study, including tissues from neonatal 
piglets, placental tissues, tissues from immune organs and tissues which 
have not previously been studied in the d/d pig to date. These tissues are a 
valuable resource for conducting a detailed tissue survey of SLA class I 
expression using the RT-PCR primers and conditions described by Crew et 
al (2004). Importantly, examination of non-classical SLA expression in 
placental tissues may allow a functional equivalent of HLA-G to be found in 
the pig, which remains an important question.
Studying the promoter regions of SLA class I has permitted a greater 
understanding o f the regulation of class I genes at the molecular level and 
helps to explain locus specific differences in levels of class I expression. 
Four regulatory motifs within SLA class I promoters mediate transcriptional 
responses to cytokines and transcription factors. Future studies should 
examine which transcription factors physically bind to these motifs both 
constitutively and following cytokine stimulation in order to confirm the 
results. In addition, SLA class I promoter motifs should be cloned upstream 
of reporter genes and so that the transcriptional responses of individual 
promoter motifs to cytokine and transcription factors can be assessed. In 
addition, a detailed comparison of classical and non-classical SLA promoters 
should be made. Finally, reporter constructs should be made which contain 
individual regulatory motifs in isolation, and responses to cytokines and 
specific transcription factors analysed. In particular, the promoter region of 
SLA-5 has not been examined, these are important experiments because the 
expression of SLA-5 and the function of this gene as a bona fide classical
SLA is not known. Similarly, the promoter region of SLA-8 must be examined 
in order to gain a better understanding of the transcription of this non- 
classical gene. Perhaps the most interesting aspect of this study was the 
examination of non-classical SLA-6 and -7 promoters, as the functions of 
these genes in the pig are not well understood.
The additional tools described above would also be valuable for 
studying SLA class I expression during viral infections. In this study, the 
affect of CSFV infection on SLA class I was investigated. Classical swine 
fever is a constant threat to the UK and European herd and outbreaks of 
disease cause substantial economical losses; the last outbreak in Europe is 
estimated to have cost US$ 2.3 billion and required the slaughter of 11 
million pigs (Oleksiewicz et al.,2003). It is therefore imperative that 
mechanisms of controlling this disease are developed. In order to achieve 
the ultimate goal of providing a safe, efficient and inexpensive vaccine, a 
greater understanding of the virus, the porcine immune system and crucially 
how the virus interacts with the porcine immune system, must be gained. 
The continuous interactions between host and pathogens during their co­
evolution have not only shaped the immune system, but also the counter 
measures used by pathogens. Down-regulation of cell surface MHC class I 
expression is a common immune evasion strategy employed by viruses to 
avoid recognition by CTLs and selective disruption of specific MHC class I 
alleles allows a virus to avoid NK cell lysis (see Lilley & Ploegh, 2005 for a 
review). This project addressed two important questions; does CSFV disrupt 
SLA class I expression ? and if so, how ? Using FACS, these studies have
shown that SLA class I expression on Max cells is down-regulated early 
during viral infection, within 24 hours. This thesis also showed that SLA 
class I promoter activity was compromised during CSFV infection and 
conclude that down regulation of cell surface SLA class I expression is 
achieved by inhibition of SLA class I transcription. Many viruses target 
stages of the peptide presentation pathway in order to prevent MHC 
expression. It is very likely that CSFV targets multiple steps in the peptide 
presentation pathway, such as inhibition of TAP or ER retention to prevent 
SLA class i from reaching the cell surface, this should be explored in future 
studies by analysing expression, activity and trafficking of individual 
components of the peptide presentation pathway. The next question to 
answer is which viral protein allows CSFV to disrupt SLA class I ? This is an 
important question because targeting specific viral proteins may allow SLA 
class I expression to be restored therapeutically. Max cell lines stably 
expressing CSFV viral proteins are now being produced and studied so that 
the effect of individual CSFV proteins upon class I expression can be 
examined.
Some unexpected results from this study were that CSFV down 
regulates the expression of two reporter genes under the control of 
constitutively active promoters including SV40 driven luciferase and (3- 
galactosidase driven by a rat p-actin promoter, indicating that CSFV 
modulates host cell transcription at a global level. These results support 
results from previous and ongoing studies in this laboratory which have 
shown that CSFV down-regulates the transcription of IRF-3, NF-k B and
TFIIB. This suggests that CSFV either disrupts part of the transcriptional 
machinery or inhibits global transcription factors. Understanding CSFV 
immune evasion strategies is important work that must be continued if a 
solution to this virus is to be developed.
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